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Preface 
 
 
'EJQECTFKQITCRJ[ KU C YKFGN[ URTGCF TGNCVKXGN[ KPGZRGPUKXG VGEJPKSWG VJCV KU QHVGP
WUGF HQT PQPKPXCUKXG ECTFKCE KOCIKPI +V KU TGIWNCTN[ VJG HKTUV ECTFKCE VGUV QTFGTGF YJGP
ECTFKCE FKUGCUG KU UWURGEVGF KP C RCVKGPV DGECWUG KV RTQXKFGU CP KPVGITCVGF PQPKPXCUKXG
CUUGUUOGPV QH ECTFKCE UVTWEVWTG HWPEVKQP CPF JGOQF[PCOKEU #P GXQNWVKQP KP FKHHGTGPV
FGXGNQROGPVU QH WNVTCUQWPF KOCIKPI UWEJ CU UVTGUU GEJQECTFKQITCRJ[ O[QECTFKCN EQPVTCUV
GEJQECTFKQITCRJ[ VKUUWG &QRRNGT KOCIKPI CPF KPVTCECTFKCE GEJQECTFKQITCRJ[ JCU HWTVJGT
RQRWNCTK\GFGEJQECTFKQITCRJ['XCNWCVKQPQHTGIKQPCNQTINQDCNO[QECTFKCNHWPEVKQPD[QPGQH
VJGUGCRRTQCEJGUECPDGWUGHWNVQRTGFKEVCEJCPIGQHHWPEVKQPQTRTQIPQUKUD[VJGVKOG6JKU
VJGUKUGXCNWCVGUVJGXCNWGQHGEJQECTFKQITCRJ[KPRTGFKEVKPIENKPKECNQTHWPEVKQPCNQWVEQOG



176.+0'1(6*'6*'5+5


2CTV2TGFKEVKQPQHQWVEQOG
 
&QDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ JCU DGEQOG CP GUVCDNKUJGF KOCIKPI VGEJPKSWG
6JG CEEWTCE[ QH FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ HQT FGVGEVKQP QH UKIPKHKECPV EQTQPCT[
CTVGT[ FKUGCUG TCPIGU HTQO  
 &QDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ QHHGTU CNUQ
XCNWCDNG KPHQTOCVKQP HQT TKUM UVTCVKHKECVKQP QH RCVKGPVU 
  6JG GHHKECE[ QH RTQIPQUVKE
UVTCVKHKECVKQP KU TGNCVGF VQ VJGCDKNKV[QH VJKU VGEJPKSWG VQRTQXKFG KPHQTOCVKQPQP TGUVKPI NGHV
XGPVTKEWNCT HWPEVKQPO[QECTFKCN XKCDKNKV[ CPF UVTGUUKPFWEGF KUEJGOKC 6JG EQODKPCVKQP QH
TGUV CPF RJCTOCEQNQIKECN UVTGUU GEJQECTFKQITCRJ[ JCU DGGP UJQYP VQ IKXG KORQTVCPV
KPHQTOCVKQPQPVJGTKUMQHNCVGECTFKCEGXGPVUCPFECPDGWUGHWNVQIWKFGVJGTCRGWVKEUVTCVGIKGU
CUYGNNCUVQRTQXKFGTKUMUVTCVKHKECVKQP
*QYGXGTFKHHGTGPVCURGEVUPGGFVQDGKPXGUVKICVGF
CPFGNWEKFCVGF

As medicine develops there is a trend towards more individual diagnostic evaluation 
and clical care. However, untill now the predictive value of stress echocardiography was often 
evaluted in unselected, mixed patient groups.The first part of this thesis deals with the 
assessment of prognostic value of dobutamine stress echocardiography in specific patient 
subsets. Prediction of future cardiac events may be a clinical challenge in these patient 
groups, because of anatomical differences, inability to exercise, and preexistent repolarization 
abnormalities. Therefore the central question of part I, of the thesis is: 
 
&QGU FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ RTQXKFG KPETGOGPVCN KPHQTOCVKQP HQT VJG
RTGFKEVKQPQHECTFKCEGXGPVUKPwomen, elderly, patients with silent ischemia, and those with 
intraventricular conduction abnormalities!
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%JCRVGT  KU C U[UVGOCVKE TGXKGY GXCNWCVKPI VJG CFFKVKQPCN XCNWG QH UVTGUU
GEJQECTFKQITCRJ[ VQ EQOOQP ENKPKECN ECTFKCE TKUM HCEVQTU CPF JGOQFKPCOKE FCVC HQT VJG
CUUGUUOGPV QH RTQIPQUKU KP FKHHGTGPV UWDUGVU QH RCVKGPVUYKVJ UWURGEVGF QT MPQYP EQTQPCT[
CTVGT[FKUGCUG6JGTGXKGYKPENWFGUUVTGUUGEJQECTFKQITCRJ[TGRQTVUYJGTGGZGTEKUGKPQVTQRKE
CIGPVU
FQDWVCOKPGQTXCUQFKNCVCVQTUVTGUUQTU
FKR[TKFCOQNGQTCFGPQUKPGCTGWUGF
+P %JCRVGT  VJG GHHGEVU QH IGPFGT QP NQPIVGTO RTQIPQUKU QH RCVKGPVU WPFGTIQKPI
FQDWVCOKPGUVTGUUGEJQECTFKQITCRJ[CTGKPXGUVKICVGFFWTKPICOGCPHQNNQYWRQH[GCTU6JG
CKOUQHVJKUUVWF[YGTGVQCUUGUUVJGRTGFKEVQTUQHECTFKCEFGCVJCPFPQPHCVCNO[QECTFKCN
KPHCTEVKQP FWTKPI C NQPIVGTO HQNNQYWR KPOGP CPFYQOGP TGHGTTGF HQT FQDWVCOKPG UVTGUU
GEJQECTFKQITCRJ[CPFVQHKPFYJGVJGTIGPFGTJCUCPKORCEVQPQWVEQOGCHVGTEQPVTQNNKPI
HQT ENKPKECN XCTKCDNGU CPF UVTGUU GEJQECTFKQITCRJKE FCVC # UGRCTCVG CPCN[UKU KP OCNGU CPF
HGOCNGU YKVJ PQTOCN CPF CDPQTOCN UVTGUU VGUV YCU CNUQ RGTHQTOGF VQ QDVCKPGF C DGVVGT
WPFGTUVCPFKPI QH IGPFGT FKHHGTGPEGU KP NQY CPF JKIJ TKUM RCVKGPVU CPF CNNQY VQ CP CKOGF
VJGTCRGWVKEVTGCVOGPVHQTGCEJITQWR
5WDUGSWGPVN[ %JCRVGT  TGRQTVU QP VJG KPETGOGPVCN XCNWG QH FQDWVCOKPG UVTGUU
GEJQECTFKQITCRJ[ KP  HGOCNGU YJQ WPFGTYGPV FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ #
RTGFKEVKQPQHVJGUVTQPIGUVGPFRQKPVCNNECWUGOQTVCNKV[YCUURGEKHKECNN[GXCNWCVGF
+P %JCRVGT  NQPIVGTO RTQIPQUVKE XCNWG QH FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ KU
GXCNWCVGF KP RCVKGPVU QXGT  [GCTU 6JG UVWF[ RQRWNCVKQP EQORTKUGF  RCVKGPVU YKVJ
NKOKVGF GZGTEKUG ECRCEKVKGU 6JGUG RCVKGPVUYGTG HQNNQYGFWR FWTKPI C [GCT RGTKQF CHVGT
UVTGUUVGUV
6Q KPXGUVKICVG UKOKNCTN[ VJG RTQIPQUVKE XCNWG QH FQDWVCOKPG UVTGUU O6E
VGVTQHQUOKP 52'%6 HQT VJG RTGFKEVKQP QH OQTVCNKV[ CPF ECTFKCE GXGPVU KP GNFGTN[ RCVKGPVU
WPCDNG VQRGTHQTOGZGTEKUG VGUVKPI KP%JCRVGTENKPKECN KPHQTOCVKQPCPF52'%6TGUWNVUCTG
CPCN[\GFKPEQPUGEWVKXGRCVKGPVU≥[GCTUQNFFWTKPICOGCPHQNNQYWRQH[GCTU
%JCRVGTCUUGUUGUVJGRTQIPQUVKEUKIPKHKECPEGQHTGXGTUKDNGYCNNOQVKQPCDPQTOCNKVKGU
KPRCVKGPVUYKVJQWVCPIKPCFWTKPIFQDWVCOKPGUVTGUUGEJQECTFKQITCRJ[EQORCTGFYKVJRCVKGPVU
YKVJ U[ORVQOCVKE KPFWEKDNG KUEJGOKC 6JG UVWF[ TGRQTVU QP ECTFKCE GXGPVU KP  RCVKGPVU
FWTKPIC[GCTHQNNQYWR
+P%JCRVGT  VJG KPEKFGPEG ENKPKECN EQTTGNCVGU CPF RTQIPQUVKE UKIPKHKECPEG QH CPIKPC
FWTKPI FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ KP RCVKGPVU YKVJQWV KPFWEKDNG YCNN OQVKQP
CDPQTOCNKVKGUKUGXCNWCVGFKPRCVKGPVUFWTKPI[GCTHQNNQYWR
+P%JCRVGTRTGFKEVKQPQHECTFKCEFGCVJJCTFECTFKCEGXGPVUCPFCNNECWUGOQTVCNKV[D[
FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ YCU GXCNWCVGF KP  RCVKGPVU YKVJ C JKIJ RTGVGUV
RTQDCDKNKV[ QH EQTQPCT[ CTVGT[ FKUGCUG FWTKPI C [GCT HQNNQYWR #EEQTFKPI VQ VJG $C[GUŏ
VJGQTGO C PQTOCN UVTGUU VGUV KP VJGUG RCVKGPVU FQGU QPN[ OQFGUVN[ TGFWEG VJG RQUVVGUV
RTQDCDKNKV[QHEQTQPCT[CTVGT[FKUGCUG6JGTGHQTGKVKUPQVMPQYPYJGVJGTRCVKGPVUYKVJJKIJ
RTGVGUVRTQDCDKNKV[QHEQTQPCT[CTVGT[FKUGCUGYQWNFDGEQPUKFGTGFC NQYTKUMRQRWNCVKQP KH
VJG[JCFCPQTOCNUVTGUUGEJQECTFKQITCO
%JCRVGT  KU COGVCCPCN[UKU GXCNWCVKPI VJG CEEWTCE[ QH PQPKPXCUKXG VGEJPKSWGU HQT
FKCIPQUKU QH EQTQPCT[ CTVGT[ FKUGCUG CPF RTGFKEVKQP QH ECTFKCE GXGPVU KP RCVKGPVU YKVJ
RGTOCPGPVNGHVDWPFNGDTWPEJDNQEMQPTGUVKPIGNGEVTQECTFKQITCO0QPKPXCUKXGGXCNWCVKQPQH
EQTQPCT[ CTVGT[ FKUGCUG KP VJGUG RCVKGPVU JCU UGXGTCN NKOKVCVKQPU UKPEG RTGGZKUVGPV
TGRQNCTK\CVKQP CDPQTOCNKVKGU FWG VQ VJG CNVGTGF GZEKVCVKQP CEVKXKV[ YKVJ VJG EQPUGSWGPV
CU[PEJTQPQWU XGPVTKEWNCT EQPVTCEVKQP CPF O[QECTFKCN RGTHWUKQP CDPQTOCNKVKGU JCORGT CPF
NKOKV VJG FKCIPQUVKE CEEWTCE[ QH CNN VJG CXCKNCDNG PQPKPXCUKXG VGEJPKSWGU CU GZGTEKUG
GNGEVTQECTFKQITCOGEJQECTFKQITCRJ[CPFO[QECTFKCNRGTHWUKQPKOCIKPI#RQQNGFCPCN[UKUQH
VJGRTGUGPVN[RWDNKUJGFFCVCQPVJGCHQTGOGPVKQPGFPQPKPXCUKXGVGEJPKSWGUYCURGTHQTOGF
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5WDUGSWGPVN[ KP%JCRVGT  VJG TQNG QH FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ HQT VJG
RTQIPQUVKEUVTCVKHKECVKQPQHRCVKGPVUYKVJTKIJVDWPFNGDTCPEJDNQEMKUGXCNWCVGF#VQVCNQH
RCVKGPVUYGTGHQNNQYGFWRHQT[GCTU
%JCRVGT  TGRQTVU QP RTQIPQUVKE XCNWG QH RCEKPI UVTGUU GEJQECTFKQITCRJ[ KP 
RCVKGPVUYKVJCRGTOCPGPVTKIJVXGPVTKEWNCTRCEGOCMGTFWTKPI[GCTUQHHQNNQYWR2CEKPI
UVTGUUGEJQECTFKQITCRJ[JCUDGGPUJQYPVQJCXGCIQQFFKCIPQUVKECEEWTCE[HQTFGVGEVKQPQH
EQTQPCT[CTVGT[FKUGCUGJQYGXGTKVURTQIPQUVKEXCNWGJCUPGXGTDGGPGXCNWCVGFUKPEGPQY
+P%JCRVGTVJGRTQIPQUVKEUKIPKHKECPEGQHNGHVCPVGTKQTJGOKDNQEMKPRCVKGPVU
YKVJ UWURGEVGF EQTQPCT[ CTVGT[ FKUGCUG TGHGTTGF HQT FQDWVCOKPG UVTGUU GEJQECTFKQITCRJ[ KU
KPXGUVKICVGF


2CTV2TGFKEVKQPQHNGHVXGPVTKEWNCTHWPEVKQP
 
6YQFKOGPUKQPCNGEJQECTFKQITCRJ[
CVTGUVQTFWTKPINQYFQUGFQDWVCOKPGKPHWUKQP
KU CP GUVCDNKUJGF VGEJPKSWG VQ SWCPVKH[ TGIKQPCN CPF INQDCN O[QECTFKCN F[UHWPEVKQP 6JG
CDKNKV[ VQ CUUGUU GXGPOKPQT EJCPIG KP TGIKQPCN NGHV XGPVTKEWNCT HWPEVKQP JCU DGGP TGEGPVN[
TGFGHKPGF D[ VJG KPVTQFWEVKQP QH VKUUWG &QRRNGT KOCIKPI KP VJG ENKPKECN UGVVKPI 
 
&KHHGTGPVN[ O[QECTFKCN RGTHWUKQP GEJQECTFKQITCRJ[ GXCNWCVKPI OKETQXCUEWNCT HWPEVKQP
CNNQYUVQRTGFKEVTGEQXGT[QHHWPEVKQPKPRCVKGPVUYKVJCEWVGO[QECTFKCNKPHCTEVKQPWPFGTIQKPI
OGFKECNQTOGEJCPKECNTGXCUEWNCTK\CVKQP

+P %JCRVGT  VJG TQNG QH O[QECTFKCN XKCDKNKV[ CUUGUUGF D[ NQY FQUG FQDWVCOKPG
KPHWUKQPKPVJGNGHVXGPVTKEWNCTTGOQFGNKPIRTQEGUUCHVGTTGXCUEWNCTK\CVKQPKUCUUGUUGFKPCNCTIG
EQJQTV QH RCVKGPVU 
P YKVJ KUEJGOKE ECTFKQO[QRCVJ[ +P CFFKVKQP NQPIVGTO ENKPKECN
HQNNQYWRYCURGTHQTOGF
%JCRVGTTGRQTVUUJQTVCPFNQPIVGTOTGIKQPCNCPFINQDCNNGHVXGPVTKEWNCTHWPEVKQPCN
GHHGEVU QH RGTEWVCPGQWUN[ VTCPURNCPVGF UMGNGVCN O[QDNCUVU KP RCVKGPVU YKVJ FKNCVGF KUEJGOKE
ECTFKQO[QRCVJ[ .GHV XGPVTKEWNCT HWPEVKQP KU GXCNWCVGF KP  RCVKGPVU D[ VYQFKOGPUKQPCN
GEJQECTFKQITCRJ[ CPF VKUUWG &QRRNGT KOCIKPI CV TGUV CPF FWTKPI NQY FQUG FQDWVCOKPG
KPHWUKQPVQCUUGUUEQPVTCEVKNGTGUGTXG0GY;QTM*GCTV#UUQEKCVKQP
0;*#HWPEVKQPCNENCUU
CPFENKPKECNHQNNQYWRCVOQPVJUCTGCNUQKPENWFGF
+P %JCRVGT  CP CFFKVKQPCN XCNWG QH VJG YCNN VJKEMPGUU EQORCTGF VQ O[QECTFKCN
RGTHWUKQPGEJQECTFKQITCRJ[KUGXCNWCVGFVQRTGFKEVTGEQXGT[QHTGIKQPCNECTFKCEHWPEVKQP6JG
UVWF[ RQRWNCVKQP EQORTKUGU  RCVKGPVU YKVJ CEWVG O[QECTFKCN KPHCTEVKQP WPFGTIQKPI
RGTEWVCPGQWURTKOCT[EQTQPCT[KPVGTXGPVKQP4GEQXGT[QHO[QECTFKCNHWPEVKQPKUGXCNWCVGFCV
VYQOQPVJUHQNNQYWR
+P %JCRVGT  O[QECTFKCN EQPVTCUV GEJQECTFKQITCRJ[ KU EQORCTGF YKVJ VJG IQNF
UVCPFCTFVGEJPKSWGOCIPGVKETGUQPCPEGKOCIKPIVQRTGFKEVTGEQXGT[QHTGIKQPCNCPFINQDCNNGHV
XGPVTKEWNCT HWPEVKQP KP VJG UGVVKPI QH CEWVG O[QECTFKCN KPHCTEVKQP $QVJ VGEJPKSWGU CTG
RGTHQTOGFCHVGTRTKOCT[RGTEWVCPGQWUCPIKQRNCUV[KPRCVKGPVU
+P%JCRVGTVJGQPUGVQHFKNCVGFJ[RQMKPGVKEGXQNWVKQPCPFECTFKQXCUEWNCTGXGPVUKP
RCVKGPVUYKVJJ[RGTVTQRJKEECTFKQO[QRCVJ[KUGXCNWCVGFD[TGUVKPI&GEJQECTFKQITCRJ[
%JCRVGT  GXCNWCVGU VJG TQNG QH KPVTCECTFKCE GEJQECTFKQITCRJ[ FWTKPI RGTEWVCPGQWU
UGRVCNO[QECTFKCNCDNCVKQPKPRCVKGPVUYKVJQDUVTWEVKXGJ[RGTVQRJKEECTFKQO[QRCVJ[

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Introduction 
 
Although myocardial perfusion imaging remains the most widely used non-invasive 
imaging tool for the diagnosis of coronary artery disease (CAD), stress echocardiography is 
increasingly used over the last few decades. Recent studies have proven the clinical 
usefulness in the evaluation of CAD in various populations of patients with known or 
suspected CAD. Therefore, stress echocardiography became an accepted technology for 
evaluation of CAD in common practice. The technique allows assessment of baseline cardiac 
function and direct evaluation of inducible myocardial ischemia by imaging reversible left 
ventricular dysfunction. The diagnosis of myocardial ischemia by stress echocardiography 
relies upon the detection of new or worsening wall motion abnormalities with stress (1). Wall 
motion abnormalities occur earlier than ECG changes and angina in the ischemic cascade and 
therefore, provide a particular advantage in patients with submaximal stress test in whom the 
duration and or the severity of ischemia may not be enough to induce ECG changes or angina. 
Stress testing can be achieved using dynamic exercise or pharmacologic alternatives. Exercise 
echocardiography is the preferred method in patients who are able to exercise, because 
exercise capacity and hemodynamic data provide useful prognostic information. In patients 
with limited exercise capacity, pharmacologic stress testing is a feasible alternative (1). 
Pharmacological stress testing is accomplished by using agents that increase myocardial 
oxygen demand (such as dobutamine) or induce coronary arterial vasodilation to increase 
myocardial blood flow (such as adenosine or dipyridamole). In patients who fail to achieve 
the target heart rate, the addition of atropine increases heart rate by its vagolytic effects. In 
patients who can not achieve the target heart rate with dobutamine-atropine or have a 
contraindication for dobutamine stress test, transesophageal atrial pacing represent a feasible 
alternative.  
Furthermore, stress echocardiography has been proposed for risk stratification in 
different clinical setting, adding important prognostic information. Prognostic parameters of 
importance are resting left ventricular function, myocardial viability, stress-induced ischemia, 
vascular extent of wall motion abnormalities, and changes of end systolic volume and ejection 
fraction with stress. A large number of studies have shown stress echocardiography efficacy 
in predicting long-term cardiac events in a heterogeneous population (2-8). Additional 
information by this technique have been also reported in specific clinical settings. In patients 
with myocardial infarction the identification of residual viable tissue and myocardial ischemia 
can predict improvement of function after revascularization. The prognostic value has also 
been demonstrated in special patients subsets including patients undergoing major vascular or 
non vascular surgery, elderly, women, diabetes mellitus, systemic hypertension and patients 
with previous myocardial revascularization. The proper selection of management strategies in 
patients with suspected or known coronary artery disease should be based on an accurate 
estimation of the risk of adverse events. Recognition of patients at high risk of cardiac events 
is an essential step in guiding the use of invasive procedures and selecting patients who are 
most likely to benefit and thus avoiding the risk and cost of interventions in low risk patients. 
Patients with normal stress echocardiogram had a low cardiac event rate (1-2%) and can be 
exempted for invasive procedures. 
This review attempts to define the role of stress echocardiography for prognostication in 
coronary artery disease, pointing out the ability of this technique in identifying low-risk and 
high-risk subsets among patients with known or suspected CAD and thus guide patient 
management decisions. 
 
Outcome after a normal stress echocardiogram. Individuals with normal stress 
(exercise, dipyridamole or dobutamine) echocardiography, defined as absence of wall motion 
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abnormalities at rest and during stress have a very low event rate, which is equivalent to age 
matched population (7,9-11). Patients with resting left ventricular dysfunction but no 
inducible myocardial ischemia have an intermediate risk, whereas patients with new wall 
motion abnormalities are at increased risk for cardiac events and mortality (with an annual 
hard cardiac event rate reported up to 5.5%). In a meta-analysis of published data on the 
prognostic outcome after a normal stress echocardiogram, the overall annual hard cardiac 
event rate (cardiac death or nonfatal myocardial infarction) reported in 27 stress 
echocardiography studies (5 dipyridamole, 13 dobutamine, 9 exercise) involving 6,799 
patients (mean age 58 years, 47% men, 37% with hypertension, 10% with diabetes) with a 
mean follow-up period of 27 months was 0.9%. Patients with normal exercise 
echocardiography had a significantly better prognosis (p< 0.0001) than patients with normal 
pharmacological stress echocardiography (12). This may be explained by the higher risk 
status of patients who are unable to perform exercise stress test or possibly, by a difference in 
the sensitivity of exercise versus pharmacologic stress test for the diagnosis of CAD. 
 
Risk stratification after acute myocardial infarction. Risk stratification of patients 
who survived an acute myocardial infarction (MI) aims at identifying patients whose outcome 
can be improved through invasive procedures and coronary intervention, and patients who can 
be treated medically. Resting left ventricular function after acute MI is the major determinant 
of prognosis (13,14). Low-dose dobutamine echocardiography can identify the presence of 
stunned myocardium in the first week after reperfusion by observing contractile reserve in 
dysfunctional myocardial segments. This pattern that has been shown to predict both 
functional recovery and outcome (15,16). Pharmacological stress echocardiography can detect 
the presence, the severity and the extent of residual myocardial ischemia, which has important 
prognostic implications (17-30). The prognostic significance of myocardial viability in 
patients with previous MI detected by dobutamine stress echocardiography is controversial. In 
patients with an uncomplicated MI it has been shown to be associated with an increased risk 
of unstable angina but not hard events (21,24), whereas in patients with left ventricular 
dysfunction early after MI was shown to be associated with a higher probability of survival 
(18).  
 
Risk stratification in patients with old myocardial infarction. In patients with 
chronic ischemic left ventricular dysfunction stress echocardiography has a major role in 
detecting viable myocardium and myocardial ischemia. Patients with a substantial amount of 
dysfunctional but viable myocardium (extending to ≥25% of the left ventricle) have been 
shown to have a high likelihood to improve function and a better prognosis after myocardial 
revascularization compared to patients with an extensive myocardial scar and no contractile 
reserve (31-43). It has also been shown that the presence of viable or ischemic myocardium is 
associated with an adverse prognosis (44). Accordingly, assessment of viability can guide a 
tailored therapeutic strategy, where patients with viable myocardium should be considered for 
early revascularization (38). A substantial amount of viable myocardium detected by low does 
dobutamine echocardiography has been shown to prevent ongoing remodeling after 
revascularization and to be associated with persistent improvement of heart failure symptoms 
and a lower incidence of cardiac events (35). Combination of the LV size and 
presence/absence of viability provide a better risk stratification in these patients. In particular, 
despite the presence of viable myocardium, patients with left ventricular remodeling (mainly a 
large end-systolic volume) may not improve in left ventricular ejection fraction and have a 
worse long-term prognosis as compared with patients with a smaller left ventricular end-
systolic volume (45).  
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Evaluation of myocardial ischemia is important in the decision to revascularize 
patients with chronic left ventricular dysfunction, since improvement in left ventricular 
ejection fraction is likely to occur when a substantial amount of viable and/or ischemic 
myocardium is present (31,33). Studies of the association between myocardial ischemia and 
long-term outcome yielded discordant findings. Smart et al. (46), reported that inducible 
ischemia during dobutamine stress echocardiography was the major determinant of outcome 
in patients with chronic left ventricular dysfunction and independent of clinical data and left 
ventricular function. Conversely, Sawada et al. (47), demonstrated that the presence of 
viability was independently associated with a higher risk of cardiac death, whereas ischemia 
did not add significant prognostic value. 
 
Elderly. Demographic studies have shown that the elderly constitutes a rapidly 
expanding segment of our population, expected to constitute 20% in the next few decades. 
CAD is the leading cause of death and disability in the elderly and its clinical manifestations 
are more severe in patients older than 65 years (48,49). Thus, the identification of patients at 
high risk for coronary events who could benefit of tailored medical therapy and aggressive 
risk factors management or eventually early myocardial revascularization appears particularly 
important (50). Exercise echocardiography has been demonstrated as a useful non-invasive 
tool for evaluation of CAD in the elderly (51). The addition of exercise echocardiographic 
variables to clinical and exercise ECG data improved prediction of cardiac events. The most 
powerful exercise echocardiographic parameters were especially the change in left ventricular 
end-systolic volume with exercise and the exercise ejection fraction. However, exercise stress 
testing is not feasible in many elderly patients (52), manly because of deconditioning or 
neurologic, respiratory, peripheral vascular, or orthopaedic limitations, so that 
pharmacological stress echocardiography can be a feasible alternative in these patients 
(2,4,53). Published reports with dipyridamole, dobutamine or adenosine stress have 
documented the independent and additional value of pharmacological stress to predict cardiac 
events in the elderly during short term follow up (54-58). The long-term prognostic value of 
dobutamine stress echocardiography for prediction of all cause mortality and hard cardiac 
events has been recently studied in 1434 patients ≥ 65 years (Biagini E et al. Long-term 
Prediction of Mortality in the Elderly by Dobutamine Stress Echocardiography. The Journal 
of Gerontology: Medical Sciences, in press 2005). Patients with both resting and dobutamine 
induced wall motion abnormalities were at highest risk of cardiac events with an annual rate 
of 8%. The presence and the extent of ischemia during DSE provided incremental information 
over clinical and resting echocardiographic data for the prediction of both hard cardiac events 
and all cause mortality. 
 
Women. Despite significant advances in the diagnosis and treatment of coronary 
artery disease (CAD) in the last decades, it remains the leading cause of death in women in 
industrialized country. With the aging of the population, the overall number of cardiac deaths 
has recently increased, and the trend is expected to continue, especially in women due to a 
longer life expectancy than men (59,60). Diagnosis of CAD in women is challenging due to 
the differences in clinical presentation as well as to the diminished accuracy of some non-
invasive diagnostic techniques and the lower prevalence of the disease (61,62). 
Pharmacologic stress echocardiography, with dipyridamole or dobutamine, has been reported 
as a valuable diagnostic and prognostic tool in women, with a reported higher specificity and 
sensitivity in detecting CAD compared to exercise electrocardiography and myocardial 
perfusion imaging (63-72). Moreover, the prognostic value of stress echocardiography has 
been shown to be maintained in women as well as in men (5,73-75), with a positive predictive 
value higher compared to exercise electrocardiography (76), consistent with myocardial 
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perfusion imaging studies (77-80). A recent study (Biagini E et al. Comparison of All-Cause 
Mortality in Women with Known or Suspected Coronary Artery Disease Referred for 
Dobutamine Stress Echocardiography with Normal vs. Abnormal Test Results. Am J Cardiol, 
in press 2005), has shown that DSE provides independent prognostic information for 
prediction of all cause mortality during long-term follow-up in 1105 women with known or 
suspected CAD. Both resting and dobutamine induced wall motion abnormalities were 
associated with increased risk of death in women with and without history of CAD. 
Additionally, the effects of gender on long-term prognosis of patients undergoing 
dobutamine stress echocardiography was investigated in 2276 men and 1105 women with 
known or suspected coronary artery disease, during a mean follow-up of 7 years (6). 
Dobutamine stress echocardiography provided independent prognostic information for 
prediction of cardiac events in both genders. The prognosis after a normal dobutamine stress 
echocardiography was more favorable in women than in men, after correction for clinical 
variables. In patients with a normal DSE the annual hard cardiac event rate during 7 years of 
follow-up was 2.5% in men and 1.2% in women (p<0.0001). There was no difference in 
annual hard cardiac event rate between men and women with rest wall motion abnormalities 
(2.9% vs 2.1%, p=0.1) or men and women with both rest and new wall motion abnormalities 
(5.9% vs 4.6%, p=0.3). The outcome of patients with abnormal dobutamine stress 
echocardiography was related to severity of left ventricular dysfunction and ischemia on 
dobutamine stress echocardiography, but not related to gender after adjusting for other 
variables.  
 
Patients with diabetes mellitus. Diabetes mellitus is a major risk factor for CAD and 
its complications. Diabetic patients have higher cardiac event rates, more silent ischemia, and 
a higher morbidity after acute myocardial infarction than nondiabetic patients (81). Therefore, 
it is clinically important to determine the risk of cardiac events in patients with diabetes in 
order to select the appropriate management strategy. The use of stress echocardiographic 
results to plan further management may be confounded by the propensity to develop resting 
wall motion abnormalities in the absence of previous infarction, the occurrence of 
microvascular ischemia and the accelerated rate of progression of CAD that may limit the 
long term negative predictive value of a normal stress echocardiographic study in diabetic 
patients. Several techniques have been proposed for the prognostic stratification of diabetic 
patients, such as exercise stress testing, in conjunction with radionuclide scintigraphy (82-84) 
or echocardiography (85-88). However, many diabetic patients are unable to undergo an 
exercise stress test due to the higher prevalence of stroke, peripheral vascular disease, and 
neuropathy. Such patients generally represent a higher risk population than patients who are 
able to undergo exercise stress testing, and therefore, pharmacologic stress testing may predict 
a greater number of cardiac events in these patients (89, 90). 
 
Patients with systemic hypertension. Detection of CAD and identification of patients 
who are at high risk of mortality and cardiac events in patients with hypertension is 
particularly relevant since systemic hypertension is strongly associated with CAD (91). Non-
invasive evaluation of CAD in patients with hypertension by exercise electrocardiography is 
limited by the low specificity due to the presence of resting electrocardiographic 
abnormalities (92-95). Stress echocardiography and myocardial perfusion scintigraphy have 
been shown to be accurate techniques for the diagnosis of CAD, with some studies reporting a 
higher diagnostic specificity for stress echocardiography (96, 97). Both techniques have also 
been shown to provide prognostic information for cardiac death  (98-100) and cardiac events 
(76-78) in patients with hypertension (96, 98, 99), as well as specifically in patients with left 
ventricular hypertrophy (97). In the report of Marwick et al. (96), stress echocardiography 
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was shown to provide incremental information for the prediction of cardiac mortality rate. In 
patients who underwent exercise echocardiography, cardiac death was predicted by ischemia, 
whereas in patients who underwent DSE it was predicted by any stress echocardiographic 
abnormality. Elhendy et al. (101), reported that left ventricular ejection fraction response to 
exercise was an independent  predictor of mortality, incremental to clinical data, left 
ventricular mass index and resting left ventricular function among patients with left 
ventricular hypertrophy. The study by Sozzi et al (102-107), showed an incremental value of 
DSE for  risk stratification of patients who have hypertension after adjustment for the left 
ventricular mass index, that was also predictive of mortality rate and cardiac events. 
Therefore, another advantage of stress echocardiography is the ability to assess both left 
ventricular function and the left ventricular mass index in addition to myocardial ischemia. 
Patients with multivessel distribution of wall motion abnormalities have the highest risk and 
therefore should represent a target group of patients in whom invasive strategies should be 
implemented. 
 
Patients with normal left ventricular function. In patients with CAD a normal left 
ventricular systolic function is a powerful determinant of a good prognosis (108). However, 
inducible myocardial ischemia in these patients has been shown to be independently 
associated with increased risk of cardiac events and all cause mortality (10, 11, 109). 
Prognostic studies focused on patients with normal left ventricular ejection fraction by stress 
echocardiography are scarce (9-11), however various studies have demonstrated the 
prognostic value of myocardial ischemia during stress echocardiography in a heterogeneous 
population with and without left ventricular dysfunction (2,3, 5-8, 110).  
 
Resting ECG abnormalities. Patients with conduction defects on resting 
electrocardiogram, such as left or right bundle branch block (LBBB or RBBB) and patients 
with a permanent right ventricular pacemaker, represent a challenging subgroup for non-
invasive detection of CAD. In fact, not only exercise ECG have a reduced diagnostic accuracy 
due to the pre-existent repolarization abnormalities (111-113), but also myocardial perfusion 
imaging (114-116) have a limited diagnostic value due to the wall motion and perfusion 
abnormalities related to the altered excitation, in particular in patients with LBBB or a 
permanent pacemaker. However, detection of CAD and risk stratification for future cardiac 
events in these patients is particularly important since the presence LBBB or RBBB are 
associated with cardiovascular disease and adverse outcome, particularly in patients with 
known CAD or after myocardial infarction. Similarly, CAD may concomitantly exist in 
patients with pacemaker or may be the underlying cause of conduction. Stress 
echocardiography has been shown to have a good diagnostic accuracy in these patients groups 
(117, 118), showing a higher specificity compared to perfusion imaging in patients with 
LBBB (119-122), and an excellent diagnostic accuracy in patients with RBBB. Moreover, 
multiple studies have recently shown an efficient prognostic stratification by stress 
echocardiography in patients with LBBB or RBBB (123), addictive to clinical and resting 
echocardiographic variables. A recent report from our group (Biagini E et al. Long-term 
Prognositc Value of Pacing Stress Echocardiography. Eur J Echocardiogr. 2004;5 
(Suppl.1):S246) showed that pacing stress echocardiography in patients with a permanent 
right ventricular pacemaker can provide independent information for prediction of cardiac 
death and all cause mortality. 
 
Risk stratification in patients who undergo major vascular surgery. Patients 
undergoing major vascular surgery are at increased risk for perioperative and long-term 
cardiac complications. Despite recent advances in perioperative and long-term care, the 30-
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day cardiac death of major vascular surgery varies between 3-6%, and the cardiac event rate 
during long-term follow-up between 30-40% (79-81). The incidence of perioperative and late 
cardiac complications in these patients is associated with the prevalence of CAD (127-133). 
Thirty-six percent of patients undergoing abdominal aortic aneurysm repair and in about 28% 
of patients undergoing infrainguinal revascularization have severe CAD, and only 6% of all 
vascular patients have normal coronary artery. Cardiac risk factors and noninvasive diagnostic 
tests for CAD may help to identify high-risk patients before major vascular surgery. 
Subsequent pharmacological therapy may be utilized in these high-risk individuals in order to 
lower their risk during and after vascular surgery. Thus, preoperative identification of high-
risk patients, including perioperative cardiac risk assessment and strategies to reduce this risk 
in particular, has become crucial. Pharmacological stress echocardiography with either 
dipirydamole or dobutamine, have been shown to play an important role for the assessment of 
perioperative  (4, 124, 134-139) and late cardiac risk (140) in patients scheduled for major 
vascular surgery, particularly in those with an intermediate to high risk according to clinical 
variables. The documentation of marked induced myocardial ischemia has a strong 
independent prognostic value to identify patients at high risk of coronary complications who 
could benefit of early revascularization before peripheral vascular surgery. Conversely, the 
absence of ischemia has been shown to be powerfully associated with a very low incidence of 
cardiac events allowing a safe surgical procedure (negative predictive value between 90 and 
100%). In a recent meta-analysis , the comparative performance of six non-invasive 
techniques used for preoperative risk stratification in patients selected for vascular surgery 
was evaluated. Pharmacological stress tests showed a higher overall sensitivity and specificity 
than the other tests. In particular, dobutamine stress echocardiography showed a similar 
sensitivity to myocardial perfusion scintigraphy but a higher specificity and a better overall 
predictive performance. Dipyridamole stress echocardiography had a lower sensitivity and a 
higher specificity than myocardial perfusion scintigraphy. However, further conclusions about 
dipyridamole stress echocardiography are limited by the reported differences between studies 
and the limited number of studies reported to date. A positive trend for dobutamine stress 
echocardiography towards better diagnostic performances than the other tests was evident, but 
this only reached significant difference in comparison with myocardial perfusion scintigraphy. 
Dobutamine stress echocardiography could be the favoured test in situations where there is a 
suspicion of valvular heart disease or left ventricular systolic dysfunction.  
 
Stress echocardiography after coronary revascularization. The role of exercise and 
pharmacologic stress testing in the diagnosis of restenosis after angioplasty and graft 
occlusion after CABG has been extensively studied (53). The main advantages of this 
technique are the ability to localize restenosis or graft occlusion and to detect myocardial 
viability in resting dysfunctional regions. Scarce data are available regarding the prognostic 
value of the technique after revascularization (141-144). Some reports have shown as a 
positive stress echocardiography test after coronary angioplasty identifies patients at with a 
high risk for recurrence of angina symptoms (143-144). More recently, Bountioukos et al. 
(141), studied the prognostic value of DSE in 331 patients with previous percutaneous or 
surgical coronary revascularisation. During a mean follow up of 24 months, 37 (13%) patients 
died and 89 (30%) had at least one cardiac event (21 cardiac deaths, 11 non-fatal myocardial 
infarctions, and 68 late revascularizations). In multivariate analysis of clinical data, 
independent predictors of late cardiac events were hypertension and congestive heart failure. 
Ischemia on DSE was incrementally predictive of cardiac events. Arruda et al. (82), studied 
the value of exercise echocardiography in predicting outcome of 718 patients who were 
studied at a mean of 5.7 years after CABG. During a median follow-up of 2.9 years, cardiac 
events included cardiac death in 36 patients and nonfatal myocardial infarction in 40 patients. 
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The addition of the exercise echocardiographic variables, abnormal left ventricular end-
systolic volume response and exercise ejection fraction to the clinical, resting 
echocardiographic and exercise electrocardiographic model provided incremental information 
in predicting cardiac events.  
 
Summary and Conclusions 
 
Stress echocardiography is a useful technique for the risk stratification of patients with 
known or suspected coronary artery disease. In particular, patients with resting ECG 
abnormalities or reduced exercise capacity are candidates for stress echocardiography due to 
the low feasibility of exercise ECG under these circumstances. Patients with normal stress 
echocardiography have a very low cardiac event rate and in most instances do not require 
further diagnostic evaluation. Patients with extensive abnormalities in multi-vascular 
distribution are at a high risk of death and myocardial infarction. In these patients, coronary 
angiography and subsequent myocardial revascularization may be justified, with additional 
consideration of symptomatic status, functional capacity and resting left ventricular function. 
Evaluation of myocardial viability has a potential impact on the outcome after 
revascularization by selecting patients with significant left ventricular dysfunction in whom 
revascularization will improve myocardial function, exercise tolerance and survival. The 
development of new techniques for improved imaging quality during stress testing is expected 
to have a favorable impact on the utility of stress echocardiography in guiding management of 
patients with known or suspected coronary artery disease.  
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Abstract 
 
 Background. Dobutamine stress echocardiography (DSE) was shown to provide 
incremental prognostic information. However, its role in the prediction of mortality in the 
elderly is not well defined. We assessed the value of DSE in the prediction of mortality and 
hard cardiac events during long-term follow-up in patients older than 65 years. 
Methods. We studied 1434 patients >65 years (mean age 72 ± 3 years) who 
underwent DSE for evaluation of coronary artery disease. Ischemia was defined as new or 
worsening wall motion abnormalities. Follow-up events were total mortality and hard cardiac 
events (cardiac mortality and nonfatal myocardial infarction). Multivariable Cox regression 
analysis was used to identify the independent predictors of follow-up events. 
Results. Ischemia was detected in 675 (47%) patients. Five hundred-six patients 
(35%) had a normal study and 253 (18%) fixed wall motion abnormalities. During a mean 
follow-up of 6.5 years, 532 (37%) deaths occurred, of which 249 (17%) were due to cardiac 
causes. A nonfatal myocardial infarction occurred in 45 (3%) patients. Independent predictors 
of all cause mortality in a multivariate analysis model were age (HR:1.06 [1.05-1.08]), male 
gender (HR:1.5 [1.2-1.8]), hypertension (HR:1.2 [1.1-1.4]), smoking (HR:1.3 [1.1-1.6]), 
diabetes (HR:1.4 [1.1-1.8]), rest wall motion abnormalities (HR:1.07 [1.06-1.09]), and 
ischemia (HR:1.3 [1.1-1.6]). Independent predictors of hard cardiac events were age (HR:1.07 
[1.05-1.09]), male gender (HR:1.3 [1.1-1.7]), smoking (HR:1.3 [1.1-1.6]), diabetes (HR:1.6 
[1.2-2.2]), rest wall motion abnormalities (HR:1.13 [1.12-1.16]), and ischemia (HR:2.1 [1.5-
2.8]). 
Conclusions. DSE provides independent prognostic information to predict all cause 
mortality and hard cardiac events in elderly patients. 
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Introduction 
 
 
 Demographic studies have shown that the elderly constitutes a rapidly expanding 
segment of our population. Coronary artery disease (CAD) is a major cause of morbidity and 
mortality in the elderly and becomes more prevalent with increasing age (1, 2). Technical 
advances in myocardial revascularization procedures have recently contributed to a high 
success rate of coronary artery bypass grafting and percutaneous coronary intervention in the 
elderly (3-6) with an improved clinical outcome (7). Exercise echocardiography has been 
demonstrated as a useful non-invasive tool for evaluation of CAD in the elderly (8). However, 
exercise stress testing is not feasible in many elderly patients (9), mostly because of non 
cardiac factors, such as arthritis, obstructive lung disease, claudication and poor physical 
conditioning. Dobutamine stress echocardiography (DSE) is a feasible alternative to exercise 
in these patients (10-12). Published studies of the prognostic value of DSE in the elderly are 
limited by inclusion of small number of patients, short-term follow-up and the use of 
composite end-points. Additionally, there are currently no data to suggest a role of DSE in the 
prediction of all cause mortality in the elderly. Accordingly, the aim of this study was to 
assess the long-term value of DSE for prediction of all cause mortality and hard cardiac 
events in a large number of patients with known or suspected CAD who are >65 years old. 
 
 
Methods 
 
Patients. The study population was composed of 1606 consecutive patients >65 years 
old referred for DSE for the evaluation of suspected or known CAD at the Thoraxcenter, 
Rotterdam between January 1988 and January 2003, who were unable to perform an adequate 
exercise test. Follow-up was successful in 1590 patients (99%). A total of 156 (10%) patients 
underwent early coronary revascularization in the first 60 days after the DSE. These patients 
were excluded from the analysis, because referral to myocardial revascularization in the first 
60 days after stress testing tends to be based on the results of the test (13). Therefore, 1434 
patients represented the final population. The protocol was approved by the Hospital Ethics 
Committee. All patients gave informed consent before the test. A structured interview and 
review of records were conducted prior to the stress test to obtain clinical history and to 
determine cardiac risk factors. 
 
Dobutamine Stress Protocol. Low-high dose DSE (up to 40 µg/kg/min plus 2 mg 
atropine, if necessary) was performed according to a standard protocol as previously reported 
(12). Test end-points were achievement of target heart rate (85% of maximum age and gender 
predicted heart rate), maximal dose of dobutamine and atropine, extensive new wall motion 
abnormalities, >2 mV downsloping ST-segment depression measured 80 ms after the J point 
compared with baseline, hypertension (blood pressure >240/120 mmHg), a decrease in 
systolic blood pressure of >40 mmHg compared with at rest, significant arrhythmias, or any 
intolerable adverse effect considered to be the result of dobutamine or atropine. An 
intravenous β-blocker (metoprolol 1 to 5 mg) was available to reverse the adverse effects of 
dobutamine/atropine if these did not reverse spontaneously. 
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Echocardiographic Imaging and Interpretation. Two-dimensional 
echocardiographic images were acquired at rest, during dobutamine stress, and recovery. The 
echocardiograms were recorded in a quad-screen format. Two experienced observers, 
unaware of the clinical data, scored the echocardiograms using a standard 16-segment model. 
In case of disagreement, a consensus decision was achieved by a third observer. Regional wall 
motion and systolic wall thickening were scored on a 5-point scale (1= normal, 2= mild 
hypokinesia, 3= severe hypokinesia, 4= akinesia, 5= dyskinesia). Ischemia was defined as 
new or worsened wall motion abnormalities during stress indicated by an increase of wall 
motion score ≥1 grade in ≥1 segment. A biphasic response in an akinetic or severely 
hypokinetic segment was considered as an ischemic response. Ischemia was not considered to 
be present when akinetic segments at rest became dyskinetic during stress. For each patient, a 
wall motion score index (WMSI) was calculated by dividing the sum of scores of visualized 
segments by the total number of these segments. 
 
Follow-up. Follow-up data collection was performed by contacting the patients, 
general practitioners and by review of hospital records. The date of the last review or 
consultation was used to calculate follow-up time. Follow-up events noted were all causes of 
mortality and hard cardiac events (nonfatal myocardial infarction and cardiac death). 
Revascularization procedures were also noted. Cardiac death was defined as a death caused 
by acute myocardial infarction, significant cardiac arrhythmias, or refractory congestive heart 
failure. Sudden death occurring without another explanation was considered as cardiac death. 
Nonfatal myocardial infarction was defined by standard criteria of chest pain, cardiac 
enzymes and electrocardiographic changes. 
 
Statistical Analysis. Continuous data were expressed as mean value ± SD. The 
Student’s t test was used to analyze continuous data. Differences between proportions were 
compared using the Chi-square test. Univariate and multivariate Cox proportional hazard 
regression models (BMDP Statistical Software Inc., Los Angeles, California, USA) were used 
to identify independent predictors of end-points of interest (14). Variables were selected in a 
stepwise forward selection manner with entry and retention set at a significance level of 0.05. 
The risk of a variable was expressed as a hazard ratio with a corresponding 95% confidence 
interval. The incremental value of DSE over the clinical variables in the prediction of events 
was determined according to two models. In model I, the variable entered was the presence of 
new wall motion abnormalities during peak stress; in model II, the number of segments with 
new wall motion abnormalities at peak of DSE (extent of ischemia) was entered as a 
continuous variable. The probability of survival was calculated using the Kaplan-Meier 
method, and survival curves were compared using the log-rank test. A p value <0.05 was 
considered statistically significant. 
 
 
Results 
 
 Patient Characteristics and Hemodynamic Response. The mean age was 72 ± 3 
years, 965 (67%) were men, and 440 (31%) were over 75 years (mean 79 ± 3.2 years). 
Clinical characteristics are presented in Table 1.  
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Data are presented as number (%) of patients or mean value ± SD. 
 
 
Dobutamine stress test data are presented in Table 2. Heart rate increased significantly 
from rest to peak stress. The mean maximal dobutamine dose was 35 ± 8 µg/kg/min. Atropine 
was used in 361 (25%) patients. Side effects were non-sustained ventricular tachycardia (<10 
complexes) in 59 patients (4%), atrial fibrillation in 28 patients (2%), severe hypotension 
(decrease in systolic blood pressure >40 mm Hg compared to baseline) in 10 (0.7%) patients, 
and ventricular fibrillation in 2 (0.1%). Defibrillation was successful and no ECG or cardiac 
enzymatic changes suggestive of myocardial infarction were observed in these 2 patients. The 
test was terminated because of reaching the target heart rate in 1278 (89%) patients, maximal 
dose of dobutamine and atropine in 45 (3%) patients, ST-segment changes in 38 (3%) 
patients, minor symptoms in 30 (2%) patients, abnormal blood pressure in 15 (1%), 
arrhythmias in 14 (1%) and angina in 14 (1%) patients.  
 
 
 
Table 1. Clinical Characteristics in Patients with and without Hard Cardiac Events (Cardiac 
Death or Nonfatal Myocardial Infarction) 
 All Patients 
(n= 1434) 
Cardiac Events 
(n= 294) 
No Cardiac Events 
(n= 1140) 
P 
value 
Age (years) 73 ± 5 73 ± 5 72 ± 5 0.04 
Men 965 (67 %) 222 (75%) 743 (65%) 0.001 
Hypertension 481 (33%) 90 (31%) 391 (34%) 0.3 
Hypercholesterolemia 274 (19%) 50 (17%) 224 (20%) 0.3 
Smoking 356 (25%) 88 (30%) 268 (23%) 0.03 
Diabetes mellitus 151 (11%) 43 (15%) 108 (9%) 0.01 
History of heart failure 180 (12%) 67 (23%) 113 (10%) 0.0001 
Previous infarction 502 (35%) 148 (50%) 354 (31%) 0.0001 
β-blockers 455 (32%) 80 (27%) 375 (33%) 0.07 
Calcium channel blockers 366 (26%) 75 (26%) 291 (26%) 1 
Nitrates 401 (28%) 121 (41%) 280 (25%) 0.001 
Ace-inhibitors 382 (27%) 96 (33%) 286 (25%) 0.01 
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Table 2. Hemodynamic and Echocardiographic Data in Patients with and without Hard Cardiac 
Events 
 All Patients 
(n= 1434) 
Cardiac Events
(n= 294) 
No Cardiac 
Events 
(n= 1140) 
P 
value 
Heart rate at rest (beats/min) 71 ± 13 72 ± 13 71 ± 13 0.5 
Heart rate at peak (beats/min) 122 ± 19 121 ± 20 123 ± 17 0.04 
Rest systolic blood pressure (mmHg) 138 ± 25 136 ± 26 139 ± 25 0.06 
Peak systolic blood pressure (mmHg) 134 ± 29 131 ± 29 135 ± 30 0.06 
Rest rate pressure product  9934 ± 2503 9763±2392 9980±2675 0.2 
Peak rate pressure product  16775 ± 4254 16410±4280 16868±4203 0.1 
ST-segment depression, patients 348 (24%) 95 (32%) 253 (22%) 0.001 
Resting wall motion score index 1.27 ± 0.47 1.55 ± 0.61 1.20 ± 0.37 <0.0001 
Abnormal stress echocardiography, 
patients 
928 (65%) 239 (81%) 689 (60%) <0.0001 
New or worsening wall motion 
abnormalities, patients 
675 (47%) 202 (69%) 473 (41%) <0.0001 
Number of ischemic segments (n) 3.1 ± 4.7 4.9 ± 5.5 2.7 ± 4.3 <0.0001 
 
Data are presented as number (%) of patients or mean value ± SD. Legend: n= Number.  
 
 
Echocardiographic Data. Five hundred-six patients (35%) had a normal study, 253 
(18%) patients had fixed wall motion abnormality and 675 (47%) patients had ischemia (new 
or worsening wall motion abnormalities). Among patients with ischemia, 586 (41%) had 
resting wall motion abnormalities as well. Among patients with resting wall motion 
abnormalities, resting WMSI was lower in patients who had no inducible ischemia during 
DSE as compared to patients who had ischemia (1.39 ± 0.38 vs 1.96 ± 0.62, p<0.0001). 
 
Outcome. During a mean follow-up of 6.5 years (range 6 months-15 years), there 
were 532 (37%) deaths, of which 249 (17%) were attributed to cardiac causes. Forty-five 
(3%) patients had nonfatal myocardial infarction and 334 (9%) underwent late 
revascularization. Clinical, hemodynamic and echocardiographic data of patients with and 
without hard cardiac events are listed in Table 1 and 2. Patients with cardiac events had a 
higher incidence of ST-segment depression, a higher WMSI at rest and a higher incidence and 
extent of ischemia as compared to patients without events. 
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Predictive Value of Clinical Data and Test Results. Univariate and multivariate 
predictors of cardiac death/nonfatal myocardial infarction and all causes of mortality are 
shown in Table 3 and 4. Among clinical variables, age, male gender, smoking, and diabetes 
were multivariate independent predictors of cardiac death/nonfatal myocardial infarction and 
of all cause mortality. A history of hypertension was a predictor of all causes of mortality. 
The presence of rest wall motion abnormalities provided independent prognostic information 
for hard cardiac events and all cause mortality. Moreover, the presence and the extent of 
ischemia during DSE provided incremental information for both the end-points (Model I and 
II).  
Table 3. Univariate and multivariate Predictors of Hard Cardiac Events 
  Multivariate Analysis 
 Univariate Model I Model II 
Clinical characteristics    
  Age 1.05 (1.03-1.08) 1.07 (1.05-1.09) 1.05 (1.04-1.08) 
  Male sex 1.5 (1.2-1.9) 1.3 (1.1-1.7) 1.4 (1.1-1.9) 
  Smoking 1.3 (1.1-1.6) 1.3 (1.1-1.6) NS 
  Diabetes Mellitus  1.5 (1.1-1.9) 1.6 (1.2-2.2) 1.6 (1.2-2.3) 
  Previous myocardial infarction 1.9 (1.5-2.3) NS 1.3 (1.1-1.7) 
  History of heart failure 8.5 (0.8-94) NS NS 
Stress test results    
  Target heart rate  1.4 (1.1-1.8) 
  
  ST-segments changes 1.5 (1.2-1.8) NS NS 
DSE parameters    
  Abnormal segments at rest 1.13 (1.12-1.16) 1.09 (1.07-1.13) 1.06 (1.04-1.08) 
  New wall motion abnormalities 3.7 (2.8-4.7) 2.1 (1.5-2.8) 
 
  Number of ischemic segments 1.15 (1.13-1.18) 
 1.13 (1.11-1.16) 
Data are presented as risk ratio and 95% confidence intervals. 
 
 
Table 4. Univariate and multivariate Predictors of All Causes of Mortality 
  Multivariate Analysis 
 Univariate Model I Model II 
Clinical characteristics    
  Age 1.06 (1.04-1.08) 1.06 (1.05-1.08) 1.05 (1.04-1.08) 
  Male sex 1.6 (1.4-1.9) 1.5 (1.2-1.8) 1.5 (1.3-1.9) 
  Hypertension  1.01 (0.8-1.2) 1.2 (1.1-1.4) NS 
  Smoking 1.4 (1.2-1.6) 1.3 (1.1-1.6) 1.3 (1.1-1.5) 
  Diabetes mellitus  1.1 (0.9-1.3) 1.4 (1.1-1.8) 1.4 (1.1-1.9) 
  Previous myocardial infarction 1.3 (1.1-1.5) NS NS 
  History of heart failure 1.8 (1.5-2.1) NS NS 
DSE parameters    
  Abnormal segments at rest 1.07 (1.06-1.09) 1.06 (1.04-1.08) 1.05 (1.04-1.08) 
  New wall motion abnormalities 1.7 (1.68-1.76) 1.3 (1.1-1.6) 
 
  Number of ischemic segments 1.08 (1.07-1.10) 
 1.08 (1.06-1.10) 
Data are presented as risk ratio and 95% confidence intervals. 
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Kaplan-Meier survival curves for the end-point of cardiac death/nonfatal myocardial 
infarction in patients with normal, fixed wall motion abnormalities and ischemia are presented 
in Figure 1. The combination of rest and inducible wall motion abnormalities identified the 
group with the highest risk of hard cardiac events (p<0.0001). At 5 years of follow-up, the 
annual hard cardiac events rate was 1.8% in patients with a normal test, 2.1% in patients with 
fixed wall motion abnormalities, 4.3% in patients with ischemia, and 8% in patients with both 
resting and inducible wall motion abnormalities.  
Among patients with a normal DSE the annual hard cardiac event rate was 1.3% in 
patients 75 years or younger and 2.8% in patients older than 75 years (p = 0.1).  
 
 
 
Figure 1. Kaplan-Meier survival curves (end-point of cardiac death and nonfatal myocardial 
infarction) based on results of dobutamine stress echocardiography. 
 
 
 
Figure 2 illustrates the incremental contribution of resting wall motion abnormalities 
and ischemia during DSE to clinical data in predicting hard cardiac events and total mortality. 
Both resting and dobutamine induced wall motion abnormalities were incremental to clinical 
data in the prediction of each end-point. The major increment in prognostic information was 
made by resting left ventricular function.  
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Figure 2. Incremental prognostic value of ischemia over clinical data and resting left 
ventricular function for prediction of hard cardiac events (panel A) and all cause mortality 
(panel B). 
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Discussion 
 
 This study assessed the incremental value of DSE in the prediction of long-term 
mortality and hard cardiac events in 1434 elderly patients with known or suspected CAD. 
During a mean follow-up of 6.5 years, 532 (37%) patients died, of these 249 (17%) died 
because of cardiac causes. The annual hard cardiac event rate was 1.8% in patients with 
normal and 5.7% in patents with abnormal DSE. Patients with both resting and dobutamine 
induced wall motion abnormalities were at highest risk of cardiac events with an annual rate 
of 8%. Predictors of cardiac death/nonfatal myocardial infarction and all causes of mortality 
were age, male gender, smoking, diabetes and rest wall motion abnormalities. The presence 
and the extent of ischemia during DSE provided incremental information in a multivariate 
analysis over clinical and resting echocardiographic data for the prediction of both hard 
cardiac events and all cause mortality. Patients with fixed wall motion abnormalities showed a 
marginally higher event rate than patients with a normal DSE. This could be explained by the 
fact that the most of these patients had less severe resting left ventricular dysfunction as 
compared to patients who had both resting and inducible wall motion abnormalities.  
 
 
Comparison to Previous Studies. To our knowledge, this is the longest-term follow-
up study in elderly patients undergoing stress imaging for evaluation of CAD. Additionally 
this is the first study to document an incremental value for stress imaging in predicting all 
cause mortality in the elderly. 
Feasibility and safety of dobutamine-atropine stress test have been previously reported 
in elderly patients (15-18). However, prognostic studies are scarce. Anthopoulos et al. (19) 
studied 120 patients ≥70 years old admitted for chest pain who underwent adenosine and DSE 
and coronary angiography. During a follow-up of 17 ± 7 months, there were 9 cardiac deaths 
and 4 nonfatal myocardial infarctions. Predictors of cardiac events were any abnormality on 
stress echocardiography, cessation of stress test and involvement of two or more coronary 
vessels disease. Camerieri et al. (20), evaluated 190 patients ≥65 years old by dipyridamole 
echocardiography early after an acute uncomplicated myocardial infarction. During a follow-
up of 14 ± 10 months there were 62 events including 14 cardiac death, 7 nonfatal myocardial 
infarction, 21 cases of heart failure, and 20 revascularization procedures. Patients with a 
positive dipyridamole echocardiography test experienced significantly higher myocardial 
infarction or death (7%) compared with patients with a negative test (4%). Poldermans et al. 
(21), performed a DSE test in 179 elderly patients (mean age 75 years) referred for chest pain 
or preoperative risk assessment for major vascular surgery. Ischemia during the test was the 
only independent predictor of perioperative and cardiac events during short-term follow-up of 
16 ± 6 months. Marwick et al. (22), studied 3156 patients (mean age 63 ± 12 years) referred 
for DSE for a mean follow-up of 3.8 ± 1.9 years. DSE provided independent information for 
prediction of total and cardiac mortality, incremental to clinical variables. The annual hard 
cardiac events rate was around 2% in patients with a normal DSE and 6.3% in patients with 
an abnormal DSE. Age >65 years was associated with an incremental risk of mortality in 
patients with heart failure but a normal DSE. In particular, patients 65 to 75 years old had a 
yearly cardiac mortality of 4%, increasing to 6% yearly in patients over 75 years old.  
Arruda et al. (8), studied 2632 patients >65 years old who underwent exercise 
echocardiography. During a follow-up of 2.9 ± 1.7 years, cardiac events included cardiac 
death in 68 (2%) patients and nonfatal myocardial infarction in 80 (3%) patients. The annual 
hard cardiac events rate was 2.4% in patients with normal and 5.6% of patients with abnormal 
exercise echocardiography. Exercise echocardiographic variables provided incremental 
information to clinical, rest echocardiography and exercise electrocardiogram in predicting 
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cardiac events. In our study the cardiac death rate was higher than in the exercise study. This 
may be related to several factors such as a longer and nearly complete (99.5%) follow-up in 
our study. In general, patients who are able to exercise are considered a lower risk population 
than patients who are unable to perform exercise stress test. Nevertheless, the event rate was 
relatively lower for patients with normal DSE in our study as compared to patients with 
normal exercise echocardiography. In our study, 89% of elderly patients could achieve the 
target heart rate which may have contributed to a better sensitivity for detecting myocardial 
ischemia in our study. 
 
Limitations of the study 
 
The population of this study was recruited over 15 years. During the entire follow-up 
period there has been substantial clinical progress in the treatment of CAD with possible 
impact on interpretation of the significance of our results. Nevertheless, survival curves for 
patients with normal and abnormal DSE continued to diverge during the entire follow-up, 
indicating that the prognostic value of DSE was maintained during follow-up. Exclusion of 
patients with early revascularization may have reduced the predictive power of an abnormal 
DSE. This is however an inherent limitation of most prognostic studies which used similar 
approaches (13). 
 
Clinical Implications and Conclusions 
 
DSE provides independent prognostic information for the prediction of all cause 
mortality and hard cardiac events in the elderly. Dobutamine induced wall motion 
abnormalities are independently associated with adverse outcome, particularly in patients with 
resting left ventricular dysfunction. Patients with a normal DSE have a low cardiac event rate 
and can be exempted from further non invasive testing if they have a stable clinical course 
during the 5 years following DSE. 
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Abstract 
 
Background. Stress induced ischemia during dobutamine stress echocardiography 
(DSE) is associated with an increased risk of late cardiac events. The aim of this study was to 
compare the long-term prognosis of patients having silent versus symptomatic ischemia 
during DSE. 
Methods. Follow-up was completed in 944 patients (99.5%). Thirteen underwent 
early (<60 days) coronary revascularization and were excluded. 
Results. Silent ischemia was present 643 of the 931 remained (69%). The number of 
dysfunctional segments at rest (9.6±5.1 v 8.8±5.0, p=0.1) and of ischemic segments (3.5±2.2 
v 3.8±2.1, p=0.2) was comparable in both groups. During a mean (SD) follow-up of 5.5 (3.3) 
years, there were 169/931 (18%) cardiac deaths and 86/931 (9%) nonfatal infarctions. 
Multivariable Cox regression analysis showed age (HR 1.1, 95% CI 1.02-1.05), previous 
myocardial infarction (HR 1.4, 95% CI 1.1-2.0), and number of ischemic segments (HR 2.0, 
95% CI 1.0-3.7) as independent predictors of cardiac death and myocardial infarction. For 
every additional ischemic segment there was a two-fold increment in risk of late cardiac 
events. The annual cardiac death or myocardial infarction rate was 3.0% in patients with 
symptomatic ischemia and 4.6% in patients with silent ischemia (p<0.01). Silent induced 
ischemia was an independent predictor of cardiac death and myocardial infarction (HR 1.7, 
95% CI 1.1-2.0). During follow-up symptomatic patients were treated more often with cardio-
protective therapy (p<0.01) and coronary revascularization (145/288 (50%) v 174/643 (27%), 
p<0.001). 
Conclusions. Patients with silent ischemia had a similar extent of myocardial ischemia 
during DSE, but received less cardio-protective therapy and coronary revascularization, and 
experienced a higher cardiac event rate compared to patients with symptomatic ischemia. 
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Introduction 
 
Although angina pectoris is one of the cardinal manifestations of myocardial ischemia, 
many patients have ischemia during stress testing without associated symptoms (1-3). Studies 
of stress induced silent ischemia reported discordant results with respect to the extent of 
ischemia. Some studies reported a similar extent of ischemia in patients with and without 
angina (4-10), while others report more extensive ischemia in presence of angina (11-16). 
Dobutamine-atropine stress echocardiography (DSE) is commonly used to assess the extent, 
location, and severity of coronary artery disease (17, 18). The diagnosis of myocardial 
ischemia during DSE is based on the detection of new or worsening wall motion 
abnormalities. The extent of these abnormalities is a powerful predictor of adverse outcome 
(19, 20). A large number of studies have reported discordant data regarding the prognostic 
importance of stress induced silent ischemia, the likelihood of future coronary events related 
to the amount of ischemic myocardium, and the influence of medical treatment or 
revascularization techniques on the outcome of silent stress induced ischemia. Accordingly, 
the aim of this study was to compare the long-term prognosis of silent versus symptomatic 
ischemia in a large group of patients undergoing DSE. 
 
 
Methods 
 
Patient Selection. Between 1990 and 2002, 949 consecutive patients experienced 
stress induced myocardial ischemia during DSE. Follow-up was successful in 944 patients 
(99.5%). A total of 13 patients underwent early coronary revascularization in the first 60 days 
after the DSE and were excluded from the analysis (21). Data from the remaining 931 patients 
are reported. The protocol was approved by the Hospital Ethics Committee. All patients gave 
informed consent before the test. A structured interview and clinical history were taken and 
cardiac risk factors were assessed before DSE. 
 
 
Dobutamine Stress Protocol. Dobutamine-atropine stress testing was performed 
according to a standard protocol as previously reported (19, 22, 23). Dobutamine was 
administered intravenously, starting at a dose of 5 µg/kg/min for 5 minutes, followed by 10 
µg/kg/min for 5 minutes. Subsequently, incremental dobutamine doses of 10 µg/kg/min were 
given at 3-minute intervals up to a maximum dose of 40 µg/kg/min. If the test end-point was 
not reached at a dobutamine dose of 40 µg/kg/min, atropine (up to 2 mg) was given 
intravenously. Blood pressure, heart rate, and electrocardiography were constantly monitored. 
Test end-points were achievement of target heart rate (85% of maximum age and gender 
predicted heart rate), maximal dose of dobutamine and atropine, horizontal or downsloping 
ST-segment depression >2 mm at an interval of 80 ms after the J-point compared with 
baseline, severe angina, systolic blood pressure fall >40 mm Hg, blood pressure >240/120 
mmHg, or significant cardiac arrhythmia. An intravenous β-blocker was available to reverse 
the adverse effects of dobutamine/atropine.  
 
 
Stress Echocardiography. Two-dimensional echocardiographic images were 
acquired at rest, during dobutamine stress, and during recovery. The echocardiograms were 
recorded in a quad-screen format. Two experienced observers, unaware of the clinical data, 
scored the echocardiograms using a standard 16-segment model. Regional wall motion and 
systolic wall thickening were scored on a 5-point scale (1= normal, 2= mild hypokinesia, 3= 
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severe hypokinesia, 4= akinesia, 5= dyskinesia). Ischemia was defined as new or worsened 
wall motion abnormalities during stress indicated by an increase of wall motion score ≥1 
grade in ≥1 segment. Ischemia was not considered to be present when akinetic segments at 
rest became dyskinetic during stress. Symptomatic ischemia was defined as the presence of 
typical chest pain or anginal equivalent symptoms (epigastric pain, jaw pain, dyspnea) during 
DSE. Coronary arteries were assigned to myocardial segments based on echocardiographic 
localization, as previously described (24). The anterior, apical, septal, and anteroseptal walls 
were assigned to the left anterior descending coronary artery, the posterior and lateral wall to 
the left circumflex, and inferior and basal septal segments to the right coronary artery. The 
apical lateral segment was considered an overlapping segment between the left anterior 
descending coronary artery and the left circumflex and the apical inferior segment was 
considered an overlapping segment between the left anterior descending coronary artery and 
the right coronary artery. Overlapping segments were assigned to the regions with 
concomitant abnormalities.  
 
 
Follow-up. Follow-up data collection was performed by contacting the patient’s 
general practitioner and by review of hospital records. The date of the last review or 
consultation was used to calculate follow-up time. Outcome events were overall death, 
cardiac death, and nonfatal myocardial infarction. Cardiac death was defined as a death 
caused by acute myocardial infarction, significant cardiac arrhythmias, or refractory 
congestive heart failure. Sudden death occurring without another explanation was considered 
as cardiac death. Nonfatal myocardial infarction was defined by two of the following 
symptoms: typical chest pain, elevated cardiac enzyme levels or typical changes on 
electrocardiography.  
 
 
Statistical Analysis. Continuous data were expressed as mean value (standard 
deviation, SD). The Student’s t test was used to analyze continuous data. Differences between 
proportions were compared using the Chi-square test. Univariate and multivariate Cox 
proportional hazard regression models (BMDP Statistical Software Inc., Los Angeles, 
California, USA) were used to identify independent predictors of late cardiac events (25). 
Variables were selected in a stepwise forward selection manner, including clinical and DSE 
data, with entry and retention set at a significance level of 0.05. The risk of a variable was 
expressed as a hazard ratio with a corresponding 95% confidence interval. The probability of 
survival was calculated using the Kaplan-Meier method, and survival curves were compared 
using the log-rank test. A p value <0.05 was considered statistically significant. 
 
 
Results 
 
Patient Characteristics and Hemodynamic Results. Silent myocardial ischemia was 
present in 643/931 (69%) patients. Clinical risk factors were not significantly different 
between patients with and without angina during DSE, with the exception of history of angina 
that was more frequently observed in patients with symptomatic ischemia (Table 1).  
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Table 1. Clinical Characteristics in Patients With and Without Angina During DSE 
 
 Silent Ischemia 
(N=643) 
Symptomatic 
Ischemia 
(N=288) 
p value 
Age, mean (SD) 61 (13) 61 (11) 0.6 
Men (%) 465 (72) 233 (81) 0.009 
Previous infarction (%) 330 (51) 161 (56) 0.2 
Diabetes Mellitus (%) 78 (12) 29 (10) 0.4 
Hypertension (%) 195 (30) 79 (27) 0.4 
Hypercholesterolemia (%) 163 (25) 82 (28) 0.3 
Smoking (%) 122 (19) 88 (30) 0.3 
History of angina (%) 
History of heart failure(%) 
200 (31) 
107 (17) 
196 (68) 
38 (13) 
<0.001 
0.2 
Previous coronary angiography (%) 219 (34) 112 (39) 0.2 
Previous coronary bypass surgery (%) 96 (15) 43 (15) 1 
Previous coronary angioplasty (%) 89 (14) 56 (19) 0.04 
β-blockers (%) 243 (38) 115 (40) 0.5 
Calcium channel blockers (%) 177 (27) 99 (34) 0.04 
Nitrates (%) 180 (28) 115 (40) 0.001 
Aspirin (%) 302 (47) 158 (55) 0.005 
Statins (%) 174 (27) 92 (32) 0.01 
Indication for DSE:    
  Diagnosis of CAD (%) 350 (54) 211 (73) <0.0001 
  Preoperative evaluation before 
noncardiac surgery (%) 
186 (29) 34 (12) <0.0001 
  Risk-stratification after myocardial 
infarction (%) 
107 (17) 43 (15) 0.6 
 
 
DSE characteristics in patients with silent and symptomatic myocardial ischemia are 
shown in Table 2. There was no significant difference between patients with and without 
silent ischemia with respect to number of abnormal segments at rest and number of ischemic 
segments during DSE. No patient experienced a myocardial infarction during the test. Side 
effects were non-sustained ventricular tachycardia (<10 complexes) in 28/931 patients (3%), 
sustained ventricular tachycardia (>10 complexes) in 13/931 patients (1%), severe 
hypotension (decrease in systolic blood pressure >40 mm Hg compared to baseline) in 7/931 
(1%), atrial fibrillation in 6/931 patients (1%), and ventricular fibrillation in 1/931 (0.1%).  
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Table 2. Dobutamine Stress Echocardiographic Data in Patients With and Without Angina 
During DSE 
 
 Silent Ischemia 
(N=643) 
Symptomatic 
Ischemia 
(N=288) 
p value 
Peak heart rate (betas) 127 ± 21 124 ± 20 0.03 
Peak systolic blood pressure (mmHg) 135 ± 31 134 ± 28 0.7 
Peak rate pressure product  16573 ± 4290 17119 ± 4767 0.1 
Peak dobutamine dose (µg) 37 ± 7 38 ± 5 0.09 
Atropine use (%) 230 (36) 96 (33) 0.5 
ST-segment depression (%) 248 (38) 179 (62) <0.001 
Number of dysfunctional segments at rest 9.6 ±5.1 8.8 ± 5.0 0.1 
Number of ischemic segments 3.5 ± 2.2 3.8 ± 2.1 0.2 
Arrhythmias and hypotension during the test (%) 43 (7) 12 (4) 0.2 
Reasons for termination of the stress test:    
  85% of maximal heart rate (%) 579 (90) 250 (87) 0.2 
  Maximal dose (%) 36 (5) 14 (5) 0.8 
  Arrhythmias (%) 12 (2) 2 (1) 0.3 
  Side effects (%) 11 (2) 1 (0.3) 0.2 
  ST-segment depression (%) 5 (1) 10 (3) <0.005 
  Angina (%) 0 (0) 11 (4) <0.0001 
 
 
 
DSE and Outcome. During a mean (SD) 5.5 (3.3) years follow-up, there were 
265/931 (28%) deaths, of which 169/931 (18%) were attributed to cardiac causes. Nonfatal 
infarction occurred in 86/931 (9%) patients, and late revascularization was performed in 
319/931 (34%) patients. The annual cardiac death rate was 2.2% in the group of patients with 
symptomatic ischemia during DSE and 3.8% in the group with silent ischemia (p< 0.01). The 
annual myocardial infarction or cardiac death rate was 3.0% in patients with symptomatic 
ischemia and 4.6% in patients with silent ischemia (p< 0.01). Late revascularization was more 
frequently performed in patients with symptomatic ischemia (145/288 (50%) v 174/643 
(27%), p<0.001). Changes in medical treatment after detection of ischemia by DSE were 
observed in both groups, but patients with angina during DSE were significantly more often 
treated with β-blockers, aspirin, and statins (Table 3). On the other hand, the fact that these 
patients were less treated with nitrates and calcium channel blockers at follow-up is related to 
the higher incidence of coronary revascularization in this group. 
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Table 3. Medication Therapy at Follow-up in Patients With and Without Angina During DSE 
 Baseline Follow-up 
 Silent 
Ischemia 
(N=643) 
 
Symptomatic 
Ischemia 
(N=288) 
p value Silent 
Ischemia 
(N=643) 
 
Symptomati
c Ischemia 
(N=288) 
p value 
β-blockers (%) 243 (38) 115 (40) 0.5 276 (43) 202 (70) <0.001 
Calcium channel blockers (%) 177 (27) 99 (34) 0.04 193 (30) 89 (31) 0.06 
Nitrates (%) 180 (28) 115 (40) 0.001 193 (30) 69 (24) <0.006 
Aspirin (%) 302 (47) 158 (55) 0.005 334 (52) 236 (82) <0.001 
Statins (%) 174 (27) 92 (32) 0.1 263 (41) 245 (85) <0.001 
 
 
 
Kaplan-Meier survival curves for the end-point cardiac death and the combined 
endpoint cardiac death/nonfatal infarction are presented in Figure 1 and 2, respectively.  
 
 
 
 
 
 
Figure 1. Kaplan-Meier survival curves (end point of cardiac death) in patients with silent 
versus patients with symptomatic ischemia during DSE. 
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Figure 2. Kaplan-Meier survival curves (end point of cardiac death and nonfatal myocardial 
infarction) in patients with silent versus patients with symptomatic ischemia during DSE. 
 
 
 
Patients with silent ischemia had a significantly lower probability of survival during 
long-term follow-up compared with patients with symptomatic ischemia. Especially, patients 
with silent ischemia and multivessel disease had a poor long-term prognosis (see Figure 3).  
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Figure 3. Kaplan-Meier survival curves showing cardiac event rate in patients with: 1) silent 
ischemia and single vessel disease; 2) symptomatic ischemia and single vessel disease; 3) 
symptomatic ischemia and multivessel disease; 4) silent ischemia and multivessel disease. 
 
 
This may be related to the fact that patients with symptomatic ischemia and 
multivessel disease were more often referred for coronary revascularization than patients with 
silent ischemia and multivessel disease (111/220 (50%) v 141/509 (28%), p<0.0001). Among 
patients with symptomatic ischemia and multivessel disease, cardiac death occurred in 
11/111(11%) patients who were revascularized v 22/109 (20%) patients who were treated by 
medical therapy (p=0.05). Similarly, in patients with silent ischemia and multivessel disease, 
cardiac death occurred in 18/141 (13%) patients that were revascularized v 92/368 (25%) 
patients medically treated (p=0.004).  
No gender differences for cardiac death or hard cardiac events were present 
considering the overall population, as well as separately the two groups of patients with 
symptomatic or silent ischemia, or the two groups of patients with single or multivessel 
disease. 
 
Incremental Prognostic Value. Independent predictors of cardiac death in a 
multivariate analysis were age (HR 1.06, 95% CI 1.04-1.08), male gender (HR 1.8, 95% CI 
1.2-2.7), smoking (HR 1.5, 95% CI 1.1-2.0), and number of ischemic segments (HR 2.1, 95% 
CI 1.1-4.1). Independent predictors of cardiac death or myocardial infarction were age (HR 
1.04, 95% CI 1.02-1.05), previous myocardial infarction (HR 1.4, 95% CI 1.1-2.1), and 
presence of ischemia during DSE (HR 2.0, 95% CI 1.0-3.7). For every ischemic segment 
there was a two-fold increment in risk of late cardiac events. Silent induced ischemia was also 
an independent predictor of cardiac death and myocardial infarction (HR 1.7, 95% CI 1.1-
2.0). An interaction term between silent induced ischemia and the presence of ischemia was 
not significant. 
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Discussion 
 
The current results demonstrate that patients with silent myocardial ischemia during 
DSE have a higher incidence of long-term cardiac death and myocardial infarction compared 
to patients with symptomatic myocardial ischemia. This association was observed irrespective 
of the presence and extent of resting or dobutamine stress induced new wall motion 
abnormalities.  
Significant changes were observed in medical treatment in patients with and without 
angina during DSE. Patients with silent myocardial ischemia during DSE were less often 
prescribed β-blockers, aspirin, and statins compared to patients with symptomatic ischemia. 
In addition, late revascularization was less frequently performed in patients with 
asymptomatic ischemia during DSE. Moreover, in patients with multivessel disease and 
symptomatic or silent ischemia during DSE, cardiac death occurred more often in patients 
medically treated compared with patients who underwent myocardial revascularization.  
The worse long-term prognosis of patients with asymptomatic myocardial ischemia 
could be associated with a less aggressive anti-ischemic medical therapy and coronary 
revascularization. β-blockers have been unequivocally shown in multiple studies to reduce 
both angina and the incidence, frequency, and extension of episodes of silent ischemia (26-
28). The combination of β-blockers with other anti-ischemic medical therapy such as calcium 
channel antagonists has been also found to reduce the incidence of myocardial ischemia more 
than either type of these medications alone (29, 30). Also statin therapy has been shown able 
to decrease transient myocardial ischemia, probably due to an improved endothelial function 
(31). Furthermore, myocardial revascularization was previously shown to be associated with a 
decrease of asymptomatic ischemia and an improvement of clinical outcome compared to 
angina- or ischemia-guided strategy in a prospective study (32). In this study, the decision to 
perform coronary angiography was made on clinical grounds by the treating cardiologist. The 
prescription rate of betablockers or calcium antagonist were relatively low. It seems that in 
some patients symptoms of angina instead of signs of ischemia on DSE were the reason to 
prescribe betablockers or calcium antagonists and to perform myocardial revascularization.  
Additionally, in this study absence of symptoms during dobutamine stress induced 
ischemia was frequently observed (69%); this is in line with previous studies (4, 33, 34) and is 
physiologically explained by the ischemic cascade since systolic dysfunction precedes the 
development of angina pectoris. 
 
Comparison to Previous Studies. There are only a few studies on the long-term 
prognostic implications of silent myocardial ischemia during DSE. Bigi et al (35) studied 407 
survivors from a first uncomplicated myocardial infarction who had myocardial ischemia 
during DSE and were followed for a 10 months period. Cardiac death and nonfatal myocardial 
re-infarction occurred respectively in 6/407 (1%) and 13/407 (3%) of patients. No significant 
difference in spontaneous event-free survival was observed among patients with silent 
ischemia. Bonou et al (33) studied 289 patients with advanced age undergoing DSE. During a 
35±13 month follow-up period, 15/289 (5%) cardiac deaths and 19/289 (7%) nonfatal 
myocardial infarctions occurred. There was no significant difference in prognosis between 
patients with silent or symptomatic myocardial ischemia. In the present study the cardiac 
event rate was higher than in the previous studies; this may be related to the longer and nearly 
complete (99.5%) follow-up. Previous data in 224 patients who underwent dobutamine stress 
myocardial perfusion imaging showed a similar outcome between patients with silent and 
symptomatic ischemia (34). The different findings in that study may be related to differences 
in sensitivity between myocardial perfusion imaging and DSE, as well as a possible 
differences in management of patients following a positive study by these two techniques. 
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Some previous studies suggested a common pathway for both the electrical and 
painful response to ischemic stimulus (8). These studies showed that during exercise stress 
testing a higher incidence of ST-segment changes occurred in patients with symptomatic 
ischemia (8, 14, 15). However, the extent of ischemia was comparable in patients with and 
without symptomatic ischemia during dobutamine stress echocardiography. The mechanism 
underlying the pathogenesis of silent or symptomatic ischemia is complex and may include 
variations in pain threshold, a central nervous system alteration or a particular biochemical 
pattern of inflammatory system activation (36, 37). The relation between angina and extent of 
ischemia is not clear. Several studies have assessed the extent of ischemia in the presence and 
in absence of symptomatic myocardial ischemia during stress test with contradicting results. 
Some investigators have reported a greater extent and severity of ischemia in symptomatic 
patients than in those with silent myocardial ischemia (11-16), while other studies reported no 
difference in the amount of ischemic myocardium between patients with and without 
symptomatic myocardial ischemia during exercise or pharmacological stress testing (4-10). In 
the present study there are no significant differences between dysfunctional segments at rest 
and number of ischemic segments at peak in patients with and without symptomatic 
myocardial ischemia. Moreover, the extent of ischemia during DSE was an independent 
predictor of cardiac death and myocardial infarction so as number of vessels disease was 
related to an increased rate of cardiac events, particularly in patients with symptomatic 
ischemia. This is in line with previous studies that show the total amount of ischemic territory 
at risk is more related to the outcome than the presence of symptoms (3, 18, 19, 38, 39).  
 
Study Limitations 
 
 Data on coronary angiography were not available in all patients. 
 
 
Conclusions 
 
This study showed that patients with asymptomatic myocardial ischemia during DSE 
had a worse long-term cardiac event-free survival rate as compared to patients with 
symptomatic myocardial ischemia. Patients with asymptomatic ischemia should be treated 
with a complete medical therapy or revascularization as patients with symptomatic 
myocardial ischemia. 
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Abstract 
 
Background. The aim of this study was to assess the incidence, clinical correlates and 
prognostic significance of angina during dobutamine stress echocardiography (DSE) in 
patients without inducible wall motion abnormalities.  
Methods. We studied 2117 patients (age = 61 ± 13 years, 1149 men) who underwent 
high dose DSE and had no new or worsening wall motion abnormalities during DSE. Follow 
up events were hard cardiac events (cardiac death or non-fatal myocardial infarction) and 
myocardial revascularization.  
Results. Angina was induced in 217 (10%) patients during stress. DSE was normal in 
1198 (57%) patients, whereas 919 (43%) patients had fixed wall motion abnormalities. 
During a mean follow up of 5.5 ± 3.7 years, 143 (7%) patients died of cardiac causes and 78 
(4%) patients had non fatal myocardial infarction. Patients with angina during DSE were 
more likely to have a prior history of exertional angina (64% vs 16%, p<0.001), and had a 
higher resting wall motion score index (1.29 ± 0.5 vs 1.17 ± 0.4, p = 0.01), compared to 
patients without angina. The annual hard cardiac event rate was 2.2% in patients with 
dobutamine induced angina and 2.1% in patients without (p = NS). Myocardial 
revascularization was performed more frequently in patients with than without dobutamine 
induced angina (39% vs 14%, p<0.0001). In a Cox regression model, independent predictors 
of hard events were age (risk ratio [RR] 1.03, 95% confidence intervals [CI] 1.02-1.04, male 
sex (RR 1.6, CI 1.1-2.2), smoking (RR 1.5, CI 1.1-2.9) and resting wall motion score index 
(RR 2.6, CI 1.8-3.8).  
Conclusions. In patients without ischemia by echocardiographic criteria during DSE, 
inducible angina pectoris is associated with a high incidence of revascularization during 
follow up. However, the hard cardiac event rate is not different in patients with and without 
dobutamine induced angina. 
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Introduction 
 
Exercise induced angina has been reported as a predictor of composite cardiac events 
among patients with normal left ventricular function who had no inducible wall motion 
abnormalities with exercise echocardiogram (1). However, the clinical significance and 
prognostic implications of dobutamine induced angina among patients without 
echocardiographic ischemia are not known. It is not known whether angina in these patients is 
a non specific symptom or signifies undetected myocardial ischemia due to a potential 
shortcoming of the DSE technique. This study assesses the incidence, clinical correlates and 
prognostic significance of dobutamine induced angina (DIA), in patients without inducible 
wall motion abnormalities during DSE. 
 
 
Methods 
 
Patients. The study population consisted of 2129 consecutive patients with limited 
exercise capacity, referred for DSE between 1990 and 2002 at the Thoraxcenter, Rotterdam, 
the Netherlands who had no inducible new or worsening wall motion abnormalities or a 
biphasic response during DSE. Hypertension was defined as a blood pressure ≥140/90 mmHg, 
or treatment with antihypertensive medication. Diabetes mellitus was defined as a fasting 
glucose level ≥7.8 mmol/L or the need for insulin or oral hypoglycemic agents. 
Hypercholesterolemia was defined as a total cholesterol ≥6.4 mmol/L, or treatment with lipid-
lowering medication. Follow-up was successful in 2117 patients (99.5%) who represented the 
population of this study. The protocol was approved by the Hospital Ethics Committee. All 
patients gave informed consent before the test.  
 
Dobutamine Stress Protocol. Dobutamine-atropine stress testing was performed 
according to a standard protocol as previously reported (2). Beta blockers were discontinued 
at least 24 hours before DSE whenever possible. Other medications were not generally 
discontinued. After obtaining a baseline echocardiogram, dobutamine was administered 
intravenously, starting at a dose of 10 µg/kg/min for 3 minutes (5 µg/kg/min in patients with 
resting left ventricular dysfunction). Incremental dobutamine doses of 10 µg/kg/min were 
given at 3-minute intervals up to a maximum dose of 40 µg/kg/min. If the test end-point was 
not reached at a dobutamine dose of 40 µg/kg/min, atropine (up to 2 mg) was given 
intravenously. Blood pressure, heart rate, and electrocardiography were constantly monitored. 
Test end-points were achievement of target heart rate (85% of maximum age predicted heart 
rate), maximal dose of dobutamine and atropine, extensive new wall motion abnormalities, >2 
mV downsloping ST-segment depression measured 80 ms after the J point compared with 
baseline, hypertension (blood pressure >240/120 mm Hg), a decrease in systolic blood 
pressure of >40 mm Hg compared with at rest, significant arrhythmias, severe angina or any 
intolerable adverse effect considered to be the result of dobutamine or atropine. An 
intravenous β-blocker (metoprolol 1 to 5 mg) was available to reverse the adverse effects of 
dobutamine/atropine if needed. DIA was defined as precordial/central chest pain during or 
immediately after DSE that lasted at least 1 minute and resolved by discontinuation of the 
stress test or intravenous metoprolol. 
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Echocardiographic imaging and interpretation. Two-dimensional 
echocardiographic images were acquired at rest, during dobutamine stress, and recovery using 
the standard views. The echocardiograms were recorded in a quad-screen format. Two 
experienced observers, unaware of the clinical data or symptoms during the stress test, scored 
the echocardiograms using a standard 16-segment model (2,3). In case of disagreement, a 
consensus decision was achieved by a third observer. Regional wall motion and systolic wall 
thickening were scored on a 5-point scale (1= normal, 2= mild hypokinesia, 3= severe 
hypokinesia, 4= akinesia, 5= dyskinesia). Ischemia was defined as new or worsened wall 
motion abnormalities during stress indicated by an increase of wall motion score ≥1 grade in 
≥1 segment, or a biphasic response in a dyssynergic segment.  Patients with ischemia were not 
included per enrolment criteria. A normal test was defined as absence of wall motion 
abnormalities at rest and with stress. For each patient, a wall motion score index was 
calculated by dividing the sum of segment scores by the total number of interpreted segments. 
 
Follow-up. Follow-up data collection was performed by contacting the patient’s 
general practitioner and by review of hospital records. In addition, the vital status was 
confirmed through the civil data registry. Patients were contacted if needed after confirmation 
of their vital status. The date of the last review or consultation was used to calculate follow-up 
time. Follow-up events noted were overall mortality, hard cardiac events (cardiac death and 
nonfatal myocardial infarction), and myocardial revascularization. Cardiac death was defined 
as a death caused by acute myocardial infarction, significant cardiac arrhythmias, or 
refractory congestive heart failure. Sudden death occurring without another explanation was 
considered as cardiac death. Nonfatal myocardial infarction was defined by the usual criteria 
of chest pain, elevated cardiac enzyme levels and electrocardiographic changes.  
 
Statistical Analysis. Continuous data were expressed as mean value ± SD. The 
Student’s t test was used to analyze continuous data. Differences between proportions were 
compared using the Chi-square test. Univariate and multivariate Cox proportional hazard 
regression models (BMDP Statistical Software Inc., Los Angeles, California, USA) were used 
to identify independent predictors of follow up events. Variables were selected in a stepwise 
forward selection manner with entry and retention set at a significance level of 0.05. The risk 
of a variable was expressed as a hazard ratio with a corresponding 95% confidence interval. 
Variables were selected for the multivariate analysis if these were significant or showed a 
trend in the univariate analysis (p<0.1). The probability of survival was calculated using the 
Kaplan-Meier method, and survival curves were compared using the log-rank test. A p value 
<0.05 was considered statistically significant. 
 
 
Results 
 
Patient characteristics and stress test data. Mean age was 61 ± 13 years. There were 
1149 (54%) men. Angina during DSE occurred in 217 (10%) patients (31% of the patients 
with a history of typical angina). Atypical chest pain occurred in 112 (5%) patients. Reasons 
for termination of DSE were achievement of the target heart rate in 1905 (90%), maximal 
dose of dobutamine/atropine in 109 (5%), ST segment changes in 33 (1.5%), angina in 13 
(1%), arrhythmias in 20 (1%), abnormal blood pressure in 19 (1%), and chills or nausea in 18 
(1%) patients. Resting wall motion abnormalities without inducible ischemia were detected in 
919 (43%) patients.   
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Clinical data of patients with and without DIA are presented in Table 1. Patients with 
angina were younger, received a larger dose of dobutamine, were more frequently treated with 
calcium channel blockers, beta blockers and nitrates and more often had a history of 
hypertension, known CAD (previous myocardial infarction, and or revascularization) and 
exertional angina prior to the DSE.  
 
 
Table 1. Clinical Characteristics of Patients with and without Dobutamine Induced 
Angina 
 
Clinical data      Dobutamine induced angina      
 
 Yes 
(N=217) 
No 
(N=1900) 
p   value 
Age (years) 59 ± 10 61 ± 13 0.02 
Men 141 (65%) 1008 (53%) 0.007 
Hypertension 77 (35%) 492 (26%) 0.003 
Hypercholesterolemia 40 (18%) 295 (16%) NS 
Smoker 51 (24%) 440 (23%) NS 
History of typical angina 139 (64%) 312 (16%) 0.0001 
History of atypical chest pain 46 (21%) 278 (15%) 0.01 
Diabetes mellitus 24 (11%) 147 (8%) NS 
Previous myocardial revascularization 58 (27%) 178 (9%) 0.0001 
Previous myocardial infarction 84 (39%) 357 (19%) 0.0001 
Known coronary artery disease 117 (54%) 463 (24%) 0.0001 
β-blockers 76 (35%) 440 (23%) 0.001 
Calcium channel blockers 76 (35%) 445 (23%) 0.001 
Nitrates 117 (54%) 330 (17%) 0.0001 
Indication for stress testing   <0.0001 
 Chest pain  152 (70%) 590 (31%)  
  Multiple risk factors 26 (12%) 1082 (57%)  
 Risk-stratification after infarction or   
revascularization 
39 (18%) 228 (12%)  
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Hemodynamic data are presented in Table 2. Heart rate and systolic blood pressure 
increased significantly from rest to peak stress in both groups. ST-segment changes occurred 
more often in patients with DIA. DSE was normal in 1198 (57%) patients. Resting wall 
motion score index was higher in patients with DIA. 
 
 
 
Table 2. Dobutamine Stress Data in Patients with and without Dobutamine Induced 
Angina 
 
Stress test data      Dobutamine induced angina         
 
 Yes 
(N=217) 
No 
(N=1900) 
p value 
Resting heart rate (beats/min) 71 ±14 73 ± 13 0.01 
Stress heart rate  (beats/min) 126 ± 24 127 ± 21 NS 
Resting systolic blood pressure (mmHg) 134 ± 21 136 ± 24 NS 
Stress systolic blood pressure (mmHg) 139 ± 27 139 ± 29 NS 
Maximal dobutamine dose (µg/kg/minute) 37 ± 6 34 ± 9 0.001 
Atropine use, patients 68 (31%) 401 (21%) 0.001 
Achievement of target heart rate   194 (89%) 1711 (90%) NS 
ST-segment depression, patients 25 (12%) 71 (4%) 0.0001 
ST segment elevation, patients 25 (12%) 67 (4%) 0.0001 
Resting wall motion score index 1.29 ± 0.5 1.17 ± 0.4 0.01 
Normal stress echocardiogram, patients 120 (55%) 1078 (57%) NS 
Resting wall motion abnormalities, patients 97 (45%) 822 (43%) NS 
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Dobutamine Stress Echocardiography and Outcome. During a mean follow-up of 
5.5 ± 3.7 years, there were 435 (21%) deaths, of which 143 (7%) were attributed to cardiac 
causes. Seventy eight patients (4%) experienced nonfatal myocardial infarction. Myocardial 
revascularization was performed in 341 (16%) patients. Events in the groups with and without 
DIA are presented in table 3.  
 
 
 
Table 3. Follow-up Events in Patients with and without Dobutamine Induced Angina 
 
Events       Dobutamine induced angina           
 Yes 
(N=217) 
No 
(N=1900) 
p value 
Cardiac death 14 (6.5%) 129 (6.7%) NS 
Non fatal myocardial infarction 12 (5.5%) 66 (3.5%) 0.2 
Revascularization 
   Coronary artery bypass 
   Percutaneous interventions 
84 (39%) 
41 (19%) 
43 (20%) 
257 (14%) 
145 (8%) 
112 (6%) 
<0.0001 
 
 
Early revascularization (within 60 days) 
Late revascularization 
33 (18%) 
51 (24%) 
49 (3%) 
208 (11%) 
0.001 
0.001 
Unstable angina pectoris 30 (14%) 76 (4%) 0.001 
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Univariate and multivariate predictors of hard cardiac events and all events are 
presented in table 4.  
 
 
Table 4. Predictors of Cardiac Events 
 
      Univariate                              Multivariate 
 HR (95% CI) p HR (95% CI) p 
Hard cardiac events       
  Age 1.04 (1.02-1.05) 0.02 1.03 (1.02-1.04) 0.02 
  Male gender 1.7 (1.2-2.4) 0.01 1.6 (1.1-2.2) 0.03 
  Smoker 1.6 (1.1-3) 0.01 1.5 (1.1-2.9) 0.02 
  Resting wall motion score index 2.9 (1.7-4.1) 0.001 2.6 (1.8-3.8) 0.001 
  Diabetes mellitus 1.7 (1.1-3) 0.01 1.8 (1.2 -2.8) 0.01 
  Previous myocardial infarction 3 (1.9-4) 0.01  NS 
  Previous myocardial revascularization 1.5 (1.1-3.1) 0.02  NS 
Hard events + revascularization     
  Male gender 1.5 (1.1-1.8) 0.01 1.4 (1.1-1.7) 0.01 
  Angina pectoris 1.4 (1.2-2.2) 0.01 1.4 (1.2-2) 0.01 
  Previous myocardial infarction 1.6 (1.1-2) 0.005 1.5 (1.2-1.9) 0.01 
  Resting wall motion score index 1.9 (1.3-2.8) 0.001 1.9 (1.4-2.7) 0.001 
  Dobutamine induced angina 1.8 (1.2-2.1) 0.001 1.7 (1.2-1.9) 0.001 
  Smoker 1.4 (1.1-2.8) 0.03  NS 
  Diabetes mellitus 1.3 (1.1-2.1) 0.04  NS 
  Previous myocardial revascularization 1.7 (1.2-5.6) 0.02  NS 
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Survival curves of patients with and without DIA are shown in Figure 1 (hard event). 
There was no significant difference among patients with and without DIA regarding annual 
hard cardiac event rate (2.2% vs. 2.1%). Among patients with normal baseline left ventricular 
function, the annual hard cardiac event rate was 1.5% in patients with DIA and 1.4% in 
patients without. Among patients with resting wall motion abnormalities, the hard cardiac 
event rates were 2.8% and 2.7% respectively.  
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Figure 1. Kaplan-Meier survival curves (end-point of cardiac death and nonfatal myocardial 
infarction) in patients with and without angina during dobutamine stress echocardiography. 
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Patients with DIA had a higher incidence of unstable angina and revascularization 
during follow up. Figure 2 presents survival curves (hard events and revascularization) in 
patients with known versus patients with suspected CAD with and without DIA. Patients with 
DIA had a higher incidence of the composite end points in the groups with known as well as 
with suspected CAD. The incidence of cardiac events was higher in patients with known 
compared to patients with suspected CAD, regardless of DIA.  
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Figure 2. Kaplan-Meier survival curves (end-point of cardiac death, nonfatal myocardial 
infarction and revascularization) in patients with and without angina during dobutamine 
stress echocardiography, with and without a history of coronary artery disease. 
 
 
Discussion 
 
The findings of this study are: 1) dobutamine induced angina occurs in 10% of patients 
who do not demonstrate echocardiographic evidence of ischemia (new or worsened wall 
motion abnormalities); 2) patients with DIA are more likely to have exertional angina before 
DSE and history of known CAD; 3) patient with DIA have two to three fold higher incidence 
of revascularization during follow up as compared to patients without DIA; 4) The higher 
incidence of revascularization in patients with DIA was observed among patients with known 
as well as patients with suspected CAD; 5) the annual rate of cardiac death and non fatal 
myocardial infarction is similar in patients with and without DIA; 6) the hard cardiac event 
rate is fairly low in this population without inducible wall motion abnormalities, and is 
strongly related to the baseline left ventricular function. 
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 Transient wall motion abnormalities during DSE are the standard diagnostic markers 
of myocardial ischemia (4,5). The significance of angina in absence of transient wall motion 
abnormalities is unclear. A possible mechanism is a non specific response to dobutamine 
infusion with stimulation of pain receptors due to vigorous myocardial contractility. In our 
study, patients with angina received higher dose of dobutamine. The second mechanism 
would be the occurrence of actual myocardial ischemia that could not be depicted by the 
echocardiogram. Certain methodological limitations may contribute to this such as segmental 
suboptimal imaging quality, subjective analysis with observer variation, and modest 
sensitivity in single vessel disease (4,5). It has been demonstrated that some patients with 
CAD may have ischemia on myocardial perfusion imaging without inducible wall motion 
abnormalities or a biphasic response with DSE (6-10). A recent study showed that wall 
motion abnormalities may be demonstrated after administration of beta blockers in the 
recovery period, in patients without abnormalities at peak dobutamine stress (11). It is 
possible that administration of beta blockers or applying another imaging technique in these 
patients could have resulted in eliciting wall motion or perfusion abnormalities in some of 
them.  
 According to the ischemic cascade theory, wall motion abnormalities occur before 
electrocardiographic changes and angina during ischemia (12). In our study, the test was 
terminated because of angina in only 13 patients. It is unlikely that inadequate stress level was 
the underlying reason for absence of inducible wall motion abnormalities in patients with 
DIA, particularly considering the similar stress heart rate in patients with and without DIA.  
The amount of ischemic myocardium was shown to have no relation with symptoms of angina 
during dobutamine-induced myocardial ischemia (13-17). Therefore, it is possible (though 
speculative) that trivial ischemia may have been missed by echocardiographic imaging. The 
higher incidence of medications with nitrates and calcium channel blockers in the group with 
DIA can be explained by the higher prevalence of exertional angina and hypertension in this 
group. Although it is not a common practice to discontinue these medications before DSE, it 
is possible that these medications have attenuated the ischemic left ventricular dysfunction in 
some patients (18).  
 Many findings of this study suggest that myocardial ischemia could be the underlying 
mechanism of DIA in a significant proportion of patients. These include the higher incidence 
of ST segment changes, and the higher incidence of unstable angina and revascularization 
during follow up among patients with than without DIA. Although there is no definite 
evidence that ischemia was induced in these patients, the fact that 39% of  patients with DIA 
had significant CAD requiring revisualization during follow up makes this possibility likely. 
Patients with DIA were more likely to require revascularization during follow up. This 
was evident in the groups with known as well as with suspected CAD. Most patients had 
exertional angina and may have required revascularization for relief of angina even without 
objective evidence of myocardial ischemia. However, both exertional angina and DIA were 
independent predictors of the composite end point of cardiac events including 
revascularization, which suggests that DIA was a leading cause for invasive verification 
irrespective to clinical and echocardiographic data in some patients.  
The incidence of cardiac death and non fatal myocardial infarction was not different 
with and without DIA. Although it is possible that prognosis was improved in some of the 
high risk patients with DIA because of revascularization, a prognostic impact of 
revascularization in these patients remains speculative.  Resting left ventricular function, 
expressed as wall motion score index was the most powerful predictor of outcome in this 
population without objective evidence of ischemia. 
 Referring patients with DIA without inducible wall motion abnormalities for coronary 
angiography may be a reasonable clinical decision because of the high prevalence of 
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exertional angina in these patients prior to DSE, the fact that stress testing reproduced their 
typical complaints and the potential shortcomings of the DSE. However, because of the 
similar (and fairly low) hard cardiac event rate in patients with and without DIA, a reasonable 
alternative to coronary angiography would be the use of another imaging technique such as 
myocardial perfusion imaging and deferring the coronary angiography if both tests concur on 
the absence of ischemia. A recent study has demonstrated that up to 50% of patients with 
classic exertional angina have a normal exercise echocardiogram. These patients had a 
favourable outcome during the 3 years following the stress test (19). Shaw et al reported that 
stable chest pain patients who undergo a more aggressive diagnostic strategy have higher 
diagnostic costs and greater rates of intervention and follow-up costs. The authors concluded 
that cost differences may reflect a diminished necessity for resource consumption for patients 
with normal stress test results (20).  
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Abstract 
 
Background. There are currently no available data to suggest a role of dobutamine stress 
echocardiography (DSE) in the prediction of death among patients with high clinical pre-test 
probability. The aim of this study was to assess the prognostic value of DSE in patients with 
classic angina and no history of coronary artery disease (CAD). 
Methods. We evaluated 327 patients (63% males, mean age 64±10 years) with typical 
angina referred for DSE with a pre-test probability of CAD ≥70%. None had previous 
revascuarization or myocardial infarction. Follow-up events were cardiac and total mortality and 
hard cardiac events (cardiac mortality and myocardial infarction).  
Results. DSE was abnormal in 202 (62%) patients. During a mean follow-up of 6 years, 
89 (27%) deaths (52 cardiac death) and 21 (6%) non-fatal myocardial infarction occurred. The 
annual cardiac death, all cause mortality and hard cardiac events rates at 5 years were 1.5%, 
2.6% and 2.3% in patients with a normal DSE respectively. In patients with an abnormal DSE the 
5-year event rates were 3.6%, 5.5% and 5.4% respectively. Cox proportional hazards regression 
analysis identified myocardial ischemia as independent predictor of cardiac death (HR: 2.5, CI 
[1.3-4.8]), all cause mortality (HR: 2.1, CI [1.1-4.3]) and hard cardiac events (HR: 3.3, CI [1.9-
5.7]).  
Conclusions. In patients with a high pre-test probability of CAD, DSE yields independent 
prognostic information. Myocardial ischemia is independently associated with increased risk of 
death and hard cardiac events. A normal DSE is associated with a low event rate. These patients 
can be exempted from invasive studies unless there is a change in clinical status.  
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To the Editor: The incremental value of myocardial ischemia assessed by dobutamine 
stress echocardiography (DSE), for predicting cardiac events has been demonstrated in various 
patients group (1-3). The clinical utility of non-invasive stress testing has been mostly 
established among patients with intermediate pre-test probability of coronary artery disease 
(CAD). In patients with low pre-test probability of CAD, exercise echocardiography was shown 
to provide limited prognostic information and was not routinely recommended (4). There are 
currently insufficient data to suggest a prognostic role of myocardial ischemia assessed by stress 
echocardiography in patients with typical angina, who are determined to have a high pre-test 
probability of CAD. According to the Bayes’ theorem, a normal stress test in these patients does 
only modestly reduce the post-test probability of CAD. Therefore, it is not known whether 
patients with high pre-test probability of CAD would be considered a low risk population if they 
had a normal stress echocardiogram. We sought to assess the additional value of myocardial 
ischemia during DSE in predicting mortality and hard cardiac events in patients with angina and 
no previous history of CAD. 
The study population consisted of consecutive patients with typical angina who were considered 
to have a high pre-test probability of CAD (>0.7) referred for DSE. This was considered in the 
presence of typical angina pectoris in women ≥50 years of age and in men ≥30 years of age, 
according to the published data (5, 6). Patients were excluded if they had a previous myocardial 
infarction, myocardial revascularization or significant coronary artery stenosis by angiography. 
Criteria were fulfilled in 329 patients. The protocol was approved by the Hospital Ethics 
Committee. Follow-up was successful in 327 patients (99%), 28 (8%) underwent early coronary 
revascularization (within 60 days after the DSE).  
DSE was performed and interpreted according to a standard protocol as previously 
reported (1). Ischemia was defined as new or worsening wall motion abnormality or a biphasic 
response. An abnormal test was defined as resting wall motion abnormality or ischemia. Follow-
up was performed by contacting the patient’s general practitioner, review of hospital records, 
review of civil data registry and contacting the patients if needed after confirmation of vital 
status. Follow-up events were overall mortality and hard cardiac events (nonfatal myocardial 
infarction and cardiac death). Survival free of the end point of interest was estimated by the 
Kaplan-Meier method. Comparison between groups was performed using the log rank test. 
Univariable and multivariable association of clinical and stress echocardiographic variables with 
events were assessed in the Cox proportional hazards framework (7). Variables were selected in a 
stepwise forward selection manner with entry and retention set at a significance level of 0.05. 
The results of these analyses were summarized as risk ratios with corresponding 95% confidence 
intervals. 
Mean age was 64 ± 10 years. There were 205 (63%) men. Thirty-six (11%) patients had a 
history of diabetes mellitus, 100 (31%) had hypertension and 24 (7%) had a history of heart 
failure. There was a significant increase of heart rate and systolic blood pressure from rest to 
peak stress (from 70 ± 14 beats/min to 128 ± 15 beats/min, p=<0.0001 and from 134 ± 23 mmHg 
to 146 ± 26 mmHg, p<0.0001, respectively). Target heart rate was reached in 262 (80%) patients.  
DSE was normal in 125 (38%) patients. Fixed wall motion abnormalities were detected in 
53 (16%) and ischemia was detected in 149 (46%) patients. During a mean follow-up of 6 ± 3.8 
years, there were 89 (27%) deaths, of which 52 (16%) were attributed to cardiac causes. Twenty-
one (6%) patients experienced nonfatal myocardial infarction. Twenty-five patients out of 125 
with a normal stress test (20%) underwent to revascularization, whereas 75 out of 202 patients 
(37%) with an abnormal test were revascularized (p=0.002). Cox proportional hazards regression 
analysis for the end-points cardiac death, hard cardiac events and all cause mortality is presented 
in Table 1. The presence of myocardial ischemia was an independent predictor for all end-points.  
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Table 1. Predictors of Events by Cox Models 
 
 Univariate Multivariate 
Parameter RR (CI) RR (CI) 
Cardiac death   
Clinical Model   
  Age 1.05 (1.02 – 1.09) 1.06 (1.03 - 1.10 
  Male gender 1.8 (1.1 – 3.2) 3.2 (1.5 – 6.7) 
  Heart failure 3.4 (1.7 – 6.8) 
 
  Systemic hypertension  1.2 (1.1-1.8) 1.9 (1.1 – 3.6) 
Stress Echocardiographic Model   
  Resting heart rate 1.02 (1.01 – 1.05) 1.03 (1.01 – 1.05) 
  Resting wall motion 
abnormalities 
1.9 (1.1 – 3.2) 1.9 (1.1 – 3.7) 
  Ischemia 2.5 (1.4 – 4.2) 2.5 (1.3 – 4.8) 
All cause mortality   
Clinical Model   
  Age 1.06 (1.03 – 1.09) 1.07 (1.05 – 1.10) 
  Male gender 1.4 (1.1 – 2.0) 2.1 (1.3 – 3.5) 
  Heart failure 2.1 (1.3-3.5)  
  Systemic hypertension  1.2 (1.1 – 1.7) 1.6 (1.1 – 2.6) 
Stress Echocardiographic Model   
  Resting heart rate 1.02 (1.01 – 1.12) 1.03 (1.01 – 1.05) 
  ST depression on ECG during 
stress 
1.2 (1.1 – 2.0) 2.1 (1.1 – 4.3) 
  Resting wall motion 
abnormalities 
1.3 (1.1 – 1.8) 
 
  Ischemia 1.5 (1.1 – 2.2) 1.6 (1.1 – 2.6) 
Hard cardiac events   
Clinical Model   
  Age 1.04 (1.01 – 1.07) 1.04 (1.01 – 1.07) 
  Male gender 2.0 (1.2 – 3.2) 2.8 (1.5 – 5.3) 
  Heart failure 2.1 (1.1 – 3.9) 
 
  Systemic hypertension  1.2 (1.1-1.9) 1.9 (1.1 – 3.3) 
Echocardiographic Model   
  Resting heart rate 1.01 (1.00 – 1.03) 1.03 (1.01 – 1.05) 
  Resting wall motion 
abnormalities 
1.5 (1.1 – 2.4) 
 
  Ischemia 2.4 (1.6 – 3.8) 3.3 (1.9 – 5.7) 
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Kaplan-Meier survival curves for the end-point cardiac death are presented in Figure 1. 
Patients with an abnormal DSE had a higher incidence of cardiac death compared to patients with 
a normal study. The annual cardiac death, all cause mortality and hard cardiac event rates at 5 
years were 1.5%, 2.6% and 2.3% in patients with a normal test and 3.6%, 5.5% and 5.4% in 
patients with abnormal DSE respectively.  
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Figure 1. Kaplan-Meier survival curves (end-point of cardiac death) in patients with high pre-
test probability of coronary artery disease. 
 
 
An additional analysis was performed excluding patients with early revascularization. 
This analysis of 299 patients showed that myocardial ischemia was an independent predictor for 
cardiac death [RR 2.7, CI (1.2-5.7)], all cause mortality [RR 2.3, CI (1.4-3.8)] and hard cardiac 
events [RR 4.3, CI (2.3-8.1)]. In this group, the annual cardiac death, all cause mortality and hard 
cardiac event rates at 5 years of follow-up in patients with a normal DSE were 0.9%, 1.8% and 
1.2% respectively. In patients with an abnormal DSE event rates were 3.1%, 4.7% and 4.7% 
respectively.  
In this study DSE added independent prognostic information, additional to clinical and 
hemodynamic parameters in patients with angina and high pre-test probability of CAD. Patients 
with a normal DSE had a lower risk of death and hard cardiac events, whereas in patients with an 
abnormal DSE the incidence of all events was substantially higher. The presence of myocardial 
ischemia was the strongest independent predictor for all end-points and was associated with 
increased risk of events after adjustment to clinical data.  
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The prevalence of CAD in patients who present with typical angina is expected to be 
approximately 90% for men and 70% for women (8). In this study however, DSE was normal in 
38% of the population. The results of our study indicate that patients with a normal DSE have a 
low event rate during intermediate to long term follow up and therefore these patients, who 
represent a relatively large proportion of the study population, can be exempted from further 
(invasive) diagnostic evaluation, unless a change in clinical status occurs.  
Few studies evaluated the prognostic value of stress echocardiography in patients with 
high pre-test probability of CAD. These studies used composite endpoints that include soft 
events such as unstable angina and revascularization (9, 10), or were not powered enough to 
demonstrate an incremental value of myocardial ischemia alone (11). To our knowledge, the 
independent association of myocardial ischemia with mortality in these patients has not been 
established. A recent study by Hachamovitch et al. (12), demonstrated that myocardial perfusion 
imaging provided incremental prognostic information for predicting cardiac death in 1270 
patients with high likelihood of CAD, who underwent exercise or adenosine stress myocardial 
perfusion tomography.  
Although patients were determined to have high pre-test probability of CAD in our study, 
the annual hard cardiac event rate was moderate (4%). This can be explained by exclusion of 
patients with previous myocardial infarction, unstable symptoms and history of CAD, which 
resulted in inclusion of a stable population with preserved left ventricular systolic function. 
Although this study excluded patients with cardiomyopathy, the possible existence of other 
cardiac conditions that may be associated with cardiac death without ischemia such as cor 
pulmonale may have been confounding. However, the incremental significance of myocardial 
ischemia was demonstrated despite of this potential limitation.   
We concluded that in patients with classic angina, determined to have a high pre-test 
probability of CAD, DSE yields independent prognostic information. A negative DSE is 
associated with a relatively low event rate for cardiac and all cause mortality as well as for the 
combined end-point of hard cardiac events. These findings have important clinical implications 
since these patients can be exempted from invasive studies if they have no change in clinical 
status. Myocardial ischemia during DSE is independently associated with increased risk of death 
after adjustment for clinical data. 
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Abstract 
 
Background. Non-invasive evaluation of coronary artery disease in patients with left 
bundle branch block has limitations inherent to different modalities and the relative merits of the 
tests are unclear. This meta-analysis assessed the accuracy of the most frequently used non-
invasive techniques, including exercise electrocardiography, myocardial perfusion imaging and 
stress echocardiography, for the detection of coronary artery disease and the prediction of cardiac 
events in patients with left bundle branch block. 
Methods. A systematic review of all reports on detection of coronary artery disease and 
prediction of cardiac events in patients with left bundle branch block (published between January 
1970 and December 2004) revealed 55 diagnostic and 9 prognostic reports with sufficient details 
for calculating the sensitivity and specificity of each modality. Random effects models were used 
to calculate summary odds ratios and 95% confidence intervals. 
Results. The overall sensitivity was highest for (visually analysed) exercise 
electrocardiography and myocardial perfusion imaging compared to stress echocardiography 
(83.4% and 82.1% versus 74.6% respectively, p<0.0001); quantitatively analysed myocardial 
perfusion imaging yielded an even higher sensitivity (88.5%). stress echocardiography had the 
highest specificity (88.7%) versus myocardial perfusion imaging (41.2%) and exercise 
electrocardiography (60.1%) (p<0.0001). From 8 reports, the relative risk of cardiac death or 
myocardial infarction with an abnormal stress echocardiography and myocardial perfusion 
imaging was elevated >7-fold but did not differ by imaging modality (p=0.9).  
Conclusions. Meta-analysis of non-invasive assessment of coronary artery disease in 
patients with left bundle branch block shows that exercise electrocardiography and myocardial 
perfusion imaging have the highest sensitivity (83.4% and 82.1%), while stress echocardiography 
has the highest specificity (88.7%). Prognostic accuracy of myocardial perfusion imaging and 
stress echocardiography appears comparable. 
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Introduction 
 
 
Left bundle branch block (LBBB) is associated with adverse clinical outcome, in 
particular in patients with known coronary artery disease (CAD) or after myocardial 
infarction (1-3). Non-invasive evaluation of CAD in patients with LBBB has several 
limitations and continues to be a challenge in cardiology. Pre-existent repolarization 
abnormalities due to abnormal excitation activity with consequent asynchronous ventricular 
contraction and myocardial perfusion abnormalities hamper the diagnostic accuracy of the 
available non-invasive techniques, including exercise electrocardiography (ECG), stress 
echocardiography (SE) and myocardial perfusion imaging (MPI). In particular, a high false-
positive rate has been reported for the detection of left anterior descending (LAD) disease. In 
an attempt to improve the diagnostic accuracy of non-invasive imaging modalities, several 
investigators have examined the use of pharmacological stress instead of exercise stress, and 
have adopted different criteria to define myocardial ischemia. In addition to diagnosis of 
CAD, SE and MPI have been proposed for prognosis and subsequent risk stratification in 
patients with LBBB. Over the past 30 years, multiple studies have evaluated the diagnostic 
and prognostic value of both non-invasive techniques in patients with LBBB; however, a 
direct comparison is not available and the relative merits of the various modalities remains a 
matter of debate. Therefore, a meta-analysis of the published data on the aforementioned non-
invasive techniques has been performed for the detection of CAD and the prediction of 
(cardiac) events in patients with LBBB. 
 
 
Methods 
 
 
Data Sources. The objective of the current meta-analysis was to evaluate the 
published reports on exercise ECG, MPI and SE in patients with LBBB for: 1. the detection of 
CAD (diagnostic merit), considering coronary angiography as “the gold standard” and 2. the 
prediction of cardiac events (prognostic merit). The studies were identified by means of 
several combined search strategies. 1) A search of the MEDLINE database (January 1970 to 
December 2004) was conducted. The term LBBB was combined which each of the following 
terms: exercise ECG, non-invasive imaging, coronary artery disease, radionuclide imaging, 
SPECT, SE, thallium-201, technetium-99m sestamibi, technetium-99m tetrofosmin, 
dipyridamole, adenosine, and dobutamine. 2) A manual search of 20 cardiology and nuclear 
medicine journals from January 1970 to July 2004 was carried out. 3) The reference lists of 
the reports obtained through these searches were screened for additional articles that may 
have been missed. Only articles in English and those containing primary data were 
considered; reviews or abstracts were excluded.  
 
Data Selection. Inclusion criteria. For inclusion in the analysis on the diagnosis of 
significant CAD, the following criteria had to be met: 1) studies were included only if patients 
underwent coronary angiography; 2) the study contained sufficient details allowing 
calculation of sensitivity and specificity for detection of CAD. For inclusion in the analysis on 
the prognostic value, only studies with a minimum of 1 year of mean follow-up data 
collecting major adverse cardiac events and including >95% of enrolled patients. 
Exclusion criteria. Exclusion criteria for the diagnostic analysis were: 1) studies 
including patients with intermittent LBBB on the ECG; 2) studies in patients with LBBB and 
idiopathic dilated cardiomyopathy without angiographically significant CAD; 3) studies only 
reporting segmental analysis without per patient analysis. Exclusion criteria for the prognostic 
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analysis were: 1) studies reporting not enough data to calculate 2 x 2 tables for hard cardiac 
events (cardiac death and myocardial infarction, either individually or combined). 
 
Data Collection and Study Definitions. For each study the following characteristics 
were noted: the year of publication, the mean or frequency of clinical characteristics including 
gender, age, cardiac risk factors, the modality (exercise ECG, MPI, SE) to evaluate CAD, the 
type of stress, the radionuclide tracer (in case of MPI), and the segmental model (number of 
segments) used for analysis. The gold standard for CAD was >50% or >70% coronary artery 
stenosis on angiography. From each of the prognostic studies, the duration of follow-up, the 
frequency and events (cardiac death, infarction) were noted. 
Nuclear perfusion data were recorded in terms of normal or abnormal findings. 
Perfusion abnormalities in the LAD territory were noted separately, if available. When more 
than one stressor (i.e. exercise and pharmacological stress) was used in the same population 
with independent results, studies were included in the meta-analysis as separate results.  
Similarly, stress echocardiographic data were recorded as normal and abnormal 
findings. Wall motion abnormalities in the LAD territory were also noted, when retrievable.  
Angiographic data on coronary arteries were recorded as the presence or absence of 
angiographically significant CAD and when retrievable LAD disease or single- and multi-
vessel disease was noted. 
For prognostic purposes, only hard events were noted during follow-up and were 
recorded as (cardiac) death, non-fatal myocardial infarction, and combined cardiac events 
(cardiac death or myocardial infarction).  
 
Statistical Analysis. For each of the published reports, we discerned available clinical 
characteristics for mean age and follow-up time period as well as the relative frequency of 
men, angiographic coronary disease, hypertension, diabetes, and prior myocardial infarction. 
From the compilation of this data, the weighted average frequencies or mean was calculated.  
Diagnostic value of tests. From each of the selected reports, a 2 x 2 table was 
constructed that included false-positive and false-negative test results as well as true-negative 
and true-positive test results. Based upon this 2 x 2 frequency data, sensitivity and specificity 
were calculated for overall disease, LAD disease, single- and multi-vessel disease for exercise 
ECG, MPI and SE. In addition, for nuclear imaging, analyses were repeated for visual and 
quantitative analysis of data. From the combined data, a weighted (by the proportional sample 
size) average sensitivity (number of true positive tests divided by the total number of patients 
with angiographically significant CAD) and specificity (number of true negative tests divided 
by the total number of patients without angiographically significant CAD) was calculated. 
Overall diagnostic accuracy was defined as the total of true-positive and true-negative tests 
divided by the total number of patients.  
Subanalyses were performed to assess and compare sensitivity/specificity for the 
different modalities (when data available) for single- versus multi-vessel disease, LAD 
disease and different stressors. As well, we compared the diagnostic accuracy by the type of 
stress (pharmacologic versus exercise), when available.  
Using Comprehensive Meta-Analysis software, the summary odds ratio of a positive 
test with CAD versus a negative test with CAD was calculated (www.meta-analysis.com, 
access date: December 2004). The odds ratio (with 95% confidence intervals, CI) was 
calculated using a random effects model. A chi-square test for heterogeneity, a measure of the 
combinability of the reports, was calculated and, for all but the exercise ECG, the p value was 
>0.05 revealing that the presentation of summary odds ratio data was acceptable.  
A summary receiver operating characteristics (ROC) curve was displayed by plotting 
the false-positive rate on the X-axis by the diagnostic sensitivity values on the Y-axis for 
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individual reports using the exercise ECG, MPI and SE results. The line of best fit for the 
scatterplot was calculated using a cubic spline function optimized for the amount of 
explanatory variance. The concordance (C-) index from the ROC curve was calculated for 
exercise ECG, MPI and SE.  
Prognostic value of tests. A 2 x 2 table was generated separately for the endpoint of 
cardiac death or myocardial infarction. From the 2 x 2 data, a relative risk ratio (RR) (with 
95% CI) was calculated using Comprehensive Meta-Analysis software (www.meta-
analysis.com, access date: December 2004). A summary RR ratio (with 95% CI) was 
calculated for each technique using the random effects model calculation of Mantel-Haenszel. 
A chi-square test for heterogeneity was calculated to determine the adequacy of combining 
the individual reports. In each case, the p>0.70 such that combining the individual reports was 
deemed acceptable.  
From the summary data, the cardiac death or myocardial infarction rates were 
calculated within a range of follow-up duration varying from 6 months to 5 years. 
Accordingly, event-free survival (25th and 75th percentiles) was plotted for 5-year follow-up. 
The RR ratio (with 95% CI) was calculated at 5-year follow-up.  
To compare time-related change in event-free survival for patients with normal MPI 
findings, we compared the 6-month event rates in those with a normal MPI as compared with 
similarly-aged event rates in the general population 
(http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf, access date: January 2005). Using 
this set of comparisons, this defined the time point at which there was an increased risk for 
those with a low-risk MPI.  
 
 
 
Results 
 
 
Diagnostic Accuracy to Detect CAD. The baseline and clinical characteristics of the 
different studies focusing on detection of CAD are summarized in Table 1 and divided 
according to the non-invasive technique used. For exercise ECG, a total of 6 studies (n=182 
patients with 177 undergoing coronary angiography) met the inclusion criteria (4-9). In 
general, patients undergoing exercise ECG were younger, with a higher prevalence of male 
gender and less risk factors for CAD as compared to patients undergoing MPI or SE (p<0.05 
for each comparison). For MPI, a total of 43 studies were reported with 1,785 patients (with 
1,014 undergoing coronary angiography) (10-43). For SE, 6 studies were reported with 236 
patients (all having coronary angiography) (29, 39, 41, 44-46). 
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Table 1. Baseline Characteristics Classified According to the Non-invasive Technique 
Used 
 
 Exercise ECG MPI SE 
Years of enrollment 1974-1998 1993-2004 1995-2001 
Total nr of patients 
Patients with angiography 
182 
177 
1,785 
1014 
236 
236 
Clinical data 
  % Male 
  Mean age (yrs)** 
  % Prior MI** 
  % HTN** 
  % DM 
 
68.5% 
47±9 
26.9% 
8.7% 
NA 
 
56.2% 
62±6 
23.2% 
39.3% 
20.1% 
 
58.6% 
60±9 
4.7% 
57.5% 
16.8% 
Mean LVEF (%) NA 46±14 49±12 
Angiography 
  Absence of CAD 
  MVD 
 
56.6% 
32.0% 
 
46.8% 
24.0% 
 
42.9% 
30.7% 
Stressor 
  Exercise** 
  Pharmacological stress 
  Combined 
 
100.0% 
NA 
NA 
 
48.8% 
41.9% 
9.3% 
 
16.7% 
83.3% 
NA 
 
**p<0.05 
 
DM: diabetes mellitus; CAD: coronary artery disease; ECG: electrocardiography; HTN: 
hypertension; LVEF: left ventricular ejection fraction; MI: myocardial infarction; MPI: 
myocardial perfusion imaging; MVD: multi-vessel disease; NA: not available; SE: stress 
echocardiography. 
 
 
 
Table 2 shows the weighted average (by sample size) diagnostic accuracy for exercise 
ECG, MPI, and SE. The overall sensitivity was highest for MPI (88.5% when quantitative 
analysis was used), and both exercise ECG and MPI had a significantly higher sensitivity as 
compared to SE. The overall specificity was significantly higher for SE as compared to MPI 
and exercise ECG (88.7% versus 41.2% and 60.1% respectively, p<0.0001). The overall 
accuracy for detection of CAD was 66.4% for exercise ECG, 70.3% for MPI (improving to 
78.0% with quantitative analysis), and 84.4% for SE (p<0.0001).  
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Table 2. Weighted Average Diagnostic Accuracy for Detection of CAD 
 
 Exercise 
ECG 
MPI SE Overall 
p-value 
Comparative 
Differences 
Sensitivity 
     Overall 
 
     Single-vessel CAD 
     Multi-vessel CAD 
     LAD  
 
83.4 
- 
80.5 
95.4 
NA 
 
 
82.1 (V) 
88.5 (Q) 
83.3 
87.2 
91.9 (V) 
89.4 (Q) 
 
74.6 
- 
53.0 
93.7 
79.3 
 
 
<0.01 
- 
<0.0001 
NS 
<0.0001 
 
 
ECG / MPI vs. SE 
- 
ECG / MPI vs. SE 
- 
 
- 
Specificity 
     Overall  
 
     LAD  
 
60.1 
 
NA 
 
 
41.2 (V) 
38.2 (Q) 
54.9 (V) 
51.8 (Q) 
 
88.7 
 
91.5 
 
 
<0.0001 
 
<0.0001 
 
 
All 3 different 
- 
- 
- 
Accuracy 
 
66.4 
 
70.3 (V) 
78.0 (Q) 
84.4 
 
<0.0001 
 
ECG / MPI vs. SE 
- 
 
CAD: coronary artery disease; ECG: electrocardiography; LAD: left anterior descending; Q: 
quantitative; MPI: myocardial perfusion imaging; SE: stress echocardiography; V: visual. 
 
 
Summary Odds Ratio for Positive and Negative Tests with CAD. Figure 1 depicts 
the odds of a positive versus negative test having CAD at angiography. The odds of a positive 
echocardiogram were elevated 30.8-fold (95% CI=13.66-62.8, p<0.0001) as compared with a 
negative study. By comparison, the odds of a positive MPI were only elevated 8.3 (95% 
CI=5.1-13.64, p<0.0001) when compared with a negative perfusion study. For exercise ECG, 
the odds ratio was elevated 4.3-fold (95% CI=1.8-10.3, p=0.001) but revealed substantial 
heterogeneity around this summary measure (p<0.05).  
 
 
 
 
Figure 1. Diagnostic accuracy expressed as odds ratio and 95% CI of a positive versus 
negative test for exercise ECG, MPI and SE.  
 
 
 
  114 
 
 
Summary ROC Curves. Based upon optimal diagnostic accuracy data for exercise 
ECG, MPI and echocardiography, a plot of the false positive and diagnostic sensitivity 
revealed variable disease classification rates (Figure 2). The C-index was highest for SE 
(0.85) when compared with stress MPI (0.72) and exercise ECG (0.66).  
 
 
 
 
 
Figure 2. Summary ROC curves for exercise ECG, MPI, and SE for detection of CAD in 
patients with LBBB.  = exercise ECG; ♦= MPI; c= SE. 
 
 
 
Diagnostic Accuracy to Detect Single- versus Multi-vessel Disease. For detection of 
single-vessel disease, MPI had the highest sensitivity when compared to exercise ECG and SE 
(83.3% versus 80.5% and 53.0% respectively, p<0.001, Table 2). For detection of multi-
vessel disease, MPI and SE had comparable sensitivities (87.2% and 93.7%, NS), which were 
also comparable to exercise ECG (95.4%, NS versus MPI and SE, Table 2).  
 
Diagnostic Accuracy of Different Stressors. For MPI, 21 studies used exercise and 
18 used pharmacological stress (combined with exercise in 4 studies). The sensitivity was 
high for both exercise (92.9%) and pharmacological stress (88.5%), while the specificity was 
significantly lower for exercise stress (23.3%) as compared to pharmacological stress (74.2%, 
p<0.01, Figure 3). For SE, only one study used exercise and 5 used pharmacological stress. In 
general, SE had a lower sensitivity than MPI (76% for exercise SE and 74% for 
pharmacological SE, p<0.01 vs MPI). Conversely, the specificity of SE was superior to MPI 
(even for pharmacological MPI).  
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Figure 3. Diagnostic accuracy according to stressor (exercise vs pharmacological stress) for 
MPI and SE for detection of coronary artery disease. 
 
 
 
 
Diagnostic Accuracy to Detect LAD Disease. Detailed information of exercise ECG 
to detect LAD disease was not available. For MPI, the sensitivity was high, both for exercise 
and pharmacological stress (Figure 4A). The specificity improved significantly (from 47% to 
80%, p<0.01) when pharmacological stress was used. For SE, the sensitivity was higher for 
exercise compared to pharmacological stress (p= 0.028), whereas specificity was similar 
between the two stressors type (Figure 4B). However, only 1 report for exercise SE was 
available.  
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Figure 4. Sensitivity and specificity according to stressor MPI (Panel A) and SE (Panel B) for 
detection of LAD coronary artery disease. 
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Prognostic Accuracy. No studies on prediction of cardiac events using exercise ECG 
in patients with LBBB have been reported. Data on prognosis were collected from 9 studies, 7 
were performed using MPI, and 2 with SE using dobutamine stress (28, 47-54). All studies 
were conducted in patients with known or suspected CAD.  
 
Myocardial Perfusion Imaging. A normal MPI was present in 31.5% of patients, 
whereas any abnormality on MPI was observed in 68.5% of patients. During a mean follow-
up of 36 months (range 6 to 60 months), 163 deaths occurred (with 79 cardiac deaths) and 20 
myocardial infarctions. The summary RR for predicting any cardiac events (cardiac death or 
myocardial infarction) with an abnormal MPI was calculated from 6 reports (Figure 5). A 
report by O’Keefe et al. (28) as excluded from the analysis since available prognostic data 
were only in normal studies. Analysis of pooled data (n=6 studies, n=997 patients) showed the 
efficacy of MPI to predict cardiac events (RR of an abnormal versus normal MPI 6.93, 95% 
CI 4.28 – 11.20, p<0.0001).  
 
 
 
 
Figure 5. Prognostic accuracy for MPI and SE expressed as RR and 95% CI of a positive 
versus negative test. 
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Event-free survival curves were constructed based on the data of 7 studies where 
results on patients with normal or abnormal MPI were reported (Figure 6). Five-year event-
free survival rate in patients with a normal MPI was 98.4% (25th-75th percentile 95.3% – 
100%), whereas in patients with an abnormal study was 79.8% (25th-75th percentile 58.5% - 
94.1%). Thus, for the 5-year follow-up time period, patients with an abnormal MPI had a 
13.39-fold (95% CI 8.14-22.03) higher event rate as compared with patients with a normal 
MPI (p<0.0001).  
 
 
 
 
 
Figure 6. Summary 5-year event-free [median] survival (25th – 75th %ile) for patients with a 
normal or abnormal MPI study. 
 
 
  119
When plotting the time to increasing risk for patients with a normal MPI (to determine 
the warranty period for a normal scan), the RR was calculated across a range of follow-up 
times ranging from 6 to 60 months (Figure 7) and compared to similarly aged event rates from 
the general population. For follow-up times through 18 months, the event rate for those with a 
normal MPI were similar to that of the general population (p>0.40). However, at 24 months, a 
non-significant trend was observed (p=0.18) that continued to increase until exhibiting a 
significant increased risk at 36 months of follow-up (p=0.0225). At this point, the 95% CI 
exceeded 1.0. 
 
 
 
 
Figure 7. RR ratio and 95% CI of a cardiac event in patients with a normal MPI study when 
compared with the cardiovascular event rate in the general population. The RR becomes 
significant at 30 months after the initial MPI. 
 
 
 
Stress Echocardiography. An abnormal SE was detected in 26% of the patients (n=2 
studies, n=560 patients). During a mean follow-up of 35 months, 43 deaths occurred with 21 
cardiac deaths and 20 myocardial infarctions. The summary RR for predicting hard cardiac 
events (cardiac death or myocardial infarction) with an abnormal SE is presented in Figure 5. 
Analysis of the pooled data showed that an abnormal SE was associated with an increased 
risk of cardiac events (RR 6.54, 95% CI 1.98-21.65, p<0.0001).  
 
Comparison of MPI and SE. No significant differences were present in accuracy 
between MPI and SE for the prediction of cardiac events (p=0.9); wider CI were noted with 
MPI. Heterogeneity test for both tests revealed no significant differences.  
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Discussion 
 
The current meta-analysis of non-randomized reports on the detection of CAD and the 
prediction of cardiac events in patients with LBBB focused on the most frequently used non-
invasive techniques: exercise ECG, MPI and SE. The main findings of the current study are 
that the sensitivity for the detection of CAD in patients with LBBB is higher for MPI (in 
particular when quantitative analysis is used) and exercise ECG as compared to SE. 
Sensitivity for LAD disease in particular is poor with MPI when exercise is used, but 
improved significantly when pharmacological stress was used. Conversely, the overall 
specificity for the detection of CAD is significantly higher for SE as compared to MPI and 
exercise ECG. The overall accuracy for detection of CAD is comparable for SE and MPI 
(when quantitative analysis is used) and significantly higher compared to exercise ECG. The 
prognostic accuracy for the prediction of hard cardiac events is comparable between MPI and 
SE.  
 
Detection of CAD in Patients with LBBB. The Framingham study showed that the 
onset of LBBB in patients with known CAD is associated with an increased cumulative 
cardiovascular mortality (2, 3), whereas other studies reported that patients with LBBB 
without clinical evidence of CAD have a good long-term prognosis (1, 54). Thus, accurate 
non-invasive evaluation is clinically important in patients with LBBB and has prognostic 
implications. Non-invasive evaluation of CAD in patients with LBBB is challenging. The 
commonly used non-invasive tests (exercise ECG, MPI, and SE) generally have lower 
sensitivity and specificity values in patients with LBBB as compared to patients without 
LBBB. This is related to the fact that the interpretation of exercise ECG, MPI, and SE in the 
presence of LBBB is limited. First, evaluation of myocardial ischemia by exercise ECG is 
complicated by pre-existent repolarization abnormalities secondary to the altered 
depolarization, and exercise-induced ST-segment changes are non-specific for detection of 
ischemia in the presence of LBBB. Second, the ability of MPI to detect CAD in patients with 
LBBB suffers from the high incidence of false positive perfusion defects in the 
interventricular septum in the absence of LAD disease. Because of the electrical conduction 
defect, septal blood flow (and flow reserve) may be decreased during physiological stress 
(55), which does not necessarily reflect ischemia. Third, SE relies on detection of stress-
induced wall motion/thickening abnormalities. In patients with LBBB, mechanical 
asynchrony between left and right ventricle results in abnormal septal motion, thereby 
hampering interpretation of induction of septal wall motion abnormalities. 
This meta-analysis of currently available data shows that MPI and exercise ECG have 
the highest sensitivity as compared to SE for detection of CAD. However, SE showed a 
higher overall specificity compared to MPI and exercise ECG. The specificity of MPI could 
be improved using quantitative analysis instead of visual interpretation. These data support 
the use of either MPI or SE as first line technique for non-invasive detection of CAD in 
patients with LBBB.  
A specific comparison between exercise and pharmacological stress supported the use 
of pharmacological stress with MPI, imaging confirmed the higher sensitivity for MPI (both 
stressor types) compared to SE, whereas the specificity was higher for SE compared to MPI. 
In particular, exercise MPI had a very low specificity (23%), which increased significantly 
when pharmacological stress was used (74%), and supports the ACC/AHA guidelines in that 
patients with LBBB referred for MPI should undergo pharmacological (in particular 
vasodilator) stress (56, 57). The low specificity of exercise MPI is related to a combination of 
shortened diastolic relaxation time and asynchronous contraction which are worsened by 
exercise (or dobutamine) stress (10, 13, 55, 58). For SE it is less clear what stressor is 
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preferred: currently only 1 report on exercise SE is available (46), whereas the remaining 
studies have used pharmacological stress. 
In addition, similar results were obtained for detection of LAD disease: sensitivity was 
high for both MPI and SE using either exercise or pharmacological stress. The specificity 
however was lower for exercise MPI (47%), which could be improved by pharmacological 
stress (80%). 
 
Prognostic Value of MPI and SE to Predict Cardiac Events. Prognostic data on 
exercise ECG in patients with LBBB are not available. The current meta-analysis shows that, 
despite the aforementioned diagnostic limitations, both MPI and SE have additional 
prognostic value over clinical data. The data on prognosis after SE are limited, with only 2 
studies and 560 patients. However, the available data indicate that both modalities are equally 
useful in patients with LBBB to distinguish low- and high-risk patients. The prognosis of 
patients with LBBB and a normal MPI study is comparable to the prognosis of patients 
without LBBB with a normal test (59). An abnormal MPI or SE was associated with a 6.9 or 
6.5-fold higher risk for cardiac death or myocardial infarction. The RR varied substantially 
between studies (Figure 5) and is probably related mostly to differences in sample size but 
varying casemix and study methodology difference would also be contributory. Importantly, 
no differences were present between the 2 techniques for prediction of cardiac events.  
Finally, the warranty-period of a normal MPI study was evaluated as was previously 
described by Hachamovitch et al for patients with known or suspected CAD (60). The current 
pooled analysis shows that patients with a normal test have a similar prognosis to the general 
population until 1 year and half, whereas a trend to a higher incidence of cardiac events 
begins at two years and becomes significant at three years. This observation suggests that 
after 2-3 years non-invasive testing should be repeated to define the patient's risk. 
 
Limitations 
 
This meta-analysis of published data reveals some of the shortcomings of the currently 
available data. First of all, consistency in the imaging interpretation is needed. For MPI, not 
all studies used both fixed and reversible defects as markers for CAD, and for SE not all 
studies used resting and stress-induced wall motion abnormalities. Second, the available 
diagnostic and prognostic data series are relatively small when compared to the available 
evidence in patients without LBBB (59-61). More diagnostic data are needed in patients with 
an intermediate likelihood of CAD; the majority of studies have focused on patients with a 
relatively high likelihood of CAD. Third, more studies are needed to clearly define the 
prognostic role of imaging in patients with LBBB, in particular more SE data are needed.  
 
 
 
Conclusions and Clinical Implications 
 
Meta-analysis of available data on non-invasive testing in patients with LBBB showed 
that accuracy for detection of CAD is comparable for SE and MPI (preferably using 
quantitative analysis of data) and significantly higher as compared to exercise ECG. The 
prognostic accuracy for the prediction of hard cardiac events is comparable between MPI and 
SE. Thus, the available evidence favours the use of SE or MPI (using quantitative analysis) as 
first-line techniques for diagnostic and prognostic purposes in patients with LBBB with 
known or suspected CAD.  
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Abstract 
 
 Background. Non-invasive pacemaker stress echocardiography is a newly introduced 
method for the diagnosis of coronary artery disease in patients with a permanent pacemaker. 
The prognostic value of pacemaker stress echocardiography has not been previously studied. 
 Methods. We studied 136 patients (mean age 64±12 years) with a permanent 
pacemaker who underwent pacemaker stress echocardiography for evaluation of coronary 
artery disease. All patients underwent pacemaker stress echocardiography by external 
programming (pacing heart rate up to ischemia or target heart rate).  
 Results. Thirty-one patients (23%) had a normal study. Ischemia was detected in 75 
(55%) patients. During a mean follow-up of 3.5±2.4 years, 35 (26%) deaths (20 due to cardiac 
causes) and 2 (1%) nonfatal myocardial infarction occurred. The annual cardiac death rate 
was 1.3% in patients without ischemia and 4.6% in patients with ischemia (p=0.01), whereas 
the annual all cause mortality rate was 3.1% in patients without ischemia and 7% in patients 
with ischemia (p=0.004). The presence of ischemia during pacemaker stress 
echocardiography was the strongest independent predictor of cardiac death (hazard ratio 4.1 
CI 1.2-14.5) and all cause mortality (hazard ratio 2.7 CI 1.2-6.0) in a multivariable model.  
 Conclusions. Myocardial ischemia during pacemaker stress echocardiography is an 
independent predictor of cardiac death and all cause mortality in patients with a permanent 
pacemaker. 
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Introduction 
 
 
The number of permanent pacemaker implantations has exponentially increased in the 
last decades and may be related to the increase of the elderly population as well as to the 
expanding indications for pacing (1). Coronary artery disease may concomitantly exist in 
patients with pacemaker or may be the underlying cause of conduction defects in some cases 
(2-5). Non-invasive evaluation of coronary artery disease is challenging in these patients, 
since the electrocardiogram is often uninterpretable (6). Myocardial perfusion abnormalities 
in the septum and apex have been reported in the absence of coronary artery disease in 
patients with paced rhythm (7). Non-invasive pacemaker stress echocardiography has been 
recently introduced as a feasible method to increase heart rate and to induce myocardial 
ischemia in these patients (8, 9). There are currently no data to define the prognostic value of 
pacemaker stress echocardiography. The aim of this study was to assess the value of 
pacemaker stress echocardiography for prediction of cardiac death and all cause mortality in 
patients with known or suspected coronary artery disease who have a permanent right 
ventricular pacemaker. 
 
 
Methods 
 
 
Patients. The study population comprised 140 consecutive patients with a permanent 
right ventricular pacemaker referred to the Thoraxcenter, Rotterdam, The Netherlands, 
between 1998 and 2004 for evaluation of myocardial ischemia. Follow-up was successful in 
138 patients (99%). Two patients underwent coronary revascularization in the first 60 days 
after pacemaker stress echocardiography. These patients were excluded from the analysis, 
because referral to myocardial revascularization in the first 60 days after stress testing tends to 
be based on the results of the test, whereas referral to revascularization >60 days after testing 
tends to be based on worsening of the patients clinical status (10). Data on the remaining 136 
patients are reported. The protocol was approved by the Hospital Ethics Committee. All 
patients gave informed consent before the test. A structured interview and clinical history 
were taken and cardiac risk factors were assessed before pacemaker stress echocardiography.  
Hypertension was defined as a blood pressure ≥140/90 mmHg, or treatment with 
antihypertensive medication. Diabetes mellitus was defined as a fasting glucose level ≥7.8 
mmol/L or the need for insulin or oral hypoglycemic agents. Hypercholesterolemia was 
defined as a total cholesterol ≥6.4 mmol/L, or treatment with lipid-lowering medication. 
 
Pacemaker Stress Echocardiography. Echocardiography was performed with 
standard equipment (Sonos 5500, Andover, Massachusetts, USA) using second harmonic 
imaging (1.8MHz/3.6MHz). Images were obtained with the patient in the left lateral decubitus 
position and were acquired before the stress test and every 3 min throughout the stress test, 
using the standard parasternal and apical views. Continuous ventricular pacing was started at 
the rate of 100 beats/minute and was increased by 10 beats every three minutes until test end-
point was reached. In patients with a dual chamber pacemaker, the pacemaker stress test was 
started with atrial pacing, if target heart rate or other test end-points were not reached with 
this approach the pacemaker was programmed to ventricular pacing. Test end-points were 
achievement of target heart rate (85% of maximum age predicted heart rate), pacemaker 
maximal programmable heart rate, severe angina, systolic blood pressure fall >40 mmHg, 
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blood pressure >240/120 mmHg, or significant cardiac arrhythmia. The echocardiograms 
were recorded in a quad-screen format. Two experienced observers, unaware of the clinical 
data, scored the echocardiograms using a standard 16-segment model as suggested by the 
American Society of Echocardiography (11). In case of disagreement, a consensus decision 
was achieved by a third observer. Regional wall motion and systolic wall thickening were 
scored on a 5-point scale (1= normal, 2= mild hypokinesia, 3= severe hypokinesia, 4= 
akinesia, 5= dyskinesia). Ischemia was defined as new or worsened wall motion abnormalities 
during stress indicated by an increase of wall motion score ≥1 grade in ≥1 segment. Ischemia 
was not considered to be present when akinetic segments at rest became dyskinetic during 
stress. Myocardial septal and apical function was evaluated based on systolic thickening 
because wall motion could be influenced by ventricular pacing.  
 
Follow-up. Follow-up data collection was performed by contacting the patient’s 
general practitioner and by review of hospital records. The date of the last review or 
consultation was used to calculate follow-up time. Follow-up events noted were cardiac and 
all cause mortality. Cardiac death was defined as a death caused by acute myocardial 
infarction, significant cardiac arrhythmias, or refractory congestive heart failure. Sudden 
death occurring without another explanation was considered as cardiac death. Myocardial 
revascularization procedures were registered. 
 
Statistical Analysis. Values were expressed as means (± SD) or number, and 
compared using the Student t test or chi-squared test. Univariate and multivariate Cox 
proportional hazard models (BMDP Statistical Software Inc., Los Angeles, California) were 
used to identify variables that were independently predictive of cardiac death and all cause 
mortality 12. Variables were selected in a stepwise forward selection manner with entry and 
retention set at a significance level of 0.05. The risk of a variable was expressed as hazard 
ratios with corresponding 95% confidence intervals. Clinical data, stress test variables, and 
noninvasive imaging data were incorporated into the analysis. The incremental value of 
dobutamine stress echocardiography over the clinical value in the prediction of cardiac death 
and all cause mortality was performed according to 2 models. In model 1, only clinical data 
were entered; in model 2 dobutamine echocardiographic variables including resting wall 
motion abnormalities and myocardial ischemia were added to the clinical variables. The 
probability of survival was calculated using the Kaplan-Meier method, and survival curves 
were compared using the log-rank test. P values <0.05 were considered statistically 
significant. 
 
 
 
Results 
 
Clinical data are presented in Table 1. Ninety-eight (72%) patients had a dual-chamber 
pacemaker, and 38 (28%) had a single-lead right ventricular pacemaker. In patients with a 
dual-chamber pacemaker, pacemaker stress echocardiography using atrial pacing was 
performed in 82 (84 %) patients and ventricular pacemaker stress testing was performed in 16 
(16%).  
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Table 1. Baseline Characteristics (136 patients) 
 
 Number (%) 
Age (years) 64 ± 12 
Men 94 (69%) 
Systemic hypertension 28 (20%) 
Hypercholesterolemia  87 (64%) 
Smoker 10 (7%) 
Diabetes mellitus 27 (20%) 
Prior myocardial infarction 44 (32%) 
Prior heart failure 48 (35%) 
Beta blockers 57 (42%) 
Diuretics 34 (25%) 
Angiotensin converting enzyme inhibitors 43 (32%) 
Nitrates 49 (36%) 
Calcium channel blockers 28 (20%) 
Indications for pacemaker implantation:  
  Atrioventricular block 53 (39%) 
  Sick sinus syndrome 43 (32%) 
  Bradycardia 40 (29%) 
 
 
 
Hemodynamic data are presented in Table 2. During the pacing there was a mild 
increase of systolic blood pressure (119 ± 24 mmHg to 123 ± 26 mmHg, p<0.05). No major 
adverse effects were observed during the test. Thirty-one patients (23%) had angina during 
pacemaker stress echocardiography, Angina was the reason for the test termination in 3 of 
these patients. Other causes of test termination were achievement of the target heart rate in 
126 (93%) patients, and achievement of pacemaker maximal programmable heart rate in 5 
(4%). Two (1%) patients experienced nausea during pacemaker stress echocardiography. 
 
 
 
Table 2. Pacemaker Stress Echocardiographic Data 
 
Heart rate at rest (beats/min) 73 ± 18 
Heart rate at peak (beats/min) 124 ± 17 
Rest systolic blood pressure (mmHg) 119 ± 24 
Peak systolic blood pressure (mmHg) 123 ± 26 
Rest rate pressure product  9456 ± 2863 
Peak rate pressure product  15423 ± 4627 
Angina during stress 31 (23%) 
Resting wall motion score index 2.1 ± 0.7 
Ischemia (patients) 75 (55%) 
Number of ischemic segments 6.4 ± 5.7 
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Pacemaker Stress Echocardiography and Outcome. Thirty (22%) patients had a 
normal pacing stress echocardiogram. Fixed wall motion abnormalities were detected in 31 
(23%) patients and ischemia was induced in 75 (55%) patients. Eighteen (13%) patients 
showed ischemia only in the septum and/or apex. During a mean follow-up of 3.5 ± 2.4 years, 
there were 35 (26%) deaths, of which 20 (15%) were due to cardiac causes. Nonfatal 
myocardial infarction occurred in 2 (1%) patients. Forty-one (30%) patients underwent 
coronary angiography, within 6 months from the stress test. Late revascularization was 
performed in 36 (26%) patients, of these 17 (12%) underwent percutaneous interventions and 
19 (14%) underwent coronary bypass surgery.  
 
Predictors of Events. Predictors of cardiac death and all cause mortality in 
univariable and multivariable models are presented in Table 3. Ischemia was the strongest 
independent predictor of cardiac and all cause mortality, with incremental value to the clinical 
variables (log-likelihood, -75 to -72, p< 0.05 for cardiac death, and -140 to -136, p< 0.05 for 
all cause mortality). 
 
 
Table 3. Predictors of events by Cox models 
 
 Univariate Multivariate Model 1 Multivariate Model 2 
Parameter RR (CI) RR (CI) RR (CI) 
Cardiac Death    
  Age 1.03 (1.01-1.06)   
  Previous myocardial infarction 1.5 (1.0-2.1)   
  Diabetes mellitus 4.6 (1.2-18.0) 3.0 (1.1-9.2) 3.1 (1.1-9.6) 
  Smoking 3.4 (1.2-9.4) 2.9 (1.1-7.3) 2.9 (1.2-7.4) 
  Resting wall motion abnormalities 2.4 (0.7-8.9)   
  Ischemia 3.9 (1.2-12.2)  4.1 (1.2-14.9) 
All cause mortality    
  Age 1.03 (1.01-1.06)   
  Male gender 2.1 (0.8-5.3) 2.1 (1.1-6.2) 2.1 (1.1-5.2) 
  Previous myocardial infarction 1.4 (1.0-2.1)   
  Diabetes mellitus 5.0 (1.3-19.0) 2.4 (1.1-6.0) 2.4 (1.1-5.8) 
  Resting wall motion abnormalities 1.6 (0.6-4.3)   
  Ischemia 3.1 (1.3-7.2)  2.7 (1.2-6.0) 
 
Kaplan-Meier survival curves for the end-points cardiac death and all cause mortality 
are presented in Figures 1 and 2. Event-free survival was significantly better for patients 
without ischemia as compared to patients with ischemia. The annual cardiac death rate was 
1.3% in patients without ischemia and 4.6% in patients with ischemia (p=0.01). The annual all 
cause mortality rate was 3.1% in patients without ischemia and 7% in patients with ischemia 
(p=0.004). Patients with ischemia involving only the septum and/or the apex had a 
comparable prognosis as patients with ischemia in other regions (Figure 3).  
The annual cardiac death rate was 5.4% in patients with ischemia involving only the 
septum and/or the apex and 7.6% in patients with ischemia in other regions (p=0.9). The 
annual all cause mortality rate was 6.4% in patients with ischemia involving only the septum 
and/or the apex and 9.5% in patients with ischemia in other regions (p=0.9). 
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Figure 1. Kaplan-Meier survival curves (end-point cardiac death) in patients without 
ischemia during pacing stress echocardiography versus patients with ischemia. 
 
 
 
 
 
 
Figure 2. Kaplan-Meier survival curves (end-point all cause mortality) in patients without 
ischemia during pacing stress echocardiography versus patients with ischemia. 
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Figure 3. Kaplan-Meier survival curves for end-point cardiac death (panel A) and all cause 
mortality (panel B) in patients with ischemia involving only the septum and/or the apex versus 
patients with ischemia in the other regions. 
 
 
 
Discussion 
 
In the present study, the prognostic value of pacemaker stress echocardiography was 
evaluated in 136 patients with a permanent pacemaker and known or suspected coronary 
artery disease. During a follow-up period of 3.5 ± 2.4 years, 35 (36%) deaths occurred of 
which 20 (15%) were due to cardiac causes. The presence of ischemia during pacemaker 
stress echocardiography was associated with a significantly increased risk of cardiac and all 
cause mortality, incremental to the clinical variables. Patients without ischemia during 
pacemaker stress echocardiography had an annual cardiac death rate of 1.3%, identifying a 
lower-risk group of patients who do not need further invasive evaluation. Conversely, in 
patients with ischemia the annual cardiac death rate was 4.6%, identifying a high-risk group 
of patients who can potentially benefit from invasive evaluation. pacemaker stress 
echocardiography provided independent prognostic information for the prediction of cardiac 
death and all cause mortality. Patients with ischemia involving the septum or the apex had a 
worse outcome compared to patients without ischemia and a similar prognosis compared to 
patients with ischemia in other regions.  
There were no significant differences in mortality between patients with myocardial 
ischemia only located in the septum and/or apex compared to those with ischemia in other 
myocardial regions. This finding suggests that interpretation of (changes in) function in these 
regions is reliable for the detection of myocardial ischemia. The presence of resting wall 
motion abnormalities was not associated with cardiac death or all cause mortality. This could 
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be explained by the fact that the abnormal function at rest of the interventricular septum can 
be present in patients with permanent pacemaker and is not related to the presence of coronary 
artery disease.  
The high number of abnormal tests in this study (77%), is probably related to the 
prevalence of comorbidity in the population. Table 1 shows that a large number of patients 
had diabetes mellitus, prior myocardial infarction, prior heart failure, and obviously, 
conduction abnormalities. 
Previous studies showed that pharmacological stress echocardiography is a feasible 
and accurate alternative for the detection of coronary artery disease in pacemaker-dependent 
patients (13). However, this examination can be time-consuming and may be associated with 
a varying hemodynamic response and side-effects (14-16). Pooled data have shown that 
approximately 10% of patients fail to achieve the target heart rate during dobutamine stress 
echocardiography (14). Transesophageal atrial pacing has been proposed as an effective 
alternative technique for the detection of coronary artery disease in the general population 
(17-22). A controlled increase of heart rate can be used to assess impaired regional wall 
thickening independently from regional myocardial dysfunction due to abnormal electrical 
activation. Nevertheless transesophageal pacing is an invasive procedure and its efficacy has 
been limited by patient intolerance. Moreover, intact atrioventricular conduction and absence 
of esophageal diseases are preliminary conditions to perform the test.  
In patients with permanent pacemakers, pacemaker stress echocardiography has been 
reported as a safe, rapid and effective non-invasive tool to detect coronary artery disease (8, 
9). Picano et al (8) evaluated the feasibility, safety and diagnostic accuracy of pacemaker 
stress echocardiography in 46 consecutive patients with a permanent pacemaker with 
suspected or known coronary artery disease. Sensitivity for detection of significant coronary 
artery disease was 70%, specificity 90% and accuracy 78%. Forty-two of 46 patients (91%) 
achieved the target heart rate or positive test end-point. Four patients (9%) had a submaximal 
test. In the present study, 93% of patients with a permanent pacemaker reached the target 
heart rate, which is comparable to previous studies performed by dobutamine stress 
echocardiography (23).  
Pacemaker echocardiography is a simple, rapid, safe test for the assessment of 
prognosis in patients with permanent pacemaker and suspected or known coronary artery 
disease. Although no study directly has compared pacemaker and dobutamine stress 
echocardiography; pacemaker stress seems less time-consuming and is associated with less 
side effects. Therefore, when information on myocardial ischemia and/or prognosis is 
required, pacemaker stress echocardiography is a reasonable choice. One limitation of 
pacemaker stress echocardiography is to assess myocardial viability. Therefore, when 
information on myocardial viability is needed, dobutamine stress echocardiography should be 
preferred. 
 
Clinical Implications and Conclusions 
 
Pacemaker stress echocardiography is a safe and feasible method for the risk 
stratification of patients with permanent pacemakers. The presence of ischemia during 
pacemaker stress echocardiography is independently associated with an increased risk of 
cardiac death and all cause mortality. Pacemaker stress echocardiography identifies high-risk 
patients in whom aggressive evaluation and/or therapy is required. 
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Abstract 
 
 Background. The significance of isolated left anterior hemiblock (LAHB) in patients 
with suspected coronary artery disease (CAD) is unclear. The aim of this study was to assess 
the functional and prognostic significance of LAHB in patients with no history of myocardial 
infarction referred for dobutamine stress echocardiography (DSE).  
 Methods. We studied 1187 patients with suspected CAD and no history of previous 
myocardial infarction, who underwent DSE and were followed for occurrence of cardiac 
death. 
 Results. LAHB was detected on baseline electrocardiogram (ECG) in 159 (13%) 
patients. Ischemia occurred more frequently in patients with LAHB (43% vs 33%, p = 0.02). 
During a mean follow-up of 5.0 ± 2.5 years, 125 (11%) patients died of cardiac causes. The 
annual cardiac death rate was 4.9% in patients with LAHB and 1.9% for patients without 
(p<0.0001). Patients with both LAHB and an abnormal DSE had the highest cardiac death 
rate (6.3%). In a Cox multivariable analysis, independent predictors of cardiac death were 
age, smoking, history of heart failure, diabetes and inducible myocardial ischemia. LAHB 
was independently associated with increased risk of cardiac death among patients with normal 
DSE (HR= 1.8, 95% CI=1.1-3.8) as well as in patients with abnormal DSE (HR= 1.7, 95% 
CI=1.1-2.7). 
 Conclusions. In patients with suspected CAD referred for stress testing, LAHB is 
associated with increased risk of cardiac death. This risk is persistent after adjustment for 
major clinical data and abnormalities on the stress echocardiogram. Therefore, isolated LAHB 
should not be considered a benign ECG abnormality in these patients. 
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Introduction 
 
 
Data on prognostic significance of left anterior hemiblock (LAHB) are scarce, 
particularly among patients without history of myocardial infarction (1). In subjects with no 
evidence of cardiac disease some authors found a marginally increased incidence of coronary 
artery disease (CAD) in patients with LAHB (2). No association has been found between the 
presence of LAHB and an increased risk of cardiac death (3-5). However data in literature are 
limited by including small number of patients and the short term follow-up. LAHB is a well 
recognized complication that occurs in 3-5% of patients after acute myocardial infarction. In 
these patients, LAHB is believed to be due to ischemic injury of the anterior fascicle of the 
left conduction system. In patients with acute inferior myocardial infarction, LAHB was 
associated with a larger infarct extension and left anterior descending CAD (6). However, its 
occurrence in patients after acute myocardial infarction has not been related to a higher 
mortality rate (7-10). We sought to study the association of LAHB with abnormalities on the 
stress echocardiogram and prognosis in patients with suspected CAD who have no history of 
myocardial infarction. 
 
Patients. The study population consisted of consecutive patients with suspected CAD 
referred for DSE at the Thoraxcenter, Rotterdam, the Netherlands. Exclusion criteria were 
history of previous myocardial infarction, cardiac pacemaker, pathological Q wave, and 
complete left or right bundle branch block on baseline electrocardiogram (ECG). Criteria 
were fulfilled in 1199 patients. Follow-up was successful in 1187 patients (99%) who 
represented the final population of the study. Patients were divided in two groups according to 
the presence or absence of LAHB on baseline ECG. Criteria for LAHB were leftward QRS 
axis of -30° to -90°, with rS patterns in leads II, III, and aVF, and Q waves in aVL (11, 12). 
Left ventricular hypertrophy (LVH) was defined using the Cornell voltage-duration product, 
which was calculated as follows: RaVL ± SV3 (with 6 mm added in women) × QRS duration. 
A threshold of 2440 mm x msec was used to identify left ventricular hypertrophy (13, 14). 
The duration of the QRS complex was electronically measured by 12 lead ECG performed in 
the resting supine position ("Escribe" v15.25, Mortara Instruments, Milwaukee, USA). QRS 
detection by this system used a filter and template matching technique to identify a median 
QRS complex, which was then aligned in all leads simultaneously. QRS duration was 
measured from the earliest onset in any lead to the latest detection in any lead. The protocol 
was approved by the Hospital Ethics Committee. All patients gave informed consent before 
the test. Clinical characteristics and indications for testing were entered in a computerized 
database before DSE and were defined as previously described (15).  
 
Dobutamine Stress Test. Dobutamine-atropine stress testing was performed 
according to a standard protocol as previously reported (16). After obtaining a baseline 
echocardiogram, dobutamine was administered intravenously, starting at a dose of 5-10 
µg/kg/min for 3 minutes. Incremental dobutamine doses of 10 µg/kg/min were given at 3-
minute intervals up to a maximum dose of 40 µg/kg/min. If the test end-point was not reached 
at a dobutamine dose of 40 µg/kg/min, atropine (up to 2 mg) was given intravenously. Blood 
pressure, heart rate, and electrocardiography were constantly monitored. Test end-points were 
achievement of target heart rate (85% of maximum age and gender predicted heart rate), 
maximal dose of dobutamine and atropine, extensive new wall motion abnormalities, >2 mV 
downsloping ST-segment depression measured 80 ms after the J point compared with 
baseline, hypertension (blood pressure >240/120 mm Hg), a decrease in systolic blood 
pressure of >40 mm Hg compared with at rest, significant arrhythmias, or any intolerable 
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adverse effect considered to be the result of dobutamine or atropine. An intravenous β-blocker 
(metoprolol 1 to 5 mg) was available to reverse the adverse effects of dobutamine/atropine. 
 
Echocardiographic imaging and interpretation. Two-dimensional 
echocardiographic images were acquired at rest, during dobutamine stress, and recovery using 
the standard views. The echocardiograms were recorded in a quad-screen format. The 
interpretation of DSE studies was performed off-line from cineloops, by 2 experienced 
observers blinded to the clinical and electrocardiographic data. In case of disagreement, a 
consensus decision was achieved by a third observer. Regional function was scored using a 
16-segment 5-point scoring model (1= normal, 2= mild hypokinesia, 3= severe hypokinesia, 
4= akinesia, 5= dyskinesia). Ischemia was defined as new or worsened wall motion 
abnormalities during stress indicated by an increase of wall motion score ≥1 grade in ≥1 
segment. A biphasic response in an akinetic or severely hypokinetic segment was considered 
as an ischemic response. An abnormal DSE was defined as resting or inducible wall motion 
abnormalities. The wall motion score index (WMSI) was calculated by dividing the sum of 
regional wall motion scores by the total number of interpreted segments. 
 
Follow-up. Follow-up data collection was performed by contacting the patient’s 
general practitioner and by review of hospital records. The date of the last review or 
consultation was used to calculate follow-up time. Follow-up events noted were overall 
mortality and hard cardiac events (nonfatal myocardial infarction and cardiac death). Cardiac 
death was defined as a death caused by acute myocardial infarction, significant cardiac 
arrhythmias, or refractory congestive heart failure. Sudden death occurring without another 
explanation was considered as cardiac death. Nonfatal myocardial infarction was defined 
based on criteria of typical chest pain, elevated cardiac enzyme levels and typical changes on 
electrocardiography. Myocardial revascularization procedures were also noted. 
 
Statistical Analysis. Continuous data were expressed as mean value ± SD. The 
Student’s t test was used to analyze continuous data. Differences between proportions were 
compared using the Chi-square test. The following major clinical and stress test data were 
used in a Cox regression model to identify independent predictors of cardiac events: age, 
gender, smoking, hypertension, diabetes mellitus, history of heart failure, angina, LAHB, 
QRS duration, LVH on baseline ECG, ST segment depression during stress, peak stress rate 
pressure product, peak wall motion score index, and myocardial ischemia on DSE. The risk of 
a variable was expressed as a hazard ratio with a corresponding 95% confidence interval. The 
probability of survival was calculated using the Kaplan-Meier method, and survival curves 
were compared using the log-rank test. A p value <0.05 was considered statistically 
significant. 
 
 
 
Results 
 
Clinical and stress test data. Clinical characteristics are presented in Table 1. 
Patients with LAHB were older and more often had a history of hypertension and heart 
failure.  
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Table 1. Clinical Characteristics of Patients with and without LAHB 
 LAHB 
             Yes                            No  
         (N=159)                   (N=1028) 
p value 
Age (years, standard deviation) 66 ± 11 60 ± 13 <0.0001 
Male 95 (60%) 581 (56%) 0.5 
Hypertension 70 (44%) 363 (35%) 0.04 
Hypercholesterolemia 32 (20%) 275 (27%) 0.09 
Smoking 40 (25%) 252 (24%) 0.9 
Diabetes mellitus 15 (9%) 140 (14%) 0.2 
History of typical angina 
Atypical chest pain 
25 (16%) 
33 (21%) 
215 (21%) 
281 (27%) 
0.2 
0.1 
History of heart failure 16 (10%) 56 (5%) 0.04 
LVH 14 (9%) 90 (9%) 1.0 
QRS duration 109 ± 26 95 ± 14 <0.0001 
β-blockers 52 (33%) 338 (33%) 1.0 
Calcium channel blockers 45 (28 %) 262 (25%) 0.5 
ACE-inhibitors 44 (28%) 212 (21%) 0.06 
Nitrates 32 (20%) 167 (16%) 0.3 
 
Dobutamine stress data are presented in Table 2. Peak heart rate was lower in patients 
with LAHB, reflecting the lower maximal predicted heart rate due to older age in patients 
with than without LAHB. Ischemia (new or worsened wall motion abnormalities) occurred 
more frequently in patients with than without LAHB. Resting WMSI was comparable 
between the two groups, whereas the peak WMSI was significantly higher in patients with 
LAHB.  
 
Table 2. Dobutamine Stress Hemodynamic and Echocardiographic Data  
 LAHB 
          Yes                          No  
       (N=159)                (N=1028) 
p value 
Heart rate at rest (beats/min) 72 ± 13 74 ± 14 0.2 
Heart rate at peak (beats/min) 126 ± 16 130 ± 17 0.002 
Patients who achieved target heart rate 140 (88%) 888 (86%) 0.6 
Rest systolic blood pressure (mmHg) 136 ± 16 133 ± 23 0.2 
Peak systolic blood pressure (mmHg) 140 ± 24 138 ± 25 0.5 
Rest rate pressure product  9914 ± 2648 9877 ± 2501 0.9 
Peak rate pressure product  16796 ± 4262 17506 ± 4299 0.07 
Maximal dobutamine dose (µg/kg/minute) 33 ± 9 34 ± 8 0.1 
Atropine use, patients 54 (6%) 391 (9%) 0.4 
ST-segment depression 9 (6%) 98 (9%) 0.2 
Resting WMSI 1.1 ± 0.2 1.1 ± 0.3 0.2 
Peak WMSI 1.3 ± 0.5 1.2 ± 0.4 0.02 
Normal DSE, patients 69 (43%) 497 (48%) 0.3 
Fixed abnormalities, patients 21 (13%) 188 (18%) 0.1 
New or worsening wall motion 
abnormalities, patients 
69 (43%) 343 (33%) 0.02 
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Regional distributions of stress wall motion abnormalities in patients with and without 
LAHB are presented in Figure 1. Patients with LAHB had a higher incidence of abnormalities 
in the anterior, apical and lateral walls compared to patients without LAHB.  
 
 
 
 
 
 
Figure 1. Regional distribution of abnormalities on the dobutamine stress echocardiogram in 
patients with and without LAHB. 
 
 
Follow-up data. During a mean follow-up of 5.0 ± 2.5 years, 283 (24%) patients died, 
125 (11%) due to cardiac causes. Non-fatal myocardial infarction occurred in 54 patients 
(5%); revascularization was performed in 177 (15%) patients. Patients with LAHB had a 
higher incidence of overall mortality [53 (33%) versus 230 (22%), p=0.004] and cardiac 
mortality [32 (20%) versus 93 (9%), p<0.0001] compared to patients without LAHB. Non 
fatal myocardial infarction occurred in 11 (7%) patients with LAHB and in 43 (4%) patients 
without (p=0.1). Among patients with normal DSE, myocardial infarction occurred in 4 (6%) 
of 69 patients with LAHB, and in 19 (4%) of 497 patients without LAHB (P=0.6). Six (9%) 
out of 69 patients with LAHB and a normal DSE underwent subsequent coronary 
angiography during follow up. CAD was detected in 4 (6%) of these patients. Cardiac death 
occurred in 11 (16%) of 69 patients with LAHB and a normal DSE, and in 33 (7%) of 497 
patients without LAHB and a normal DSE (P=0.01). 
Table 3 and Table 4 present predictors of cardiac death and all cause mortality, 
respectively. Age, smoking, history of heart failure and myocardial ischemia during DSE 
were independent predictors of cardiac death. Age, gender, smoking, history of heart failure, 
LVH and myocardial ischemia during DSE were independent predictors of all cause 
mortality. LAHB was an independent predictor of both cardiac death and all cause mortality 
after adjustment for clinical and stress echocardiographic data. LAHB was independently 
associated with increased risk of cardiac death among patients with normal DSE (HR = 1.8, 
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95% CI = 1.1-3.8) as well as in patients with abnormal DSE (HR = 1.7, 95% CI = 1.1-2.7). 
The annual cardiac death rate was 1.9% for patients without LAHB and 4.9% for patients 
with LAHB (p<0.0001). The hard event rate was 2.5% for patients without LAHB and 5.9% 
for patients with LAHB (p<0.0001). 
 
 
Table 3. Univariate and Multivariate Association of Clinical and Echocardiographic 
Data with Cardiac Death 
 
 Univariate Multivariate 
Parameter Hazard Ratio (95%CI)      Hazard Ratio (95%CI)   
  Age 1.06 (1.04-1.07) 1.05 (1.03-1.08) 
  Gender 1.9 (1.4-2.6) 1.4 (0.9-2.1) 
  Smoking 2.1 (1.6-2.8) 2.0 (1.3-3.1) 
  Hypertension 0.9 (0.7-1.3) 1.2 (0.7-1.8) 
  History of heart failure 4.2 (2.5-6.8) 1.8 (1.1-3.3) 
  Diabetes mellitus 1.4 (0.9-2.1) 1.4 (1.1-2.4) 
  History of typical angina 0.8 (0.5-1.2) 0.4 (0.2-1.0) 
  LAHB 2.5 (1.6–4.0) 1.7 (1.1-2.8) 
  QRS duration (msec) 4.84 (2.12-10.9) 1.16 (0.32-4.22) 
  LVH by EcG criteria 1.6 (0.9-2.8) 1.3 (0.7-2.5) 
  ST depression 0.8 (0.4-1.4) 1.0 (0.5-2.1) 
  Peak rate pressure product 0.97 (0.94-1.00) 0.01 (0.95-1.07) 
  Peak wall motion score index 3.04 (2.39-3.86) 2.13 (0.94-4.85) 
  Myocardial ischemia 1.9 (1.2-2.7) 1.8 (1.1-2.9) 
 
 
 
Table 4. Univariate and Multivariate Association of Clinical, Electrocardiographic and 
Echocardiographic Data with All Cause Mortality 
 
 
 Univariate Multivariate 
Parameter Hazard Ratio (95%CI) Hazard Ratio (95%CI) 
  Age 1.03 (1.02-1.04) 1.04 (1.02-1.06) 
  Gender 1.9 (1.5-2.4) 1.9 (1.4-2.7) 
  Smoking 1.6 (1.3-2.1) 1.7 (1.3-2.3) 
  Hypertension 0.9 (0.8-1.2) 1.1 (0.9-1.5) 
  History of heart failure 3.8 (2.5-5.9) 1.9 (1.3-3.0) 
  Diabetes mellitus 1.1 (0.8-1.6) 1.3 (0.9-2.0) 
  History of typical angina 0.8 (0.6-1.1) 0.8 (0.5-1.2) 
  LAHB 1.7 (1.2–2.5) 1.4 (1.1-2.0) 
  QRS duration (msec) 0.64 (0.26-1.58) 0.71 (0.30-41.64) 
  LVH by ECG criteria  1.8 (1.5-2.6) 1.5 (1.1-2.3) 
  ST depression 0.6 (0.4-1.0) 0.9 (0.6-1.6) 
  Peak rate pressure product 0.95 (0.92-0.99) 0.93 (0.90-0.97) 
  Peak wall motion score index 1.39 (0.76-2.59) 1.38 (0.75-2.57) 
  Myocardial ischemia 1.8 (1.2-2.6) 1.5 (1.1-2.2) 
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Kaplan-Meyer survival curves in patients with normal DSE (figure 2a) and in patients 
with abnormal DSE (Figure 2b) demonstrated a lower event free survival among patients with 
LAHB in both groups.  
 
 
 
Figure 2. Kaplan-Meier survival curves (end point of cardiac death) in the presence and in 
the absence of LAHB in patients with normal dobutamine stress echocardiogram (Panel A) 
and in patients with abnormal dobutamine stress echocardiogram (panel B). 
 
 
The annual cardiac event rates according to combination of LAHB and abnormalities 
on DSE are presented in Figure 3. The presence of LAHB in both groups of patients with 
normal and abnormal DSE identified a significantly higher risk population for cardiac death 
and hard cardiac events. Patients with both LAHB and abnormal DSE were at the highest risk. 
  153
 
Figure 3. Annual cardiac event rates according to combinations of ECG and stress 
echocardiographic findings. 
 
Discussion 
 
In this study we assessed the functional and prognostic significance of LAHB on 
resting 12 lead ECG in patients with suspected CAD, who had no history or ECG evidence of 
prior myocardial infarction. LAHB was detected in 159 patients (13%). Patients with LAHB 
had 2.5 fold higher incidence of cardiac death and 1.5 fold higher incidence of all cause 
mortality as compared to patients without LAHB during a mean follow-up of 5 years. The 
associated risk of death was independent of clinical parameters, QRS duration, LVH on the 
ECG, and abnormalities on the DSE. The higher incidence of cardiac death in association 
with LAHB was observed among patients with normal as well as patients with abnormal 
DSE. The combination of LAHB and abnormal DSE identified patients with the highest 
incidence of cardiac death and hard cardiac events.  
 
Echocardiographic data and prognosis. Patients with LAHB had 10% higher 
incidence of ischemia on DSE. This indicated that LAHB is associated with higher prevalence 
of significant CAD. However, this modest difference does not alone explain the large 
difference in cardiac mortality, particularly with the similar resting WMSI in both groups and 
the fact that Cox model adjusted for myocardial ischemia. The reason for the independent 
association of LAHB with cardiac mortality after adjustment for DSE data is unclear. It is 
possible that LAHB is associated with ultrastructural myocardial damage that can not be 
grossly identified by echocardiographic imaging. Because of the small size of the left anterior 
fascicle, it is vulnerable for blockage in the presence of trivial ischemia in the region of its 
course. Another explanation could be higher propensity for fatal arrhythmias in the presence 
of a substrate of myocardial dysfunction, LHAB and triggering ischemia. Another possibility 
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would be a higher rate of false negative DSE in patients with LAHB. However, because of the 
very small number of patients who underwent coronary angiography during follow up, a 
lower sensitivity of DSE in patients with LAHB remains speculative. 
LAHB and LVH were independent predictors of all cause mortality, whereas QRS 
duration was not. The lack of independent association of QRS duration with outcome may be 
explained by exclusion of patients with complete bundle branch block and patients with 
previous myocardial infarction and thereby including a population with preserved left 
ventricular function. 
 
Regional abnormalities with LAHB. The occurrence of LAHB in association with 
myocardial ischemia is thought to be related to left anterior descending CAD (17, 18). 
However, there are no previous reports on tomographic localization of functional 
abnormalities in these patients. 
Analysis for regional distribution of stress wall motion abnormalities in our study 
showed a higher incidence of abnormalities in the anterior and apical regions in patients with 
compared to patients without LAHB. This is in concordance with anatomic studies showing 
that the left anterior division of the left bundle branch block runs across the septal surface 
towards the antero-lateral aspect of the free wall of the left ventricle and is supplied by the left 
anterior descending coronary artery. The higher incidence of abnormalities in the lateral wall 
among patients with LAHB, with a similar incidence of abnormalities in the posterior and 
inferior walls, suggest that abnormalities noted in the lateral wall in some of these patients are 
due to diagonal rather than left circumflex CAD.  
 
Previous studies. Previous data on the correlation between LAHB and cardiac disease 
in the general population are scarce (2-4). Corne et al. (2), found a relation with systemic 
hypertension and cardiac disease in 390 men of 30 years and over with LAHB compared with 
age and sex matched control group. Studies of the prognostic significance of isolated LAHB 
in the general population or in subjects without clinical evidence of cardiac disease are limited 
but have reported no effect on mortality (3, 4). Yano et al. (3), followed 70 clinically normal 
subjects with LAHB for periods ranging from 3 to 6 years and found no increase in the 
mortality risk ratio compared with normal controls. Ostrander et al. (4), analysed data from 
the Tecumseh Communities Health Study and found that 102 subjects with left axis deviation 
and no other findings suggestive of heart disease had no excess of morbidity or mortality 
during an average observation of 4 years.  
LAHB is not uncommonly observed in patients with acute myocardial infarction. 
Development of LAHB during inferior acute myocardial infarction has been correlated with 
significant stenosis in left anterior descending coronary artery and multivessel disease (6-19). 
Assali et al. (6), studied 87 patients with an first inferior wall acute myocardial infarction. 
Seventeen (19%) developed a LAHB. Significant stenosis of the left anterior descending 
artery was found in 82% of patients with LAHB and in 21% of patients without LAHB (p= 
0.001). By logistic regression analysis, the odds ratio for development of LAHB was 27.5 
(p=0.0001) for left anterior descending artery stenosis compared with 2.92 (p=0.053) and 0.3 
(p= 0.3) for circumflex and right coronary artery. However, LAHB after acute myocardial 
infarction has not been found to be related to an increased mortality (7-10).  
Information regarding the prognostic significance of LAHB in patients referred for 
stress test is limited. In the study by Cortigiani et al. (20), the prognostic implication of 
intraventricular conduction defects in patients with suspected CAD referred for 
pharmacologic stress echocardiography was evaluated during a mean follow-up of 3 years. 
Out of a total of 1230 patients, 173 had complete left bundle branch block, 98 isolated right 
bundle branch block, 43 right bundle branch block plus LAHB and 106 isolated LAHB. The 
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presence of right bundle branch block together with left anterior hemiblock was associated 
with a poor prognosis and was an independent predictor of mortality. The presence of isolated 
LAHB was not associated with all-cause mortality in a multivariate analysis.  
 
Limitations 
 
LVH was evaluated by ECG criteria, with possible underestimation of incidence of 
LVH by echocardiographic criteria (21). Nevertheless, LVH as defined by ECG was an 
independent predictor of mortality in this study despite possible underestimation of the true 
incidence of LVH. The ECG has been generally used as an acceptable method to define LVH 
in outcome trials (22) Finally, this study could not determine whether the increased risk in 
association with LAHB is related to a lower sensitivity of DSE in patients with LAHB or not,  
since only a small number of patients underwent coronary angiography. Further studies are 
needed to assess the diagnostic performance of DSE in patients with LAHB. 
 
Conclusions 
 
Isolated LAHB is an independent predictor of total and cardiac mortality in patients 
with suspected CAD who have no history of myocardial infarction. The increased risk of 
mortality is persistent after adjustment for clinical data, left ventricular function and inducible 
ischemia on DSE. Among patients with a normal DSE, the presence of LAHB is associated 
with a worse prognosis. Patients with both LAHB and abnormal DSE had the worst outcome. 
Therefore, isolated LAHB should not be considered a benign ECG abnormality in these 
patients and should be considered along with other clinical and stress test data in estimating 
the risk of cardiac events. 
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Abstract 
 
Background. There is experimental evidence that transplanted skeletal myoblasts 
(SM) into post-infarction myocardial scar improve regional and global left ventricular (LV) 
function. The aim of this study was to evaluate short- and long-term regional and global LV 
functional effects of percutaneously transplanted SM in patients with ischemic heart failure. 
Methods. Ten patients (mean age 60 ± 10 years, 8 males) with dilated ischemic 
cardiomyopathy underwent percutaneous injection of autologous myoblasts. Regional and 
global LV function was evaluated by 2-dimensional echocardiography and tissue Doppler 
imaging (TDI) at rest and during low-dose dobutamine infusion to assess contractile reserve. 
After a baseline examination, sequential follow-ups were performed at 1-, 3-, 6-months and 1 
year. Repeated measurements were compared using repeated measurements analysis of 
variance (ANOVA) to evaluate differences across the time.  
Results. NYHA functional class decreased from 2.7 ± 0.5 to 1.9 ± 0.5 (p<0.01). LV 
function and volumes at rest remained unchanged while contractile reserve significantly 
improved during follow-up. At low-dose dobutamine infusion, the peak systolic velocity in 
the regions of myoblasts injection significantly increased at TDI examination (from 7.7 ± 2.1 
to 8.6 ± 1.8 cm/sec, p=0.02); LV ejection fraction improved (from 40 ± 9% to 46 ± 8%, 
p<0.0001) and end-systolic volumes decreased (from 56 ± 28 to 50 ± 25 ml/m2, p=0.001) at 1 
year.  
Conclusions. In patients affected by ischemic heart failure, undergoing percutaneous 
autologous SM injection, NYHA functional class along with regional and global LV 
contractile reserve improved during follow-up. The effect was sustained up to 1 year after 
treatment.  
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Introduction 
 
The clinical syndrome of heart failure has become the most prevalent cause of 
mortality, morbidity and hospitalization in industrialized countries over the last decades (1, 2) 
and the incidence is expected to increase as patients more frequently survive acute myocardial 
infarction, that represents the aetiology of heart failure in >70% of patients (3). The 
mechanisms leading to congestive heart failure after acute myocardial infarction are only 
partially understood (4, 5) and according to the current belief, a progressive decrease in the 
number of viable myocytes after an acute myocardial infarction could at least partially explain 
such a transition. Therefore, myocardial infarction and subsequent heart failure can be viewed 
as a disease of cellular deficiency (6). 
Myocardial cell replacement therapy by transplantation of skeletal myoblasts (SM) or 
bone marrow stem cells into the region of infarcted myocardium has been proposed as an 
alternative treatment in patients with ischemic cardiomyopathy and severe, drug-refractory 
heart failure (7-9). Indeed, recent studies have suggested that the transdifferentiation of c-kit-
positive bone marrow cells into cardiomyocytes is controversial and the number of cells 
undergoing this process may be too low to affect cardiac function (10). SM are the only cell 
types that have been proven to form areas of cellular engraftmenet with histological evidence 
of viability (development into myotubes and expression of human myosin heavy chain) (11, 
12) when injected into the heart. Moreover, they are relatively more resistant to myocardial 
ischemia compared to cardiomyocytes. Studies in animal models have shown improvement in 
regional and global LV function late after myoblast transplantation, and initial observations 
on humans have confirmed this finding (13-18). However, skeletal myotubes fail to 
overexpress gap-junction proteins such as connexin-43 and N-cadhering both in vitro and in 
vivo, which makes the electromechanical coupling unlikely to occur (19).  
Although cardiac magnetic resonance (MRI) has emerged during the last decade as a 
gold standard to assess regional and global LV function, its availability may be limited on a 
large scale study patients. Moreover, the need to implant a cardioverter-defibrillator may 
further limit the use of MRI in this patient population. Two-dimensional echocardiography 
with dobutamine infusion is an established technique to quantify regional and global 
myocardial systolic dysfunction (20). Moreover, the ability to assess even minor change in 
regional LV function has been recently redefined by the introduction of tissue Doppler 
imaging (TDI) in the clinical setting (21, 22). Therefore we sought to evaluate the short- and 
long-term impact of percutaneously transplanted SM in patients with ischemic heart failure as 
assessed by two-dimensional echocardiography and TDI during dobutamine infusion. 
 
Methods 
 
Patient Population. Patients with a previous myocardial infarction involving the 
anterior, lateral or inferior walls, depressed LV function (LV ejection fraction [EF] between 
20% and 45%), and NYHA class ≥ II despite an optimized medical therapy were included in 
the study. Myocardial infarction had to be >4 weeks old at the time of implantation. The 
presence and location of a myocardial scar were defined by: akinesia or dyskinesia at rest 
during echocardiography or LV angiography and no contractile reserve during dobutamine 
stress echocardiography (DSE). Exclusion criteria for myoblast injections were: target region 
wall thickness <5 mm by echocardiography, presence of ischemia during dobutamine stress 
echocardiography, and positive serologic test results for human immunodeficiency virus, 
hepatitis B or C, or syphilis. Five patients were part of a previously reported (9) monocenter 
pilot study on safety and feasibility, whereas the remaining 5 have been enrolled in a 
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multicenters European study (005-006). A TDI substudy was performed only in patients 
enrolled at the Thoraxcenter, in Rotterdam.  
 
Muscle Biopsy. Biopsy of the quadriceps muscle was done under local anesthesia. All 
biopsy procedures were uneventful and done on an outpatient basis. Biopsies were placed in a 
bottle containing a proprietary solution designed to preserve the biopsy during controlled 
shipment. The bottle was put in an insulated thermobox with frozen and refrigerated gel packs 
to maintain temperatures between 2°C and 8°C during transit. The transport conditions were 
monitored by the use of a programmable temperature monitor (Sensitech, Beverly, 
Massachusetts). The container was sent to clinical Good Manufacture Practice (BioWhittaker, 
Cambrex Corp., Walkersville, Maryland) for myoblast cell isolation and expansion.  
 
Cell Transplantation. The cell-culturing process was performed as previously 
described (9). The cell transplantation procedure was done in the cardiac catheterization 
laboratory. Access was obtained through the femoral artery, and 100 IU/kg heparin was given. 
The target activated clotting time was between 250 s and 300 s and was regularly checked 
every half hour. After a coronary and biplane LV angiogram (left anterior oblique 60° and 
right anterior oblique 30°) was obtained, an outline of the LV chamber in end diastole was 
drawn on transparent tabloids that were taped to the fluoroscopy monitors for navigation help 
and documentation of injection locations. Then a 3D electromechanical NOGA map  (23) of 
the LV was obtained using a 7F NOGASTAR catheter (F-curve) connected to the NOGA 
console (Biosense-Webster, Waterloo, Belgium).  
After mapping the LV, the mapping catheter was exchanged for the injection catheter 
(Myostar, Biosense-Webster, Waterloo, Belgium). Injections of 0.1 cc each (approximately 15 
million cells per injection) were made, using the acquired NOGA map for navigating the tip 
of the injection catheter along the endomyocardium to the target locations. After the injection 
procedure, a control biplane LV angiogram was obtained. Afterward, patients were ECG 
monitored for 18 h, and cardiac enzymes were checked twice at 6- to 8-h intervals. 
 
Two Dimensional Echocardiography. Two-dimensional echocardiography was 
performed at baseline and 1, 3, 6-months and 1 year of follow-up using a commercially 
available imaging system equipped with a 1.8 MHz transducer and second harmonic imaging 
to optimize endocardial border (Hewlett Packard Sonos 5500, Andover, Massachusetts, 
USA). Short-axis parasternal view and apical 4-, 3-, and 2- chambers views were recorded in 
a quad-screen format.  
 
Dobutamine Stress Protocol. Before cell transplantation was performed, patients 
underwent a complete dobutamine stress test targeting the achievement of 85% of maximal 
age- and gender-predicted heart rate. Dobutamine-atropine stress testing was performed 
according to a standard protocol as previously reported (24). After obtaining a baseline 
echocardiogram, dobutamine was administered intravenously at a starting dose of 5-10 
µg/kg/min for 5 minutes (low-dose). Incremental dobutamine doses of 10 µg/kg/min were 
given at 3-minute intervals up to a maximum dose of 40 µg/kg/min. If the test end-point was 
not reached at a dobutamine dose of 40 µg/kg/min, atropine (up to 2 mg) was given 
intravenously. Blood pressure, heart rate, and electrocardiography were constantly monitored. 
Subsequent tests at 1-, 3-, 6-months and 1 year were performed at low-dose dobutamine 
infusion and were stopped after data acquisition at 10 µg/kg/min dobutamine infusion.  
Two-dimensional echocardiographic images were acquired at rest, during dobutamine 
stress, and recovery. The echocardiograms were recorded in a quad-screen format. Two 
experienced observers, unaware of the clinical data, scored the echocardiograms using a 
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standard 16-segment model. In case of disagreement, a consensus decision was achieved by a 
third observer. Regional wall motion and systolic wall thickening were scored on a 5-point 
scale (1= normal, 2= mild hypokinesia, 3= severe hypokinesia, 4= akinesia, 5= dyskinesia). 
Ischemia was defined as new or worsened wall motion abnormalities during stress indicated 
by an increase of wall motion score ≥1 grade in ≥1 segment. For each patient, a wall motion 
score index (WMSI) was calculated by dividing the sum of scores of visualized segments by 
the total number of these segments. LV volumes were measured from both resting and low-
dose dobutamine stress echocardiography (before and sequentially after myoblast injection). 
All measurements were performed off line in random order by 2 experienced readers blinded 
to patient data and time of the studies. LV volumes were measured by the biplane modified 
Simpson’s rule (25). LV volumes were normalized by the body surface area to obtain the end-
diastolic volume index and the end-systolic volume index (26). The intraobserver variability 
was 4±1 ml/m2 for the end-diastolic volume index and 3±1 ml/m2 for the end-systolic volume 
index . The interobserver variability was 5±1 ml/m2 for the end-diastolic volume index and 
4±1 ml/m2 for the end-systolic volume index. 
 
Tissue Doppler Imaging. Pulsed-wave TDI was performed with the same system 
used for the assessment of wall motion abnormalities, with a pulse repetition frequency of 45 
to 60 KHz and a sample volume of 4 mm3. To minimize the variability induced by respiration, 
(21) the measurement of myocardial velocity was sampled using a six-segment model in 3 
apical views (4-chamber, 2-chamber, and long-axis) close to the mitral annulus and during a 
minimum of 5 consecutive beats. The depth of the sample volume of every region was kept 
constant during dobutamine stress echocardiography to make sure that LV myocardium was 
sampled close to the mitral annulus. The electrocardiogram and phonocardiogram were 
simultaneously recorded with the pulsed-wave TDI velocity profile. Images were both 
recorded on tape and digitally stored on an Enconcert workstation (Philips, Eindhoven, the 
Netherlands). The velocity values (centimeters per second) were obtained on calibrated still 
frames by manually measuring the distance between the zero baselines and the peak Doppler 
profile of the ejection phase, in reference to the electrocardiogram and calculated as the mean 
value of 3 measurements. Cardiac cycles with extrasystolic, postextrasystolic beats, or rhythm 
disturbance were excluded. Recordings and measurements were performed at baseline and 
during low-dose (10 µg/kg/min) dobutamine infusion rate. A second observer, blinded to the 
results of the first observer, measured tissue Doppler velocities of the same patients. The 
interobserver and intraobserver agreement for systolic velocities were 96% and 97%. 
 
Statistical Analysis. Continuous data were expressed as mean value ± SD. The 
Student’s t test was used to analyze continuous data. Proportions for dichotomus data were 
compared by Chi-square analysis. Repeated measurements were analyzed using repeated 
measurements analysis of variance (ANOVA) to evaluate differences across the time. For all 
tests, a two-tailed p value <0.05 was considered statistically significant. 
 
Results 
 
Patients Characteristics. Baseline clinical characteristics and cell-culturing results of 
the 10 patients (mean age 60 ± 10 years, 80% men) are listed in Table 1. Mean time since the 
occurrence of previous myocardial infarction and the procedure was 7 years (from 2 to 18 
years).  
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Table 1. Baseline Characteristics (n=10) 
 
Age, (means ± SD) 59 ± 11 
Male 8 (80%) 
Smoking 1 (10%) 
Hypercholesterolemia 3 (30%) 
Diabetes mellitus 1 (10%) 
Previous AMI (years ago) 7.0 ± 4.7 
Previous CABG or PCI 3 (30%) 
History of angina 4 (40%) 
NYHA class 3.0 ± 0.2 
Patent LAD 7 (70%) 
Cells at Harvest x 106 297 ± 154 
Cells Injected x 106 217 ± 111 
Desmin staining  64 ± 27 
Cell viability 95 ± 2.8 
Potency 81 ± 20 
 
 
Legend: AMI: acute myocardial infarction; CABG: coronary artery by-pass graft; PCI: 
percutaneous coronary intervention; LAD: left anterior descending coronary artery. 
 
 
No procedural complication occurred. A minor elevation of creatine kinase and MB 
(<2 times upper level) and troponine T (<0.16µg/l) was noted after the procedure in 3 
patients.  
At 1 year follow-up NYHA functional class decreased from 2.7 ± 0.5 to 1.9 ± 0.5 
(p<0.01). During a mean follow-up of 29 ± 8 months, 1 patient was readmitted to the hospital 
due to heart failure symptoms. Two patients out of the 6 with an ICD had appropriate shocks 
due to major arrhythmias. No patients experienced myocardial infarction.  
 
Resting Contractile Function and Contractile Reserve. The mean LV EF at 
baseline was 36 ± 8% at rest and 41 ± 9% during low dose dobutamine infusion. In 160 
segments evaluated at baseline echocardiography, 23 (14%) were defined having a normal 
contractile function, while 137 (86%) were defined as dysfunctional, including 29 (18%) 
mildly hypokinetic, 51 (32%) severely hypokinetic, and 57 (36%) akinetic. Of the 137 
dysfunctional segments, 105 (77%) showed contractile reserve during dobutamine infusion 
(increase in WMSI by one grade or more during low-dose dobutamine infusion). No segments 
showed myocardial ischemia at peak of stress. The baseline WMSI at rest and during low-
dose dobutamine infusion was respectively 6.4 ± 1.9 cm/sec and 7.8 ± 2.5 cm/sec. The 
hemodynamic response at rest and during dobutamine test at baseline is shown in Table 2. 
The protocol was completed in all patients without side effects.  
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Table 2. Dobutamine Stress Echocardiographic Data 
 
Parameters  
Heart rate at rest (beats/min) 68 ± 13 
Heart rate at low dose dobutamine (beats/min) 77 ± 12 
Heart rate at peak (beats/min) 138 ± 18 
Rest systolic blood pressure (mmHg) 123 ± 17 
Systolic blood pressure at low dose dobutamine (mmHg) 130 ± 22 
Peak systolic blood pressure (mmHg) 144 ± 19 
Rest rate pressure product (mmHg/sec) 8153 ± 1439 
Peak rate pressure product (mmHg/sec) 19872 ± 5100 
Angina during dobutamine stress 1 (10%) 
Resting wall motion score index 2.45 ± 0.60 
Peak wall motion score index 2.06 ± 0.46 
 
 
 
WMSI and TDI Changes during the Follow-up. There were no significant changes 
of WMSI at rest and low-dose dobutamine infusion at 1 year follow-up (from 6.4 ± 1.9 to 6.4 
± 0.9 cm/sec for resting WMSI, p= 0.33, from 7.8 ± 2.5 to 8.0 ± 1.9 cm/sec for stress WMSI, 
p=0.51), (Table 3). Similarly, no significant improvement of the global peak systolic velocity 
determined by TDI at both rest echocardiogram (from 6.5 ± 1.9 to 6.5 ± 1.2 cm/sec, p=0.19) 
and during low-dose dobutamine infusion (from 7.9 ± 2.4 to 8.2 ± 2.1 cm/sec, p=0.13) was 
found at 1 year follow-up. Selecting systolic velocity in the regions of myoblasts injections, 
no significant changes were found at 1 year follow-up in rest measurements, whereas a 
significant improvement was observed during low-dose dobutamine infusion (from 7.7 ± 2.1 
to 8.6 ± 1.8 cm/sec, p=0.02) (Table 3 and Figure 1 and 2).  
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Figure 1. Changes in peak systolic velocity measured by TDI in the region of myoblast 
injection during 1 year follow-up. The white and gray boxes indicate resting and low dose 
dobutamine infusion measurements, respectively. 
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Figure 2. Peak systolic velocity in the region of myoblast injection measured by TDI at 
baseline (upper part) and at 1 year of follow-up (lower part) at rest (panel A and B) and 
during low dose dobutamine stress echocardiography (panel C and D). A significant increase 
in velocity is shown during low dose dobutamine infusion between baseline and 1 year follow-
up.  
 
 
 
Ejection Fraction and Left Ventricular Volumes. No significant improvement in 
resting LV EF was observed at 1 year follow-up (Table 4 and Figure 3). Similarly, resting 
end-diastolic and end-systolic volumes index did not significantly change during the follow-
up. Conversely, during low-dose dobutamine infusion, a significant improvement in EF was 
observed (from 40 ± 9% to 46 ± 8%, p<0.0001). LV end-diastolic volume index did not 
significantly change, whereas end-systolic volume index significantly decreased (from 56 ± 
28% to 50± 25%, p=0.001).  
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Figure 3. Changes in LV EF at rest (panel A) and during low dose dobutamine infusion 
(panel B) during 1 year follow-up.  
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Discussion 
 
Transplantation of SM into the region of infarcted myocardium has recently emerged 
as a promising alternative treatment for severe ischemic LV dysfunction. Our substudy 
investigation showed an improvement of target wall systolic velocity and of global LV 
function during low-dose dobutamine infusion, indicating an improvement of contractile 
reserve. Noteworthy, the observed improvement in LV performance was sustained over time, 
persisting up to 1 year, underscoring the potential of this novel percutaneous approach in the 
treatment of end-stage ischaemic LV dysfunction. The wide-available and relatively 
inexpensive stress two-dimensional echocardiography and TDI appeared as promising tools 
able to monitor the effect of SM injections in this patient population. 
 
Comparison to Previous Studies. Experimental studies have suggested an 
improvement on regional and global LV performance after cell transplantation. Ghostine et al. 
(18), studied global and regional LV function changes by echocardiography and TDI, in a 
sheep model (n=16) of infarction 4 and 12 months after in-scar injections of autologous SM 
(n=8) or culture medium (n=8). LV end-diastolic volume increased to a greater extent over 
time in the control group compared to myoblast group at 4 months, whereas LV EF 
significantly decreased in the control animals but remained unchanged in the myoblast 
animals. TDI analysis showed a decrease in the systolic myocardial velocity gradient in the 
control group but an increase in the myoblast group, with a limit of significance in the 
difference between the two groups.  
Menasché et al (8), studied 10 patients who underwent autologous skeletal myoblast 
transplantation during bypass surgery in patients with severe ischemic cardiomyopathy. In 8 
of the 9 operative survivors LV EF significantly increased after treatment, due to a decrease 
of end-systolic LV volume, whereas the end-diastolic volume remained unchanged 
postoperatively. Moreover, 14 out of 22 implanted in-scar segments demonstred new-onset 
echocardiographic systolic shortening. However, the improvement in regional and global 
systolic function may reflect the efficacy of myocardial revascularization and can not be 
related only to the injection of myoblasts.  
In a recent pilot study (9), our group reported an initial experience in 5 patients who 
underwent catheter-based cell transplantation with autologus skeletal myoblasts. A significant 
improvement in LV EF was observed at three months by angiography but not by nuclear or 
magnetic resonance imaging assessment. At six months, a trend toward increased LV EF was 
observed by both angiography and nuclear scan. Similarly, the TDI results showed a trend 
toward increased contraction velocity at six months follow-up.  
 
Possible Explanation for the Findings. The mechanism whereby an improvement of 
regional and global function occurs during low-dose dobutamine infusion indicating an 
improvement of contractile reserve remains unsettled. In animal models an increase in 
contractility assessed by two-dimensional echocardiography as well as TDI or color kinesis 
has been shown to be related, at least in part, to the success of the outcome (13, 18). The 
assumption that the islets of implanted cells could be mechanically recruited by the 
contraction of the surrounding recipient myocardium, even in absence of gap junctions, may 
explain an improvement of contractile reserve and systolic function under catecholamine 
stimulation. 
Although the improvement in global LV function during low-dose dobutamine 
infusion at follow-up could be related to a compensatory phenomenon of the myocardium 
adjacent to the scar-tissue, the improvement of systolic velocity in the sites of myoblasts 
injection assessed by TDI can be only explained by an increased systolic contractility of these 
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regions. Moreover, no patients developed an increase in LV volumes and subsequent LV 
remodeling during the follow-up. Initial data suggested that in patients with ischemic 
cardiomyopathy the preservation of ongoing LV remodeling after revascularization have to be 
considered an important end-point (27), and myocardial viability (assessed by the presence of 
contractile reserve) represents the most important parameter to determine the direction of LV 
volumes changes (28). 
 
Limitations 
 
The study population is limited. Further studies, including larger number of patients, 
are ongoing in the attempt to confirm and possibly extends our current findings. Current 
echocardiographic measurements were not analyzed by independent core lab. 
 
 
Clinical Implications and Conclusions 
 
In patients with ischemic heart failure who undergo percutaneous injection of 
autologous myoblasts, regional and global LV systolic function improves during low-dose 
dobutamine infusion, indicating an improvement in contractile reserve, at 1 year follow-up. 
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Abstract 
 Background. The relative merits of myocardial contrast echocardiography (MCE) and 
magnetic resonance imaging (MRI) to predict myocardial function improvement after 
percutaneous coronary intervention (PCI) have not been evaluated until now. 
 Methods. Thirty-five consecutive patients with acute myocardial infarction (AMI) 
were studied after PCI by MCE and MRI using first-pass imaging for evaluation of 
myocardial perfusion. Delayed-enhancement MRI was included as another methodology to 
differentiate viable from infarcted tissue. MCE was performed by power modulation and 
intravenous Sonovue. A 16-segment model of the left ventricle was used to analyze all MCE 
and MRI images. At 60 days follow-up, a MCE study showed improvement of function in 
115 (60%) of 192 dysfunctional segments.  
 Results. The sensitivity, specificity and accuracy for the prediction of functional 
improvement were comparable between MCE (87%, 90%, 88%), first-pass MRI (87%, 60%, 
79%), and delayed-enhancement MRI (75%, 100%, 82%), all p=NS.  
 Conclusions. MCE and MRI allow prediction of myocardial function improvement 
after PCI. MCE has a comparable accuracy and as a bed-side technique may be an alternative 
tool in the acute phase of AMI. 
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Introduction 
 
Restoration of coronary blood flow in acute myocardial infarction (AMI) after 
percutaneous coronary intervention (PCI) is related to an improved clinical outcome (1). 
However, successful recanalization of the occluded vessel does not always result in recovery 
of myocardial function, since both microvascular integrity and myocytes may be irreversible 
damaged after AMI  (2). Lack of contractile function after PCI may be caused by reversible 
(myocardial stunning) or irreversible myocardial damage (necrosis). Distinction between 
these two pathophysiological entities may help to define individual tailored therapy, justifying 
the use of mechanical support as well a relative caution with the inotropic therapy in patients 
with myocardial stunning (3). Myocardial contrast echocardiography (MCE) and contrast-
enhanced magnetic resonance imaging (MRI) are both non invasive techniques able to assess 
myocardial function and perfusion, additionally delayed contrast enhanced MRI is able to 
asses irreversible cellular damage. Several studies have confirmed the ability of MCE to 
predict the improvement of myocardial function after reperfusion in AMI (4-12). Recently, it 
has become clear that contrast-enhanced MRI can be performed in humans early after AMI 
and allows prediction of functional improvement (13-19). Contrast-enhanced MRI can be 
performed to evaluate myocardial perfusion during first-pass of the contrast agent or 
alternatively to detect necrosis using delayed contrast-enhancement 20 minutes after contrast 
injection. Currently, the relative merits of these non invasive techniques are not clear. The aim 
of this study was to compare MCE and contrast-enhancement MRI to assess myocardial 
perfusion/viability and to predict improvement of myocardial function after PCI in AMI. 
 
 
Methods 
 
Patients and Study Protocol. This prospective study comprised 42 consecutive 
patients with ST-elevation AMI who underwent PCI within 6 hours of symptom onset. The 
diagnosis of AMI was made on the basis of symptoms consistent with myocardial ischemia 
for ≥30 min and ≥2 mm ST-segment elevation in ≥2 contiguous electrocardiographic leads. 
The infarct related artery was identified by the site of the coronary occlusion during coronary 
angiography (using CAAS system, Pie Medical, Maastricht, Netherlands) and 
electrocardiographic criteria. Stent implantation was performed in all patients. The local 
Hospital Ethics Committee approved the study protocol and all patients gave informed 
consent. MCE was performed within 48 hours after the coronary intervention and with a time 
distance not longer than 48 hours from the MRI study, although in the majority of the cases 
the two techniques were performed on the same day. In 5 patients a MRI study could not be 
performed due to claustrophobia in 2 patients and to the necessity of an aortic balloon device 
in 3 patients who presented unstable clinical conditions. Two patients were excluded due to 
not optimal delay-enhancement images quality. Therefore, the final population consisted of 35 
patients. Improvement of resting regional and global contractile function was assessed with a 
MCE follow-up study at 60 days in all patients, using left ventricular opacification for a better 
detection of the endocardial border, exactly as in the baseline examinations. The mean 
difference time between baseline and follow-up was 68 ± 7 days. 
 
Contrast Echocardiography Studies. Echocardiography was performed with a 
Philips Sonos 5500 system (Andover, Massachusetts, USA) using second harmonic imaging 
(1.8MHz/3.6MHz), between 24 and 48 hours after revascularization to assess regional and 
global left ventricular function. After recording the baseline images, myocardial perfusion 
images were obtained during contrast injection in real-time (power modulation) using a low 
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mechanical index (MI: 0.1). A slow bolus of 0.75 ml of sulfur hexafluoride (Sonovue, Bracco, 
Italy) was intravenously injected followed by a slow saline flush (5 ml) over 5 seconds. If left 
ventricular opacification and myocardial perfusion were not optimal, additional doses of 
0.5ml of contrast agent were injected. Real-time power modulation imaging was started 
before contrast injection and “flash” imaging with high mechanical index (MI: 1.6) was used 
at peak contrast intensity to destroy the microbubbles in the myocardium in order to exclude 
artifacts and to visualize myocardial contrast replenishment (15 cycles). After the real time 
perfusion study, left ventricular opacification images for endocardial border assessment were 
recorded using a 0.4 mechanical index to improve quantitative assessment of regional and 
global myocardial function (20). Left ventricular volumes and ejection fraction were 
measured using the modified biplane Simpson’s rule (21). An improvement in left ventricular 
ejection fraction ≥5% at follow-up was considered clinically significant (22). Images were 
digitally stored on (Philips, Eindhoven, the Netherlands).  
 
Analysis of Echo Studies. Regional wall motion and myocardial perfusion were 
scored by two observers who had no knowledge of the clinical, MRI and angiographic data, 
using standard parasternal long-and short-axis views and apical two-, three and four-chamber 
views. The left ventricle was divided according to a standard 16-segment model (21). Only 
segments related to acute infarct territory were considered for the analysis. The myocardial 
segments were assigned to the coronary arteries as previously described (23). Segments were 
scored as 1=normal; 2=hypokinetic, 3=akinetic; and 4=dyskinetic. Myocardial contrast 
perfusion was scored semiquantitatively using a 3-point grade scale: grade 0, no opacification, 
grade 1, reduced/patchy opacification, and grade 2, normal/homogenous opacification. 
Segments with a hypokinetic or akinetic wall motion pattern were considered dysfunctional. 
Recovery of contractile function was defined as an improvement of segmental wall motion 
score by ≥1 grade at the follow-up. As reported previously (7) in each patient, an MCE score 
index was derived by averaging the perfusion scores from each dysfunctional segment 
dividing by the number of dysfunctional segments. A patient was considered to have adequate 
reperfusion if the MCE score index was ≥1 (7). 
 
Contrast-enhancement MRI Studies. All patients were studied in a supine position, 
with a 4-channel quadrature body phased array coil placed over the thorax, in a 1.5T whole 
body MRI system (General Electric, Milwaukee, WI, USA; Signa CV/i, with an amplitude of 
40 mTm-1 and a slew rate of 150 Tm-1s-1). For semiquantitative analysis 2-, 3-, 4-chamber 
and approximately 10 to 12 cine short-axis series (slice thickness 8 mm, gap 2 mm) covering 
the heart from base to apex where acquired using a breath-hold cardiac triggered steady state 
free precession sequence (FIESTA) with a TR and TE of 3.5 and 1.3 ms respectively and a 
flip angle of 45°. Additional imaging parameters were: Field of View of 360 x 270 mm, a 
matrix of 160x128, the number of shots of 12 resulting in a temporal resolution of 42 ms. 
After the cine images were acquired, the patients received an intravenous bolus of 0.1 
mmol/kg Gadolinium-DTPA (Magnevist, Schering, Berlin , Germany) at a rate of 5 mL/s by 
means of an infusion pump. A first-pass perfusion scan was acquired simultaneously with the 
bolus injection for 40 to 50 heartbeats. First-pass perfusion images (early hypo-enhancement) 
were acquired by using an ECG-gated saturation recovery interleaved gradient echo-planar 
imaging pulse sequence, covering the heart with 5 to 8 evenly spaced slices every heart beat. 
Imaging parameters were as follows: TR 6.8 ms, TE 1.2 ms, echo train length 4, image matrix 
96x128 interpolated to 256x256 pixels, saturation pulse 90°, flip angle 20°, bandwidth 125 
kHz,, spatial resolution 2.8x3.75x8mm. A rectangular field of view of 75% was used. The 
acquisition window of one image per slice location was approximately (0.75 x 96 x 6.8)/4 = 
120 ms. Using the slice selective ”notched” prepulse and interleaved acquisitions strategy an 
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effective TI of approximately 160 ms was achieved (24). Ten to twenty minutes after the 
injection, delayed-enhancement images (hyper-enhancement) were acquired by using an 
inversion-recovery prepared gated fast-gradient echo-pulse sequence, similar to that recently 
described (25). Imaging was performed with the following parameters: TR 7.3 ms, TE 1.6 ms, 
image matrix 256x192, rectangular field of view of 75%, flip angle 20°, inversion pulse 180°, 
and inversion time 200 to 250 ms, spatial resolution 1.6x1.6x8mm. The delayed-image 
prescriptions had the same slice thickness and spacing as the cine short-axis images.  
 
Analysis of MRI. Regional MRI myocardial perfusion and delayed hyper-
enhancement imaging were scored using the 2-chamber, 4-chamber and short-axis series 
using the same 16-segment model as for MCE. Only segments related to acute infarct territory 
were considered for the analysis. Using first-pass imaging, regional myocardial early hypo-
enhancement was graded using a 3-point grade scale: grade 0, severe hypo-enhancement; 
grade 1, subendocardial hypo-enhancement; grade 2, no hypo-enhancement. Delayed hyper-
enhancement imaging on inversion-recovery MRI was scored using a 5-point grading scale 
assessing the transmural extent of hyper-enhancement: grade I, no hyper-enhancement; grade 
II, 1%-25% of the wall thickness; grade III, 26%-50%; grade IV, 51%-75%; and grade V, 
76%-100% of the wall thickness. MRI images were scored by two observers unaware of 
clinical, MCE and angiographic data. Similarly to MCE, in each patient an MRI score index 
regarding both hypo- and hyper-enhancement was derived by averaging the perfusion scores 
from each dysfunctional segment dividing by the number of dysfunctional segments. A 
patient was considered to have adequate reperfusion if the hypo-enhancement score index was 
≥1 and hyper-enhancement score index ≤3 (>50% of the wall thickness), and inadequate 
otherwise. 
 
Statistical Analysis. All continuous data are expressed as mean ± SD. Differences 
between proportions were compared using the Chi square test. The agreement between MCE 
and first-pass perfusion imaging for detecting viable segments was assessed by 2 x 2 tables 
using weighted kappa statistics (26). The individual values of sensitivity, specificity and 
accuracy of each technique to predict improvement of myocardial function were calculated on 
the base of an improvement at follow-up of left ventricular ejection fraction ≥5% in both 
groups of patients with or without an adequate reperfusion. These values were compared 
using McNemar analysis. Repeated measurements, as left ventricular end-diastolic volume 
(EDV), end-systolic volume (ESV) and ejection fraction were analyzed using repeated 
measurements analysis of variance (ANOVA) to evaluate differences across the time. All tests 
were two-sided. Statistical significance for all tests was stated at the classical tests multiple 
times. A value of p < 0.05 was considered statistically significant.  
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Results 
 
 
 Patients Characteristic and Perfusion/Enhancement Pattern at Baseline. 
Baseline characteristics of the 35 patients (30 men, mean age 52±12 years) are summarized in 
Table 1.  
 
 
Table 1. Patients Characteristics (n=35) 
 
 
Age (years) 52 ± 12 
Men 30 (86) 
Smoking 22 (63) 
Diabetes mellitus 3 (1) 
Hypertension 12 (34) 
Hypercholesterolemia 9 (26) 
Family history of coronary artery disease 12 (34) 
Left ventricular ejection fraction 42 ± 8 
Creatine kinase peak (International units) 3418 ± 2462 
Creatine kinase MB peak (International units) 299 ± 237 
Anterior infarction 20 (57) 
Number of diseased vessels 1.6 ± 0.8 
 
Values are presented as number (%) or mean ± standard deviation. TIMI = thrombolysis in 
myocardial infarction. 
 
 
 Mean time from symptom onset to first balloon inflation was 4.1±1.8 hours. In 3 out 
of 35 patients (8%) the infarcted-related coronary artery was suboccluded with a TIMI 3 flow 
when the angiography was performed. In 241 segments related to the acute infarct territory 72 
(30%) were defined hypokinetic and 120 (63%) akinetic according to MCE. Myocardial 
perfusion in the 192 (80%) dysfunctional segments was evaluated using both MCE and first-
pass perfusion MRI, with a good agreement (91%, kappa=0.80). At 60 days follow-up, 115 
(60%) out of 192 dysfunctional segments evaluated by MCE showed an improvement of 
function.  
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 Improvement of Myocardial Function at Follow-up. Perfusion/enhancement 
patterns detected by real time perfusion MCE, first-pass imaging and delayed-enhanced MRI 
in the 192 dysfunctional segments are presented in Table 2. At 60 days follow-up 58 (95%), 
53 (66%) and 4 (8%) of the segments with normal, partial, and no perfusion detected by MCE 
exhibited improvement in function respectively. Considering cine MRI with first-pass 
perfusion imaging (hypo-enhancement), 66 (81%) of segments with no defects, 46 (71%) of 
segments with a subendocardial defect, and 3 (6%) of segments with a severe hypo-
enhancement improved in regional myocardial function. Delayed-enhanced MRI 
demonstrated that 38 of 39 (97%) segments without hyper-enhancement improved, whereas 
31 (96%), 36 (92%), 7 (22%), and 3 (6%) of segments with grade II, III, IV, and V had 
improved at follow-up. 
 
 
Table 2. Perfusion/enhancement Patterns Detected by MCE and Contrast-enhancement 
MRI in Dysfunctional Segments and Improvement of Myocardial Function at Follow-
up. 
 
TECHNIQUE Dysfunctional 
Segments (N=192) 
Recovery at 
60 Days Follow-up
MCE    
Normal perfusion 61 58 (95%) 
Patchy perfusion 80 53 (66%) 
Absence of perfusion 51 4 (8%) 
MRI: FIRST-PASS IMAGING  
(Hypo-enhancement) 
  
No Defect 81 66 (81%) 
Subendocardial defect 65 46 (71%) 
Severe hypo-perfusion defect 46 3 (6%) 
MRI: DELAYED-ENHANCEMENT IMAGING 
(Hyper-enhancement) 
  
0% of the wall thickness 39 38 (97%) 
0-25% of the wall thickness 32 31 (96%) 
26-50% of the wall thickness 39 36 (92%) 
51-75% of the wall thickness 32 7 (22%) 
76-100% of the wall thickness 50 3 (6%) 
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 Relation of Adequate Reperfusion Assessed by MCE and Contrast-enhanced 
MRI to Improvement of Global Myocardial Function. Sensitivity, specificity, predictive 
value and accuracy for MCE and contrast-enhanced MRI in predicting myocardial function 
improvement were analyzed on a per patients basis (Table 3). One patient did not show any 
myocardial dysfunction and was not considered in the analysis. Twenty-one out of 22 patients 
(95%) with adequate reperfusion by MCE showed an improvement of left ventricular ejection 
fraction at follow-up. Conversely 3 out of 12 patients (25%) without an adequate reperfusion 
improved in ejection fraction. On MRI hypo-enhancement evaluation, 21 out of 25 (84%) 
patients with an adequate reperfusion improved in ejection fraction at follow-up, whereas 3 
out of 9 (33%) patients with no adequate reperfusion showed an increasing in ejection fraction 
≥5%. Finally, all 18 patients with a hyper-enhancement MRI score index ≤3 showed an 
increase in ejection fraction, whereas only 6 out of 16 (37%) showed an improvement at 
follow-up. Sensitivity was comparable between MCE (87%), first-pass perfusion MRI (87%) 
and hyper-enhancement MRI (75%), p values = 1.0 between MCE and first-pass MRI, 0.1 
between MCE and hyper-enhancement MRI, and 0.1 between first-pass and hyper-
enhancement MRI (Table 3). Similarly, specificity was not significantly different between 
MCE (90%), first-pass perfusion MRI (60%) and hyper-enhancement MRI (100%), p values 
= 0.1 between MCE and first-pass MRI, 1.0 between MCE and hyper-enhancement MRI, and 
1.0 between first-pass and hyper-enhancement MRI. No significant differences were present 
in accuracy between all techniques (MCE: 88%, first-pass perfusion MRI: 79%, delayed-
enhancement MRI: 82%, p values = 0.1 between MCE and first-pass MRI, 0.3 between MCE 
and hyper-enhancement MRI, and 0.7 between first-pass and hyper-enhancement MRI).  
 
 
Table 3. Sensitivity, Specificity, Predict Values, and Accuracy of MCE, First-pass 
Perfusion and Delayed-enhancement MRI to Predict Improvement of Myocardial 
Function after PCI 
 
 MCE MRI: 
First-pass imaging 
MRI: 
Delayed-enhancement
Sensitivity 87 (76-99) 87 (76-98) 75 (60-89) 
Specificity 90 (80-100) 60 (34-87) 100 
Positive predictive value 95 (88-100) 84 (72-96) 100 
Negative predictive value 75 (60-89) 67 (51-83) 62 (49-75) 
Accuracy 88 (77-99) 79 (65-92) 82 (69-95) 
 
Values are expressed as percentage (95% confidence interval). 
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Figure 1 illustrates the relation between MCE and MRI using both first-pass and delayed-
enhancement imaging (hypo- and hyper-enhancement pattern) in a patient who underwent 
PCI of the left anterior descendent coronary artery.  
 
 
 
 
 
Figure 1. MCE and MRI images of a patient who underwent PCI of the left anterior 
descending coronary artery. Panel A: MCE shows a defect of perfusion involving the anterior 
and posterior septum till the apex in short axis, 4- and 3-chamber views. Panel B: MRI shows 
a defect of perfusion detected by first-pass imaging (hypo-enhancement) and transmural 
delayed hyper-enhancement involving the anterior and posterior myocardial septum (short 
axis images on the left and middle part respectively). Delayed hyper-enhancement involves all 
the anterior septum till the apex (3-chamber view on the right side). 
 
 
 
 To study the time course of left ventricular remodeling after PCI, the EDV was 
compared to the results of MCE, first pass perfusion and delayed enhancement MRI: Table 4 
shows that patients with adequate reperfusion had a small decrease of EDV during follow-up, 
whereas patients with inadequate reperfusion had adverse LV remodeling with a gradual 
increment of EDV over time. 
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Discussion 
 
 In patients who underwent PCI in the setting of AMI, both MCE and contrast-
enhanced MRI allow early assessment of microvascular integrity and prediction of 
improvement of myocardial function. The main finding of the current study is that these 
modalities provide a comparable sensitivity, specificity and accuracy for the assessment of 
recovery of contractile function after PCI. 
 
 Comparison of MCE with Contrast-enhancement MRI to Predict Improvement 
of Myocardial Function. Previous studies have showed the efficacy of MCE to assess 
microvascular flow restoration after revascularization in AMI and the ability of MCE in 
distinguishing stunned from non-reperfused myocardium (9). Ito and colleagues used MCE to 
define the “no-reflow” phenomenon after revascularization in AMI (27) and showed how this 
phenomenon was related to subsequent increased post-infarction complications (28). 
Bolognese et al. (7), studied 124 patients with AMI who underwent PCI by intracoronary 
MCE, during a mean follow-up of 46 ± 32 months. Patients who presented microvascular 
dysfunction by MCE before PCI had a higher mean creatinine kinase, higher baseline wall 
motion score index and lower baseline left ventricular ejection fraction. At 6 months follow-
up, these patients showed left ventricular remodeling (increasing in left ventricular end-
systolic and end-diastolic volumes), whereas patients who had an adequate reperfusion 
showed a decreased end-systolic volumes. Only a slight and not significant improvement of 
left ventricular ejection fraction characterized patients with inadequate reperfusion, whereas 
patients who had an adequate reperfusion showed a significant improvement. In our study 
similar results were found. The grade of myocardial reperfusion was the most important 
independent predictor of left ventricular dilatation. Moreover, patients with microvascular 
dysfunction at baseline had a worse outcomes in term of cardiac death and combined events 
compared to patients with adequate reperfusion. The presence of microvascular dysfunction 
was the only predictor of both end-points by multivariate Cox analysis. In line with the study 
of Bolognese et al. (7), baseline differences in volumes and ejection fraction between the two 
groups could be explained by the occurrence of a smaller infarct size in patients with adequate 
reperfusion.  
 Previously, MRI studies showed that an hypo-enhancement pattern detected by first-
pass perfusion MRI, representing the no-reflow area after AMI, is associated with a 
permanent dysfunction at follow-up (13, 29). Wu et al. (13), studied 44 patients after AMI by 
MRI during a mean follow-up of 16 ± 5 months. Patients with microvascular obstruction 
showed a greater increasing in left ventricular volumes and scar formation at 6 months 
compared to patients without obstruction. The present data confirm and extend the previous 
studies in line with pathological findings which indicate that hypo-enhanced myocardium 
represents myocardial tissue with microvascular damage and obstruction (no-reflow 
phenomenon) (30, 31). On the other hand delayed hyper-enhancement in AMI appears to be 
related to myocardial necrosis considering that gadolinium is a contrast agent able to pass 
through the microvascular vessels wall and the membrane of damaged cells. Conversely, 
contrast agents used for MCE remain inside the microvascular circulation allowing to detect 
exclusively microvascular integrity and therefore myocardial perfusion. Previously, Gerber et 
al (16) showed that persistent myocardial dysfunction seems to be better correlated with 
myocardial necrosis assessed by delayed-enhancement MRI than with microvascular damage 
and obstruction as detected by first-pass MRI. An additional benefit of contrast-enhanced 
MRI is the higher spatial resolution that allows assessment of the transmural extent of 
necrosis in the infarct region. In the current manuscript, MRI achieved 100% specificity and 
was superior to MCE in correctly identifying patients who did not improve in function after 
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revascularization. Thus, MRI may be advantageous over MCE in identifying patients who 
may be at increased risk for an adverse outcome and who may need special medical attention. 
Moreover, data on improvement of regional myocardial function pointed out as predictive 
accuracy for MCE was high for segments with normal or absent perfusion, but it was limited 
for segments with a “patchy” perfusion pattern (around 70%). In contrast, the finer scale 
applied with MRI using delay-enhancement technique, allowed for a better distinction 
between segments with high or low probability for functional recovery, with a sharp 
demarcation at the 50% transmural hyper-enhancement level.  
 Both MCE and MRI can be used to assess recovery of contractile function after PCI, 
the choice for either MCE or MRI mainly depends on patients characteristics and local 
availability and expertise. MCE is a rapid real-time bed-side technique that can be easily 
performed in intensive care units in the acute phase of myocardial infarction, also in unstable 
patients. Moreover, this technique is less time-consuming compared to contrast-enhanced 
MRI and is a relatively inexpensive tool. Besides, not all patients can be safely referred to 
MRI, because of the presence of intra-aortic balloon devices, pacemakers, or claustrophobia. 
On the other side, MCE is not yet widely applied in clinical routine mainly due to a lack of 
standardized image acquisition and contrast administration protocols and image interpretation. 
In contrast, these issues are largely resolved for MRI using delay-enhancement technique. 
Moreover, MRI may be the preferred modality in patients with a poor acoustic window. 
 
Study limitations 
 
 Several limitations of this study need to be addressed. Although a 16-segment model 
of the left ventricle was used both by MCE and MRI, some misalignment between the 
different images may have occurred. Due to limited time slots available for MRI these exams 
were not always performed on the same day. To minimize the influence of time both MRI and 
MCE were correlated to wall motion scores by the same technique on the same day. Patients 
with intra-aortic balloon devices or who were clinically instable longer than 48 hours were not 
included in the study. Although a quantitative analysis of MCE could have been advisable, 
this technique is not still widely used in daily clinical practise. Although the agreement 
between wall motion derived by echocardiography and MRI was excellent (kappa 0.88, 93% 
agreement), a potential bias towards echocardiography can not be completely excluded since 
it was used to assess improvement of wall motion. Bolus administration of contrast compared 
to continuous infusion is a potential limitation of this study. However previous studies have 
shown the effectiveness of the assessment of myocardial perfusion using repeated injections 
of contrast agents by slow bolus, that represents a practical use in a busy echocardiography 
laboratory (9). Finally, the use of different contrast agents, infusion protocols or echo-
software may give different results so that the described findings should be extrapolated with 
caution to other scenarios. 
 
Conclusions 
 
This study compares the value of MCE with contrast-enhanced MRI to predict myocardial 
functional improvement in patients after PCI for AMI. Both techniques allow prediction of 
myocardial function improvement after PCI. MCE has a comparable accuracy to MRI and as 
a bed-side technique may be an alternative tool in the acute phase of AMI. 
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Abstract 
 
Background. The aim of this study was to investigate incidence, risk factors and 
prognosis of dilated-hypokinetic evolution in a large cohort of patients with hypertrophic 
cardiomyopathy (HCM) followed at a cardiological center serving both the pediatric and adult 
population. 
Methods. 222 consecutive HCM patients (65% men, 19% ≤18 years) were 
prospectively evaluated for a mean follow-up of 11 ± 9 years.  
Results. Diagnosis of dilated-hypokinetic HCM was made in 12 patients at first 
evaluation, (11 without previous septal myectomy surgery; prevalence= 4.9%) Twelve of the 
210 patients with ‘classic’ HCM at first evaluation underwent dilated-hypokinetic evolution 
(incidence= 5.3/1000 patient-years). Patients with prevalent/incident dilated-hypokinetic 
evolution were younger at first evaluation (32 ± 14 vs 41 ± 21 years, p= 0.04), and more often 
had a family history of HCM (61% vs 26%, p= 0.002) or sudden death (43% vs 19%, p= 0.01) 
with respect to patients who maintained ‘classic’ HCM. Moreover, they showed greater 
interventricular septum (23 ± 3mm vs 19 ± 6mm, p= 0.004) and posterior wall (15 ± 3mm vs 
13 ± 4mm, p= 0.006) thickness. Cardiovascular death-free survival was lower among patients 
with dilated-hypokinetic HCM (p<0.04). Cox proportional hazards regression analysis 
identified left ventricular wall thickness (HR=1.07, 95%CI 1.01–1.14; p= 0.03) and end-
diastolic diameter (HR=1.08, 95%CI 1.04–1.11; p= 0.0001) as independent predictors of 
cardiovascular death. 
Conclusions. Dilated-hypokinetic evolution is rare but not exceptional in HCM. 
Young age at diagnosis, family history of HCM, and greater wall thickness are incremental 
risk factors for dilated-hypokinetic HCM, which carries an ominous prognosis. 
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Introduction 
 
Most patients with hypertrophic cardiomyopathy (HCM) have normal systolic 
function (in terms of left ventricular ejection fraction [LVEF] and other ejection indices) in 
the context of impaired diastolic function and reduced left ventricular (LV) end-diastolic 
volume. However, in a minority of patients HCM evolves in to a phase characterized by 
systolic dysfunction, LV dilatation and wall thinning, resembling the morphologic and 
functional features of dilated cardiomyopathy (Figure 1).  
 
 
 
 
Figure 1. A representative example of evolution to dilated-hypokinetic HCM in a female 
pediatric patient. Left. The basal echocardiogram (at age 13 years) shows HCM with massive 
LV hypertrophy involving the intraventricular septum and the left posterior wall, 
accompanied by diminutive LV cavity size. Right. Three years later (at 16 years), the LV 
cavity has become enlarged and the walls have thinned in the context of severe heart failure 
requiring heart transplantation. 
 
This dilated-hypokinetic evolution of HCM is often designated as ‘end-stage’, ‘burn-
out phase’ (1-10) or ‘progressive disease’ (11). This peculiar disease pathway, which had 
already been clearly described in the 1980s (1, 2, 4-7, 9), has recently attracted renewed 
scientific interest for at least two reasons. On pathogenetic grounds, it has recently been 
reported that mutations in sarcomere protein genes can cause either HCM or dilated 
cardiomyopathy, stimulating two different pathobiological events that remodel the heart (12). 
Clinically, dilated-hypokinetic evolution is one of the pathophysiological substrates for heart 
failure in patients with HCM, among whom it is also the single most frequent indication for 
heart transplantation (3, 13, 14).  
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The available data on the occurrence of dilated-hypokinetic evolution of HCM mainly 
regards prevalence (rather than incidence) of adult cases, with very little being known about 
the pediatric population (15, 16). In the present study, we investigated incidence, risk factors, 
natural history and prognostic implications of dilated-hypokinetic evolution of HCM in a 
large population of patients with HCM routinely followed at a cardiological center serving 
both the pediatric and adult population. 
 
 
Methods 
 
Eligibility Criteria and Recruitment. The population of this observational study 
comprised 222 patients with a diagnosis of HCM under observation between 1964 and 2002 
in the standard inpatient/outpatient clinics of our cardiologic center in a public teaching 
hospital open to a large local and regional population. In particular, the study regarded all 
patients with either a de novo diagnosis of HCM made in our center or an existing diagnosis 
of HCM who were referred to us for follow-up purposes (all instrumental and clinical 
findings, including familial analysis with pedigree reconstruction, are routinely stored in an 
electronic database). The single inclusion criterion was diagnosis of HCM based on 2-
dimensional echocardiographic evidence of a non-dilated and hypertrophic LV—defined as 
wall thickness of ≥15 mm in adults, or the equivalent with respect to body-surface area in 
children (16)—in the absence of another cardiac or systemic disease that could produce a 
similar degree of hypertrophy (17). Exclusion criteria were presence of Friedreich’s ataxia or 
Noonan syndrome (based on careful clinical analysis of phenotype); Pompe’s disease (clinical 
and enzymatic evaluation); mitochondrial disease (exclusion of multiorgan involvement, 
and—in selected patients—histologic evaluation of skeletal muscle biopsy or mitochondrial 
DNA analysis). In patients evaluated before echocardiography was introduced into our 
clinical practice (in 1984), the diagnosis of HCM was made by typical electrocardiographic 
features combined with angiographic findings (17) and was subsequently confirmed by 
echocardiography (18). 
Those patients residing within easy reach of the clinic were regularly followed in our 
outpatient clinic according to our routine institutional program, comprising two planned 
clinical checks-up and one echocardiographic examination per year. The remainder of the 
population (38 patients) was recalled (by mail and then telephone) for an echocardiographic 
and clinical check up at the end of the study period. Data regarding time and circumstances of 
death were obtained from relatives and physicians (consulting clinical records and death 
certificates when necessary). All patients provided written informed consent to anonymous 
use of their data for research purposes. In line with national and European guidelines, no 
specific ethical approval was required for this observational study without invasive 
procedures.  
 
Definitions. Dilated-hypokinetic evolution of HCM was defined as development of 
hypokinetic and dilated LV, with an end-diastolic cavity dimension measured by M-mode 
echocardiography exceeding the reference upper 95% confidence limit (95%CI) for body 
surface area and a LVEF <50% (2, 4, 19). In patients who already presented at our center with 
a dilated and hypokinetic LV, diagnosis of HCM always included previous echocardiographic 
documentation of classic HCM. ‘Medical treatment at first examination’ refers to 
pharmacological treatment ongoing/started at that time. 
Other definitions were those commonly used. Sudden cardiac death was defined as 
unexpected sudden collapse within 1 hour of onset of symptoms occurring in patients who 
had previously experienced a relatively stable or uneventful clinical course. Heart failure-
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related death was defined as death occurring in the context of cardiac decompensation and 
progressive disease course ≥1 year before death.  
 
Statistical Analysis. The SPSS statistical package (SPSS Statistical Software Inc., 
Chicago, IL) was used for all analysis. When not otherwise specified, data are expressed as 
mean ± 1 standard deviation, or as number of patients (percentage). Prevalence of dilated-
hypokinetic HCM was calculated as the ratio between patients with a diagnosis of dilated-
hypokinetic HCM at the first evaluation and the total number of study patients. Analysis of 
incidence was performed among those patients without dilated-hypokinetic HCM at first 
evaluation. Incidence was calculated as the number of patients who developed dilated-
hypokinetic HCM during the follow-up period divided by the total number of person-years of 
observation accumulated in the study population; patients who underwent 
myotomy/myectomy or percutaneous transluminal septal myocardial ablation were included 
in the analysis only up to the time of the procedure. Differences between means were 
determined using the unpaired or paired Student’s t test, as appropriate. Differences between 
proportions were determined using the chi-square test. To assess the prognostic role of 
dilated-hypokinetic HCM in terms of risk of cardiovascular death, a multivariate Cox 
proportional hazards model was fitted to the data (20). The following variables were included: 
gender, age at first evaluation, family history of sudden-death, NYHA class I–II or III–IV, 
medical treatment at first evaluation, non-sustained ventricular tachycardia, LV outflow 
obstruction, maximum LV wall thickness, posterior wall thickness, LV end-diastolic 
diameter, end-systolic left atrial diameter, and (as a time-dependant covariate) dilated-
hypokinetic evolution. Variables were selected in a stepwise forward selection manner with 
entry and retention set at a significance level of 0.05. Probability of cardiovascular death-free 
survival was calculated using the Kaplan-Meier method, and survival curves were compared 
using the log-rank test.  
 
Results 
 
Study Population. The mean age at first evaluation was 40 ± 20 years; 144 (65%) 
patients were men, 42 (19%) ≤18 years. Baseline clinical and echocardiographic 
characteristics of the entire population as well as of the two groups of patients with either 
dilated-hypokinetic or ‘classic’ HCM at first evaluation are summarized in Table 1. During a 
mean follow-up of 11 ± 9 years, 29 (13%) patients developed persistent atrial fibrillation, 65 
(29%) had heart failure episodes and 20 (9%) experienced syncope. Holter monitoring data 
were available for 190 (85%) patients; non-sustained ventricular tachycardia were present in 
64/190 (34%). A permanent pacemaker or cardioverter-defibrillator were implanted in 10 
(4%) and 11 (5%) patients respectively. During the follow-up period, 10 patients (4%) 
underwent heart transplantation and 50 (23%) died. The cause of death was sudden in 20 (9%) 
patients, heart failure-related in 13 (6%), stroke-related in 3 (1%) and due to non-cardiac 
causes in 14 (6%). 
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Table 1. Baseline Characteristics of the Overall Population, Patients with ‘Classic’ 
HCM, and Patients with Dilated-hypokinetic HCM at First Evaluation 
 
 Overall 
population 
(n=222) 
Dilated-hypokinetic 
HCM  
(n=11)* 
‘Classic’ 
HCM 
(n=210) 
p value† 
 
Male gender 144 (65%) 8 (73%) 135 (64%) 0.8 
Family history of HCM 65 (29%) 7 (64%) 58 (28%) 0.03 
Family history of sudden death 47 (21%) 4 (36%) 43 (20%) 0.3 
Age at diagnosis (yr) 38 ± 18 27 ± 18 39 ± 18 0.05 
Age at first evaluation (yr) 40 ± 20 34 ± 16 40 ± 21 0.3 
Pediatric age (≤18 yr) at first evaluation 42 (19%) 3 (27%) 37 (18%) 0.6 
NYHA class III–IV 22 (10%) 3 (27%) 19 (9%) 0.1 
NYHA class (mean) 1.5 ± 0.7 2.1 ± 1.1 1.4 ±1.0 0.1 
Syncope 21 (9%) 1 (9%) 19 (9%) 1 
Medical treatment at first examination 160 (72%) 9 (82%) 151 (72%) 0.7 
Persistent atrial fibrillation  3 (1%) 0 (0%) 3 (1%) 1 
Heart failure episodes 12 (5%) 3 (27%) 9 (4%) 0.01 
Outflow obstruction 67 (30%) 0 (0%) 68 (32%) 0.05 
Maximum LV wall thickness (mm) 19 ± 6 17 ± 6 20 ± 6 0.2 
Interventricular septal width (mm) 18 ± 6 16 ± 6 19 ± 6 0.2 
Posterior wall thickness (mm) 13 ± 4 14 ± 4 13 ± 4 0.4 
LV end-diastolic diameter (mm) 43 ± 11 61 ± 9 41 ± 10 NA 
End-systolic left atrial diameter (mm) 43 ± 10 49 ± 8 42 ± 10 0.02 
LVEF (%) 67 ± 8 32 ± 10 66 ± 8 NA 
Apical HCM 8 (4%) 0 (0%) 68 (32%) 0.05 
 
∗One patient with previous septal myectomy surgery was excluded from this analysis. †The p 
values refer to comparison between patients with dilated-hypokinetic and patients with 
‘classic’ HCM at first evaluation. NA= not applicable (separation into subgroups was based 
on these variables)  
 
 
 
Prevalence of Dilated-hypokinetic Evolution of HCM. Diagnosis of dilated-
hypokinetic HCM was made in 12 patients at the first evaluation. One of these patients, who 
had entered this phase following septal myectomy surgery, was excluded from the analysis. 
Therefore, 11 patients were deemed to have dilated-hypokinetic HCM evolution at first 
evaluation corresponding to a prevalence of 4.9%.  
 
Incidence of Dilated-hypokinetic Evolution of HCM. Twelve of the 211 patients 
with ‘classic’ HCM at first evaluation underwent dilated-hypokinetic evolution (their changes 
in LV cavity dimension, LVEF and maximum wall thickness are individually represented in 
Figure 2). 
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Figure 2. Changes in LV maximal wall thickness (A), LV end-diastolic diameter (B) and 
LVEF (C), in the 12 HCM patients who underwent dilated-hypokinetic evolution during the 
study period. 
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Since all 12 of these patients belonged to the subgroup with regular follow-up data 
from our institutional program, an actuarial incidence curve was constructed (Figure 3). The 
events (onset) were distributed rather evenly over almost the entire follow-up period (mean 11 
± 9 years, range 4 month to 42 years). The overall incidence of development of dilated-
hypokinetic HCM was 5.3 per 1000 patient-years. Of note, a ‘restrictive left ventricular filling 
pattern’ was present at echo-Doppler evaluation in 3/12 patients at the time of detection of 
dilated-hypokinetic evolution.  
 
 
 
 
 
Figure 3. Actuarial incidence curve of dilated-hypokinetic evolution among 210 patients with 
‘classic’ HCM at first evaluation.  
 
 
Characterization of Patients with Dilated-hypokinetic HCM and Prediction of 
Onset. We first looked at the clinical/morphological profile of patients with prevalent dilated-
hypokinetic HCM at baseline (n=11). A comparison between their clinical/morphological 
characteristics and those of the rest of the population at first evaluation is shown in Table 1.  
To look for possible predictors of evolution, we then analyzed the baseline 
characteristics of patients who had prevalent/incident dilated-hypokinetic HCM (n=23). Table 
2 shows a comparison of the baseline characteristics of patients with dilated-hypokinetic 
HCM and patients who maintained ‘classic’ HCM (it should be noted that for those patients 
with prevalent dilated-hypokinetic HCM, measurements were retrieved from prior 
echocardiographic documentation). At univariate analysis, the two subgroups were similar as 
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regards gender, symptoms, LV end-diastolic volume and LVEF. On morphologic grounds, 
patients with dilated-hypokinetic HCM showed greater LV parietal thickness at the posterior 
as well as interventricular septal level. They also more often had a family history of HCM or a 
family history of sudden death. They were significantly younger both at the original diagnosis 
of HCM and at first examination. Due to the small number of patients with dilated-
hypokinetic evolution, it was not possible to construct a valid multivariate model.  
Of note, the 23 patients with prevalent/incident dilated-hypokinetic evolution belonged 
to 18 distinct families. Among these 18 nuclei, we could identify 3 pedigrees containing both 
sudden death in the context of non-dilated HCM and death from heart failure due to end-stage 
evolution. 
 
Table 2. Baseline Clinical and Echocardiographic Features of Patients with 
Prevalent/incident Dilated-hypokinetic HCM and Patients who Maintained ‘Classic’ 
HCM 
 
 Dilated-hypokinetic 
HCM  
(n=23) 
‘Classic’ HCM 
 
(n=198) 
p 
value 
Male gender 17 (74%) 126 (64%) 0.5 
Family history of HCM 14 (61%) 51 (26%) 0.002 
Family history of sudden death 10 (43%) 37 (19%) 0.01 
Age at diagnosis (yr) 28 ± 15 39 ± 18 0.03 
Age at first evaluation (yr) 32 ± 14 41 ± 21 0.04 
Pediatric age (≤18 yr) at first evaluation 9 (39%) 34 (17%) 0.02 
NYHA III-IV at first evaluation 0 (0%) 19 (9%) 0.5 
NYHA class (mean) 1.5 ± 0.6 1.4 ± 0.7 0.8 
Syncope at first evaluation 2 (9%) 18 (9%) 0.99 
Medical treatment at first examination  17 (74%) 141 (71%) 1 
Outflow obstruction 4 (17%) 67 (30%) 0.2 
Maximum LV wall thickness (mm) 24 ± 3 20 ± 6 0.001 
Interventricular septal width (mm) 23 ± 3 19 ± 6 0.004 
Posterior wall thickness (mm) 15 ± 3 13 ± 4 0.006 
LV end-diastolic diameter (mm) 43 ± 4 41 ± 9 0.7 
End-systolic left atrial diameter (mm) 45 ± 7 42 ± 10 0.1 
LVEF (%) 66 ± 4 66 ± 8 1 
 
 
Prognostic Implications of Dilated-hypokinetic HCM. Figure 4 shows actuarial 
cardiovascular death-free survival curves for patients with prevalent or incident dilated-
hypokinetic HCM (n=23) and the rest of the study population: patients with dilated-
hypokinetic evolution had a poorer cardiovascular death-free survival (p=0.04). In particular, 
out of the 23 patients with dilated-hypokinetic evolution, 4 died of congestive heart failure 
and 3 died suddenly.  
Cox proportional hazards regression analysis identified LV wall thickness (HR=1.07, 
95%CI 1.01–1.14; p=0.03) and LV end-diastolic diameter (HR=1.08, 95%CI 1.04–1.11; 
p=0.0001) as independent predictors of cardiovascular death; dilated-hypokinetic evolution 
(considered as a time-dependant covariate) did not appear to affect cardiovascular death-free 
survival (p=0.51).  
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Figure 4. Kaplan-Meier estimates of cardiovascular death-free survival of patients with and 
without prevalent/incident dilated-hypokinetic HCM. 
 
 
Clinical events observed during follow-up among the subgroups of patients who did 
and did not develop dilated-hypokinetic HCM during the study period are summarized in 
Table 3. Overall, patients who developed dilated-hypokinetic HCM more often had persistent 
atrial fibrillation, episodes of heart failure, ventricular tachycardia (on 24-h Holter 
monitoring) and heart transplantation. It should be noted, however, that this subgroup had a 
longer follow-up (14±6 vs 10±7 years, p=0.05). The first signs of LV dilatation and 
hypokinesis in these 12 ‘incident’ patients became evident within 13 ± 8 years (ranging from 
5 to 33 years) after the diagnosis of HCM (mean age of patients 42 ± 17 years). The mean 
interval from echocardiographic appearance of LV dilatation to development of heart failure 
(NYHA class III-IV) was 3 ± 2 years (1–7 years). During follow-up, 2 (17%) patients died 
and 5 (45%) underwent heart transplantation. The mean time between identification of dilated 
evolution and death or heart transplantation was 5 ± 3 and 5 ± 4 years respectively. 
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Table 3. Clinical Events Observed in Patients who Underwent Dilated-hypokinetic 
Evolution during Follow-up and in Patients who Maintained ‘Classic’ HCM 
 
 Dilated-
hypokinetic 
evolution (n=12) 
‘Classic’ HCM
(n=198) 
P value
Persistent atrial fibrillation  5 (42%) 22 (11%) 0.009 
Heart failure episodes 10 (83%) 48 (24%) 0.0001 
Syncope 2 (17%) 19 (9%) 0.8 
Nonsustained/sustained VT on Holter ECG 9/12 (75%)  49/175 (28%) 0.002 
Pacemaker 1 (8%) 8 (4%) 1 
ICD 2 (17%) 8 (4%) 0.2 
Cardiovascular death 2 (17%) 26 (13%) 0.1 
   -Sudden death 1 (8%) 17 (9%) 1 
   -Heart failure-related death 1 (8%) 9 (4%) 1 
   -Stroke-related death 0 (0%) 3 (1%) 1 
Non-cardiovascular death 0 (0%) 14 (7%) 0.7 
Heart transplantation 5 (42%) 1 (0.5%) 0.0001 
 
VT= ventricular tachycardia; ICD = implanted cardioverter-defibrillator. 
 
 
Five of 12 (42%) patients who experienced dilated-hypokinetic evolution during 
follow-up were younger than 19 years of age at first evaluation; in this subgroup, dilated-
hypokinetic evolution occurred at 8 ± 4 years (range 5–16) from HCM diagnosis. After LV 
dilatation occurred, these patients developed heart failure symptoms earlier compared with 
adult patients (1 ± 0.5 vs 5 ± 3 years, p<0.05). Moreover, 4/5 (80%) pediatric patients 
underwent heart transplantation (at 5 ± 4 years from appearance of dilatation) and 1 (8%) died 
of heart-failure occurred in 1 patient (at 2 years from dilatation).  
 
 
Discussion 
 
Dilated-hypokinetic evolution of HCM is responsible for severe heart-failure 
symptoms and is the single most frequent indication to heart transplantation among HCM 
patients (3, 13, 14). This study of a large population of HCM patients routinely followed at a 
single cardiologic center provides valuable data on the incidence of dilated-hypokinetic 
evolution among both children and adults, as well as on possible clinical and 
echocardiographic risk factors for development of this peculiar disease pathway. 
 
Prevalence and Incidence of Dilated-hypokinetic HCM. Since the 1980s, dilated-
hypokinetic (‘end-stage’) evolution of HCM has become an established clinical entity, whose 
recognition is clearly based on the presence of cavity size enlargement and LV systolic 
dysfunction, commonly accompanied by ventricular wall thinning (1, 2, 4-7, 9). Our 
definition of dilated-hypokinetic HCM was based on the simultaneous presence of LV cavity 
dilatation and reduced LVEF, not obligatorily associated with thinned LV walls. It is 
noteworthy however that LV wall thinning was documented during the study period in all but 
one patient (Figure 2). Outside heart transplantation centers, prevalence of dilated-hypokinetic 
HCM has generally been reported ranging from about 5% to 15% (4). However, these figures 
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were produced without excluding patients who had previously undergone myotomy-
myectomy, and are likely to give rise to a somewhat distorted picture (since myectomy can 
alter left ventricular end-diastolic diameter as routinely measured by M-mode according to the 
recommendations of the American Society of Echocardiography, whereas percutaneous septal 
myocardial ablation can induce left ventricular remodeling with increased volumes (21)). 
After exclusion of such cases, the recorded prevalence of dilated-hypokinetic HCM in our 
center was 4.9%.  
To our knowledge, this is the first time that the incidence of dilated-hypokinetic 
evolution has been studied in a large population of HCM patients not submitted to 
surgical/ablative myectomy. The overall incidence recorded was 5.3 per 1000 patient-years, 
with a rather even distribution of onset over almost the entire follow-up period (Figure 3).  
 
Prediction of Onset of Dilated-hypokinetic Evolution. Increased posterior wall 
thickness was the most peculiar morphologic trait in patients with (prevalent/incident) dilated-
hypokinetic HCM (Table 2). The pathogenetic significance of this morphologic peculiarity is 
unclear. One attractive hypothesis is that this phenotypic peculiarity might constitute a marker 
of a distinct genotype (unfortunately, our study did not contemplate systematic genotyping). 
Alternatively, it is conceivable that a widespread distribution of LV hypertrophy might 
exacerbate myocardial ischemia—a very common phenomenon in HCM—and eventually lead 
to global LV dysfunction. HCM characterized on echocardiography by marked thickening of 
the posterior left ventricular free wall has been previously described to be associated with 
early (before age 40) onset of severe symptoms, such as dyspnea, syncope, chest pain and 
palpitations (22). However, no relation between this peculiar morphologic feature of HCM 
and dilated-hypokinetic evolution has been previously reported.  
 
Natural History and Prognostic Implications of Dilated-hypokinetic Evolution. 
Despite the younger age at first evaluation of patients who developed dilated-hypokinetic 
HCM during follow-up, the interval from diagnosis to LV enlargement was rather long. 
However, once the dilation was established, the evolution towards heart failure and hence 
transplantation or death was rapid. The vast majority of our patients with dilated-hypokinetic 
evolution of HCM had severe symptoms (NYHA class IV), were refractory to medical 
treatment in spite of a depression of LVEF which might be considered only moderate in 
comparison with heart transplantation candidates with idiopathic dilated cardiomyopathy 
(Figure 2). A combination of both diastolic and systolic dysfunction could explain this 
apparent discrepancy. 
 
Pathogenesis of Dilated-hypokinetic Evolution in HCM. The most likely 
pathogenetic mechanisms of dilated-hypokinetic evolution of HCM have been widely 
discussed in the literature. Based on histology, importance has been given to small-vessel 
disease, myocardial disarray or replacement fibrosis (10, 11, 23-26). Recently, gadolinium-
enhanced cardiac magnetic resonance has provided in vivo confirmation that interstitial and 
replacement fibrosis is the most frequent myocardial substrate of this evolutionary pathway 
(11). The present study was not designed to clarify the pathogenetic mechanism of dilated-
hypokinetic HCM. However, analysis of the clinical and morphologic data regarding our 
prevalent and incident cases can provide some hints regarding the likely pathogenesis. In our 
two analyses (Tables 1 and 2), dilated-hypokinetic evolution was most often already present 
in the third decade of life, and about one-third of the cases were actually pediatric; 
furthermore, age at diagnosis of HCM appeared to be lower in patients with dilated-
hypokinetic evolution as compared with the rest of the population. These observations make a 
strict aging-related mechanism seem rather unlikely. On the other hand, they fit quite well 
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with the hypothesis that dilated-hypokinetic HCM often has a genetic basis (27-29). In some 
families, evolution to the dilated-hypokinetic evolution of HCM seems to occur with a 
particularly high frequency. A number of mutations in genes encoding proteins of the cardiac 
sarcomere have been reported in HCM patients in the dilated-hypokinetic evolution. It is 
unlikely that the propensity to develop this clinical course is exclusively due to any specific 
HCM-causing mutant gene. Interestingly, Seidman et al (12) recently demonstrated that 
mutations in the same gene (heavy-chain β-myosin) can cause either hypertrophic or dilated 
cardiomyopathy. The development of left ventricular wall thinning and systolic dysfunction 
probably represents a more complex phenomenon influenced by modifier genes as well as 
environmental factors. 
 
Considerations Regarding the Pediatric Population. Our data indicate that HCM 
patients diagnosed at a pediatric age are a high-risk subgroup not only as regards sudden death 
but also congestive heart failure. It is known that the morphologic basis for congestive heart 
failure in newborns with HCM is massive biventricular hypertrophy, frequently associated 
with right and/or left ventricular obstruction. Our data set reveals that dilated-hypokinetic 
evolution is another pathophysiologic substrate, apparently affecting older children and 
adolescents. In the clinical arena, this peculiar disease pathway of ‘classic’ HCM must be 
distinguished from other genetically determined entities that share the same phenotype of 
symmetrical LV hypertrophy and LV systolic dysfunction, and especially cardiomyopathies 
associated with mitochondrial disease. The latter, however, are generally characterized by 
multiorgan involvement, which should provide a valuable clue for a differential diagnosis. 
 
 
Clinical Implications and Conclusions 
 
The evolution toward a dilated-hypokinetic phase is rare but not exceptional in HCM, 
particularly among young patients with hypertrophy not confined to the interventricular 
septum, but also involving the posterior wall. Recognition of this risk profile in individual 
patients should encourage close follow-up, aimed at timely detection and treatment of 
congestive heart failure. We think that the option of heart transplantation deserves 
consideration (and discussion with the patient) on the first appearance of heart-failure 
symptoms, even if these occur before overt deterioration of systolic function.  
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Abstract 
 
Background. Intra-procedural myocardial contrast echocardiography using 
tranthoracic 2-D echocardiography has been shown to be crucial during percutaneous septal 
myocardial ablation (PTSMA) in patients with obstructive hypertrophic cardiomyopathy 
(HCM). The role of intracardiac echocardiography in guiding PTSMA has not been 
previously investigated.  
Methods. Intracardiac echocardiography was performed in 18 consecutive patients 
with obstructive HCM during PTSMA. A magnetic resonance imaging (MRI) was performed 
four days after the procedure in 12 patients. 
Results. The target septal branch was chosen on the basis of the risk-area visualized 
using intracardiac echocardiography after selective septal intracoronaric injection of an 
ultrasound contrast agent. Ethanol (2.1 ± 0.7 ml) was subsequently injected. The maximum 
width of the interventricular septum measured by intracardiac echocardiography was on 
average 21 ± 4 mm and correlated with MRI measurements (22 ± 4 mm, r = 0.70). During 
ethanol administration a backscatter signal enhancement of the infarct area (ablated area) was 
detected. The ablated area on planimetry was 1.8 ± 0.8 cm2 and correlated with the infarct 
size detected by MRI (22 ± 7 cc, r = 0.80). Resting left ventricular outflow tract gradient was 
reduced from 74 ± 35 mmHg to 8 ± 16 mmHg (p<0.0001) at the end of the procedure.  
Conclusions. Intracardiac echocardiography can be used to monitor ethanol 
administration during PTSMA in patients with obstructive HCM and reasonably predict the 
extent of the infarct area assessed by MRI. 
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Introduction 
 
In patients with hypertrophic cardiomyopathy (HCM), resting left ventricular outflow 
tract (LVOT) obstruction is an important and independent predictor of progression to severe 
symptoms of heart failure and of death (1-3). Surgical myectomy is the gold standard for 
treatment of severely symptomatic patients with obstructive HCM who are refractory to 
medical therapy (4, 5). Percutaneous transluminal septal myocardial ablation (PTSMA) has 
emerged as less invasive alternative treatment in these patients and results in clinical and 
hemodynamic improvement (6-8) in patients with obstructive HCM.. Intra-procedural 
transthoracic myocardial contrast echocardiography has been shown to be crucial during 
PTSMA for target vessel selection. Furthermore, improvement of clinical and hemodynamic 
results, and prevention of misplacement of the ethanol-induced necrosis as a source of 
potentially fatal complications were observed with this approach (7, 9, 10). Intracardiac 
echocardiography is an invasive tool that has been recently introduced in the clinical setting 
(11-13). This technique has the ability to provide a precise cardiac anatomy visualization and 
to guide interventional procedures. The aim of this study was to evaluate the role of 
intracardiac echocardiography during PTSMA in patients with obstructive HCM. 
 
Methods 
 
Patient Population. Between September 2003 and February 2005, 19 consecutive 
patients with obstructive HCM underwent PTSMA at the Thoraxcenter, Rotterdam, the 
Netherlands. The indication for PTSMA was based on a significant LVOT gradient as 
documented by transthoracic echocardiography and New York Heart Association (NYHA) 
functional class II to IV despite medical treatment. All subjects demonstrated a dynamic 
LVOT gradient of at least 50 mmHg at rest or on provocation. All but 1 procedures were 
performed under intracardiac echocardiography guidance. In 1 patient intracardiac 
echocardiography was not performed, due to the occurrence of a venous dissection. Twelve 
patients underwent magnetic resonance imaging (MRI) 4 days on average after the procedure.  
 
Intracardiac Echocardiography Procedure. The AcunavTM –intracardiac probe is a 
10F catheter equipped with a linear phased array bifrequency (6-7 MHz) transducer. The 
catheter has a quadridirectional steerable tip, with a proximal control unit for tip deflection. 
The insertable length of the catheter is 90cm. Regular 2D echocardiography along with colour 
Doppler, pulsed and continuous wave Doppler allows comprehensive anatomical and 
physiological assessment. The probe was interfaced with Sequoia or Cypress platform 
(Siemens Acuson, Mountainview, California), and the images were digitally recorded. 
Bilateral femoral arterial and venous accesses were obtained by a modified Seldinger 
technique. A 11F venous sheath was placed on the left side to introduce the intracardiac 
echocardiographic probe. A temporary pace-maker lead was positioned in the right ventricle. 
The tip of the intracardiac echocardiography probe was advanced into the right atrium with 
the piezo-electric crystal facing the free wall of the right atrium, then was gradually deflected 
towards the atrial septum and advanced into the right ventricle to obtain a long axis of the left 
ventricle. Left ventricular outflow tract and mitral valve were evaluated in echocardiographic 
secta scan, by Doppler mode. The M mode of mitral valve in this plane confirmed the systolic 
anterior motion and thickness of the interventricular septum. The probe was locked in this 
position so as to view the entire proximal and mid septum for further imaging during 
myocardial contrast injection and ablation. Coronary angiography was performed in multiple 
projections to delineate the septal perforator branches. The supposed target vessel artery was 
identified and cannulated with a 0.014 inch guide wire. A 2.5x9 mm over the wire balloon 
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was advanced into the vessel and inflated at 5-6 atm to prevent the flow back into the left 
anterior descending coronary artery. Subsequently 1 ml of an ultrasound contrast agent 
(Sonovue, Bracco, Milan, Italy), was injected through the balloon catheter. Hence the 
myocardial area supplied by the vessel (risk area) could be visualized and any leakage form 
the septal branch or an anomalous distribution excluded. PTSMA was performed according to 
standard protocol (14). The images obtained during infusion of ethanol revealed the 
progressive appearance of a sharply demarcated area with increased echo density in the 
septum within the contrast area producing a marked shadowing effect (Figure 1). The 
procedure was completed by obtaining the 2-D and M mode images in long axis. The patients 
were sent to the coronary care unit for 24 hours. Serial cardiac enzyme samples were obtained 
at baseline and at 12, 24, 36, 48, 60, and 72 hours. 
 
 
 
 
 
Figure 1. Image of the ablated area (with ethanol) visualized by intracardiac 
echocardiography during PTSMA and characterized by marked shadowing effect.  
 
 
 
Measurements. The gradient across the LVOT was continuously monitored with 
simultaneous pressure recording in the left ventricle and in the ascending aorta, using a pig 
tail and a guiding catheter respectively. The LVOT gradient was assessed at rest and after 
premature ventricular beats or post pacing. 
Measurements included maximal septal thickness, septal thickness at the site of 
treatment, mitral regurgitation grade, severity of SAM an LVOT gradient. Septal thickness 
was measured by intracardiac echocardiography in the long-axis of the ventricle as described 
above, in an end-diastolic still-frame. Mitral regurgitation severity was assessed by color flow 
Doppler intracardiac echocardiography echocardiography and graded on a scale from 0 (no 
regurgitation) to 4 (severe regurgitation). SAM of the anterior leaflet was graded as 0 
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(absent), 1+ (mild; minimal mitral-septal distance > 10 mm during systole), 2+ (moderate; 
minimal mitral-septal distance ≤10 mm during systole) or 3 (marked; brief or prolonged 
contact between the anterior mitral leaflet and septum) (15). 
The myocardial hyperechoic area developed during alcohol injection (ablated area) was off-
line planimetrized.  
 
MRI Protocol. A clinical 1.5-Tesla MRI scanner with a dedicated cardiac four 
element phased-array receiver coil was used for imaging (Signa CV/i, GE Medical systems, 
Milwaukee, Wisconsin). Repeated breath-holds and gating to the electrocardiogram were 
applied to minimize the influence of cardiac and respiratory motion on data collection. The 
ce-MRI protocol consisted of cine-MRI and DE-imaging.  
Left ventricular volumes and wall dimensions were assessed with cine-MRI using a 
steady-state free-precession technique (FIESTA) with the following imaging parameters: 6-10 
seconds per breath-hold per slice (depending on heart rate), 24 phases per slice location, Field 
of View: 36 x 36 cm; TR 3.4; TE 1.4; flip angle 45 degrees; matrix 160 x 128, bandwidth 83 
kHz, 0.75 NEX.) To cover the entire left ventricle, 9 to 12 consecutive slices of 8 mm were 
planned in short axis view (gap of 2 mm) perpendicular to the horizontal long axis (4-chamber 
view) of the left ventricle.  
Myocardial distribution of DE was studied 10-20 minutes following intravenous 
administration of Gadolinium-DTPA (0.1 mmol/kg, Magnevist®, Schering). A 2-dimensional 
T1-weighted inversion recovery gradient-echo sequence with the following imaging 
parameters was used; FOV: 40 x 32 cm, slice  thickness 8 mm gap 2 mm, TR 7.3, TE 1.6, flip 
angle 20 degrees, TI 180 - 275 ms, matrix 256 x192, 1 NEX, bandwidth 17.9 kHz. The 
inversion time was adjusted per patient to null the signal of remote myocardium. Slice 
locations of the DE-images were copied from the cine images. A myocardial segment was 
judged as non-assessable if the region of DE could not be differentiated clearly from the 
healthy myocardium (breathing artefacts, erroneous ECG triggering). 
 
Analysis of MRI. The maximum width of the interventricular septum was measured on 
cine-images in the LVOT-plane. DE-myocardium was clearly differentiated from remote 
myocardium (nulled signal) with the use of an inversion recovery pulse sequence. Data from 
one patient had to be excluded since image quality was impaired. The volume of DE was 
quantified by manually selecting the enhanced regions from the consecutive 2D slices 
encompassing the left ventricle with dedicated software (Cine, GE, 3.4.0, USA).  
 
 
Results 
 
Eighteen patients (mean age 62 ± 13 years; 12 (67%) men) completed the procedure 
under intracardiac echocardiography guidance. The mean baseline NYHA class was 2.5 ± 0.5. 
All patients had sinus rhythm at baseline electrocardiography. 
The maximum widths of the interventricular septum measured by intracardiac 
echocardiography ranged from 15 to 30 mm, (mean 21 ± 4 mm). These measurements 
correlated with MRI measurements of interventricular septum (22 ± 4 mm, r=0.70). Width of 
interventricular septum measured by intracardiac echocardiography at the level of alcohol 
injection was on average 20 ± 4 mm. The mean grade of systolic anterior motion judged by 
M-mode and 2-D intracardiac echocardiography was 2.2 ± 0.9. Moderate mitral insufficiency 
was present in 3 patients (17%).  
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Ethanol dose injected during the procedure was on average 2.1 ± 0.7 ml. Resting LVOT 
gradient was reduced from 74 ± 35 mmHg to 8 ± 16 mmHg (p<0.0001) at the end of the 
procedure LVOT gradient after extrasystolic beats or post pacing was reduced from 130 ± 49 
mmHg to 34 ± 33 mmHg (p<0.0001). In 1 patient the not extremely proximal localization of 
the ablated area associated with a low reduction of the resting LVOT gradient (20 mmHg), 
droved the decision of selecting a second more proximal septal branch. The procedure was 
successful and the reduction of gradient was higher (50mmHg). Peak of creatinekinase-MB 
and troponine was 161 ± 58 IU and 2.5 ± 1.1 UI.  
The ablated area (with ethanol) on planimetry was on average 1.8 ± 0.8 cm2 and 
correlated with the infarct size detected by delay-enhancement MRI at four days after the 
procedure (22 ± 7 cc, r=0.80) (Figure 2, 3, 4, 5). In 1 patient intracardiac echocardiography 
guidance was not performed due to a venous dissection occurred in the attempt of position the 
venous long sheat. No complications related to the intracardiac echocardiography guidance 
occurred in the other patients.  
 
 
 
 
Figure 2. Relation between the ablated area on planimetry measured by intracardiac 
echocardiography and the infarct size measured by delay-enhancement MRI. 
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Figure 3. Extensive ablated area visualized by intracardiac echocardiography during PTSMA 
(panel A) and corresponding infarct area visualized by delay-enhancement MRI long (panel 
B) and short axis (panel C). 
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Figure 4. Triangular shaped ablated area visualized by intracardiac echocardiography 
during PTSMA (panel A) and corresponding infarct area visualized by MRI long axis (panel 
B). 
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Figure 5. Ablated area visualized by intracardiac echocardiography and corresponding 
infarct area visualized by MRI long axis (panel B) in a patients who underwent PTSMA of two 
septal branches. 
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Discussion 
 
Intracardiac echocardiography during PTSMA is a safe imaging technique and can be 
used to guide ethanol administration during PTSMA in patients with obstructive HCM, 
particularly in the selection of appropriate septal branch. The planimetric ablated area 
visualized by intracardiac echocardiography correlates with the infarcted size measured by 
delay-enhancement MRI at 4 days after the procedure.  
Myocardial contrast echocardiography using transthoracic 2-dimensional 
echocardiography has been shown to be useful in guiding and monitoring PTSMA procedure, 
with a cumulative impact on the interventional strategy reported in about 15-20%. Moreover, 
it can be helpful in defining the end of the procedure. An appropriate impregnation of the 
target region has been reported to represent a possible marker to interrupt the procedure, 
independently of the hemodynamic result since the remodeling process that lately occurs, 
plays a role in the reduction of the obstruction (16). A dose of 2.0 ml of ethanol on average 
has been described to be as safe and efficacious as higher doses (around 4.0 ml) reported 
during the initial experiences from different centers (16, 17). During an invasive procedure as 
PTSMA, intracardiac echocardiography could be a complementary tool to transthoracic 
myocardial contrast echocardiography in guiding the procedure. This technique may be 
managed in a completely autonomous fashion by the same interventional team and the 
constant presence of an ehocardiographic machine and/or an additional operator during the 
entire procedure could be avoided. Moreover, intracardiac echocardiography provides a clear 
definition of the cardiac structures and a higher resolution of the images compared to the 
transthoracic approach. It can overcome the major limitations of a 2- D transthoracic imaging 
approach, including anatomic acoustic barriers (ribs and lungs), obesity, thoracic wall 
deformity, pulmonary conditions, and the fact that patients are examined in a supine position 
during PTSMA. 
 
Conclusions 
 
Intracardiac echocardiography can be used to monitor ethanol administration during 
PTSMA in patients with obstructive HCM, since it provides high quality and continous 
imaging of the treated segment of the septum during the whole procedure. Moreover, the 
planimetric ablated area visualized by intracardiac echocardiography can predict the infarcted 
size measured by delay-enhancement MRI.  
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Summary and conclusions 
 
 
In this thesis multiple echocardiographic approaches and techniques to predict clinical 
and functional outcome were evaluated.  
The value of high-dose dobutamine stress echocardiography for the prediction of long-
term cardiac events was evaluated in various clinical settings in patients with known or 
suspected coronary artery disease. Low-dose dobutamine stress echocardiography and tissue 
Doppler imaging were used to evaluate myocardial viability and left ventricular remodelling 
in patients with ischemic cardiomyopathy who underwent myocardial revascularization or 
percutaneous transplantation of skeletal myoblasts. The value of myocardial contrast 
echocardiography was studied to predict functional recovery in patients with acute myocardial 
infarction who underwent primary coronary intervention. Next, resting 2-D echocardiography 
was used to predict the onset of dilated-hypokinetic evolution and cardiovascular events in 
patients with hypertrophic cardiomyopathy. Finally, the role of intracardiac echocardiography 
was investigated for prediction of the infarct area in patients with obstructive hypertrophic 
cardiomyopathy who underwent percutaneous septal myocardial ablation.  
 
 
 
Role of dobutamine stress echocardiography for prediction of cardiac events in patients 
with known or suspected coronary artery disease. 
 
Dobutamine stress echocardiography has a high accuracy for the detection of coronary 
artery disease (1). Additionally it provides clinically useful prognostic information, such as 
resting left ventricular function, myocardial viability, stress-induced ischemia, vascular extent 
of wall motion abnormalities, and changes of end systolic volume and ejection fraction with 
stress (Chapter 1). The timing, extent and severity of the stress-induced wall motion 
abnormalities are important determinants of long-term prognosis. Previous studies have 
shown the efficay of stress echocardiography in predicting long-term cardiac events in mixed 
patient groups and the value of this test in selected patient subsets (2-6).  
In this thesis specific patient groups were evaluated. The prognostic value of 
dobutamine stress echocardiography was studied in multiple patient subsets, as described in 
the Table.  
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Clinical predictors of cardiac events: 
- As demonstrated in the Table, age was an important independent predictor of adverse 
events. Age had a homogeneous predictive power in the different settings of the population, in 
particular in females (Chapter 3). However, in patients with a permanent pacemaker (Chapter 
11) it was not predictive f cardiac events, probably due to the relatively small size of the study 
population. 
- Male gender was another important and constant independent predictor of cardiac events in 
different patient subsets. In the general population (Chapter 2) male gender was an 
independent predictor of hard cardiac events (cardiac death and myocardial infarction) in 
patients with a normal test. Conversely, the outcome of patients with abnormal dobutamine 
stress echocardiography was related to the severity of left ventricular dysfunction and 
ischemia on dobutamine stress echocardiography, but not to gender (after adjusting for the 
other variables). These data indicate that women with abnormal DSE should be treated as 
aggressively as men considering the clinical and echocardiographic risk profiles since the risk 
imposed by these parameters was not gender related. In patients with permanent pacemaker 
(Chapter 11) male gender was not a significant predictor of cardiac events, probably due to 
the relatively small size of the study population.  
- Smoking was, in most of the studies in this thesis, an independent predictor of cardiac 
events, together with the other important risk factors such as systemic hypertension, history of 
heart failure and diabetes mellitus. 
 
Echocardiographic predictors of cardiac events: 
- Resting wall motion abnormalities were in the majority of the described studies, an 
important independent variable for prediction of clinical outcome. However, resting wall 
motion abnormalities were not predictive of cardiac events in: 1) patients with myocardial 
ischemia (where probably this last echocardiographic variable resulted much stronger than 
resting left ventricular function), 2) in patients with permanent pacemaker (probably due to 
the small number of patients), and 3) in patients with suspected coronary artery disease where 
the significance of left anterior hemiblock was investigated (since patients with history of 
previous myocardial infarction, cardiac pacemaker, pathological Q wave, and complete left or 
right bundle branch block on baseline electrocardiogram were excluded). 
- New wall motion abnormalities or myocardial ischemia was the strongest independent 
predictor of cardiac events substantially in all patient subsets (see Table). In patients with 
right bundle branch block an abnormal stress echocardiogram was significantly associated 
with cardiac events.  
In the elderly, the presence and the extent of myocardial ischemia during dobutamine 
stress echocardiography provided incremental information over clinical and resting 
echocardiographic data to predict all cause of mortality (Chapter 4). However, in not all 
patients stress echocardiography can be performed due to patient characteristics as a poor 
acoustic window. This thesis showed that in the elderly, myocardial perfusion imaging using 
Tc-tetrofosmin SPECT provides incrmental prognostic information on total mortality, cardiac 
death, and hard cardiac events. 
In patients with a left bundle branch block, the diagnosis of coronary artery disease 
and the prognostic stratification is challenging because of the pre-existent repolarization 
abnormalities. To elucidate this clinical issue, a meta-analysis (Chapter 9) of the published 
data on exercise electrocardiography, myocardial perfusion imaging and stress 
echocardiography for the detection of coronary artery disease and the prediction of cardiac 
events in patients with a left bundle branch block was performed. Analysis of pooled data 
showed that the relative risk of cardiac death or myocardial infarction in patients with an 
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abnormal stress echocardiography and myocardial perfusion imaging was elevated >7-fold 
but did not differ by imaging modality (p=0.9). 
 
In conclusion, dobutamine stress echocardiography had an incremental prognostic 
value in various patient subsets, as well as in patients with resting electrocardiographic 
abnormalities. 
 
In all studies described in this thesis, myocardial ischemia on stress echocardiography 
was predictive of future cardiac events. This may seem somewhat strange, because, 
nowadays, with good medical therapy and recent developments in revascularization 
procedures, one may expect that patients who received a complete treatment have the same 
prognosis as patients with a normal stress echocardiography. Several factors may cause this 
apparent discrepancy. First, dobutamine stress echocardiography is a relative new technique, 
introduced at the Thoraxcenter in 1990, with a systematic and consistent organization. 
Substantial clinical progress in the treatment of coronary artery disease has occurred during 
the long follow-up period with possible impact on interpretation of results of this test. Recent 
trials have demonstrated the benefit of a complete medical therapy with aspirin, beta-blockers, 
ACE-inhibitors, spironolacton and statins in patients with documented coronary artery 
disease. The prescription rate of beta-blockers, calcium antagonist, ace-inhibitors and statins 
in the population studied in this thesis, was relatively low, even in those with myocardial 
ischemia. Second, not all the patients with myocardial ischemia on dobutamine stress 
echocardiography underwent coronary revascularization. There may have been good clinical 
reasons for this; in some patients, coronary anatomy, high age and comorbidities may have 
limited the possibility of myocardial revascularization. The decision to perform coronary 
angiography was made on clinical grounds by the treating cardiologist. In general, it seems 
that dobutamine stress echocardiography was not always used for clinical decision making. 
Probably the extent of induced ischemia also could be the cause of an inadequate optimization 
of medical therapy or the detainment from myocardial revascularization. Third, as stated in 
Chapter 6, it seems that in some patients, symptoms of angina instead of signs of ischemia on 
dobutamine stress echocardiography were the reason to prescribe betablockers or calcium 
antagonists and to perform myocardial revascularization. Nevertheless, survival curves for 
patients with normal and abnormal dobutamine stress echocardiography continued to diverge 
during the entire follow-up, indicating that the prognostic value of dobutamine stress 
echocardiography was maintained during follow-up. Last, the natural progression of 
underlying coronary artery disease may be a cause of the adverse prognosis of patients with 
ischemia on dobutamine stress echocardiography, even if these patients recieve a complete 
therapy/coronary revascularization.  
 
Recent advances in technology, such as second harmonic imaging or the use of 
contrast agents may have resulted in changes in sensitivity and specificity of dobutamine 
stress echocardiography. Echocardiographic machines equipped with second harmonic 
imaging were introduced in 1998 in our center, whereas the use of contrast agents for 
visualization of left ventricular endocardial border was introduced in 1999. These technical 
changes could have contributed to an improvement in sensitivity and specificity of 
dobutamine stress echocardiography in predicting cardiac events. Moreover, other new 
modalities, such as automatic border detection, could further improve the accuracy in 
detection myocardial ischemia during stress echocardiography, since it is well known that this 
technique is operator-dependent and high competence and experience are necessary. Despite 
these limitations, dobutamine stress echocardiography provides unique information (not 
provided by other non-invasive tests), that may be important for clinical decision making,  
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 From the content of this thesis can be derived that the proper selection of management 
strategies in patients with suspected or known coronary artery disease should be based on an 
accurate estimation of the risk of adverse events. Recognition of patients at high risk of 
cardiac events is an essential step in guiding the use of invasive procedures and selecting 
patients who are most likely to benefit and thus avoiding the risk and cost of interventions in 
low risk patients. Dobutamine stress echocardiography is an effective tool for risk 
stratification in these patients. Patients with normal stress echocardiogram had a low cardiac 
event rate (1-2%) and can be exempted for invasive procedures. Negative tests confer a high 
negative predictive value for cardiac events irrespective of clinical risk. Patients with 
extensive abnormalities in multi-vascular distribution are at a high risk of death and 
myocardial infarction. In these patients, coronary angiography and subsequent myocardial 
revascularization may be justified, with additional consideration of symptomatic status, 
functional capacity and resting left ventricular function.  
 
 
Myocardial viability detected by low dose dobutamine infusion and tissue Doppler 
imaging. 
 
 The role of myocardial viability in patients with dilated ischemic cardiomyopathy was 
evaluated by low dose dobutamine stress echocardiography in patients who underwent to 
different treatments.  
 In patients who underwent myocardial revascularization (Chapter 13), the relation 
between viable myocardium and ongoing or reversed remodeling was evaluated. Substantial 
myocardial viability prevented ongoing left ventricular remodeling after revascularization and 
was associated with improvement of symptoms and favorable long-term prognosis. 
 In patients who underwent percutaneous transplantation of skeletal myoblasts (Chapter 
14), resting left ventricular function and myocardial viability were evaluated by resting and 
low dose dobutamine echocardiography and by tissue Doppler imaging examination. During 
low-dose dobutamine infusion, the peak systolic velocity in the regions of myoblasts injection 
significantly increased at tissue Doppler imaging examination; left ventricular ejection 
fraction improved and end-systolic volumes decreased at 1 year. Thus, in these patients, 
regional and global left ventricular contractile reserve showed a sustained improvement, up to 
1 year after treatment.  
 
 
Myocardial contrast echocardiography. 
 
 In patients with acute myocardial infarction, myocardial contrast echocardiography 
may be useful to assess dysfunctional myocardium after primary percutaneous 
revascularization and distinguish reversible (myocardial stunning) from irreversible 
myocardial damage (no-reflow phenomenon). Moreover, several studies demonstrate that 
myocardial contrast echocardiography can predict the recovery of regional function after 
primary percutaneous coronary intervention.  
 In chapter 15 the additional value of end-diastolic myocardial wall thickness was 
evaluated together with myocardial contrast echocardiography to predict recovery of regional 
left ventricular function after primary coronary intervention. A relatively simple measurement 
of end-diastolic myocardial wall thickness, obtained with 2-D echocardiography combined 
with contrast agent, predicted recovery of regional contractile function. Using end-diastolic 
myocardial wall thickness alone, dysfunctional segments with an end-diastolic myocardial 
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wall thickness ≥11 mm showed a high likelihood of recovery of regional contractile function 
two months after primary coronary intervention. Moreover, it appeared that when at least 50% 
of the dysfunctional segments showed an EDWT ≥11 mm, global recovery may be 
anticipated. 
 The relative merits of myocardial contrast echocardiography and magnetic 
resonance imaging to predict myocardial function improvement after percutaneous coronary 
intervention was evaluated in Chapter 16. The sensitivity, specificity and accuracy for the 
prediction of functional improvement were comparable between myocardial contrast 
echocardiography, first-pass magnetic resonance imaging, and delayed-enhancement 
magnetic resonance imaging. Thus, myocardial contrast echocardiography, as bed-side 
technique, may be an alternative tool in the acute phase of myocardial infarction. 
 
 
Predictive echocardiography in hypertrophic cardiomyopathy. 
 
 The incidence, risk factors and prognosis of dilated-hypokinetic evolution in 222 
consecutive patients with hypertrophic cardiomyopathy was evaluated over 11 years in 
Chapter 17. Patients with prevalent/incident dilated-hypokinetic hypertrophic cardiomyopathy 
were younger at first evaluation, more often had a family history of hypertrophic 
cardiomyopathy or sudden death, and showed greater myocardial wall thickness compared 
with patients who maintained ‘classic’ hypertrophic cardiomyopathy. Cox proportional 
hazards regression analysis identified left ventricular wall thickness and end-diastolic 
diameter both measured by 2-D echocardiography as independent predictors of cardiovascular 
death. 
 In patients with obstructive hypertrophic cardiomyopathy who underwent 
percutaneous septal myocardial ablation, the role of intracardiac echocardiography was 
evaluated in Chapter 18. This imaging modality was useful in the selection of the appropriate 
septal branch and in guiding ethanol administration. The planimetric ablated area (with 
ethanol) visualized by intracardiac echocardiography correlated with the infarct size measured 
by delay-enhancement magnetic resonance imaging at 4 days after the procedure.  
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Samenvatting en conclusies 
 
 
In dit proefschrift werden verschillende echocardiografische benaderingen 
geëvalueerd om klinisch en functioneel herstel te voorspellen. Eerst werd de prognostische 
waarde van dobutamine stress echocardiografie geëvalueerd in verschillende klinische 
situaties bij patiënten met (mogelijk) coronair lijden. Vervolgens werd tissue Doppler 
imaging, gedurende dobutamine stress echocardiografie uitgevoerd om het korte en lange 
termijn effect op regionale en globale linker ventrikel functie te evalueren van coronaire 
revascularizatie en percutaan getransplanteerde skelet myoblasten bij patiënten met 
ischemisch hartfalen. Verder werd de waarde van myocardiale contrast echocardiografie voor 
het voorspellen van herstel van functie bij patiënten met een acuut myocard infarct 
bestudeerd. Vervolgens werd het nut van 2-D echocardiografie onderzocht om het beloop van 
patiënten met een hypertrofische obstructieve cardiomyopathie te voorspellen. Tenslotte werd 
de rol van intracardiale echocardiografie bij het uitvoeren van percutane septale myocard 
ablatie bij patiënten met obstructieve hypertrofische cardiomyopathie onderzocht. 
 
 
De rol van dobutamine stress echocardiografie voor het voorspellen van cardiale events 
bij patiënten met (mogelijk) coronair lijden. 
 
Dobutamine stress echocardiografie is een nuttige techniek voor risico stratificatie bij 
patiënten met (mogelijk) coronair lijden (1). Deze test verschaft klinisch bruikbare 
prognostische informatie over linker ventrikel functie, myocard vitaliteit, stress geïnduceerde 
ischemie, uitgebreidheid van myocardischemie, en veranderingen van eindsystolisch volume 
en ejectie fractie met stress (Hoofdstuk 1). Eerdere studies hebben aangetoond dat stress 
echocardiografie nuttig is voor het voorspellen van cardiale events op lange termijn (2-6). In 
dit proefschrift werd de prognostische waarde van deze test in verschillende klinische situaties 
onderzocht. 
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Klinische voorspellers van cardiale events: 
- Zoals wordt getoond in de Tabel, was leeftijd een belangrijke voorspeller van cardiale 
events. Leeftijd had een homogene voorspellende kracht in verschillende groepen, vooral bij 
vrouwen (Hoofdstuk 3). Echter bij patiënten met een permanente pacemaker (Hoofdstuk 11) 
was leeftijd geen voorspeller van cardiale events, waarschijnlijk door de relatief kleine studie 
groep. 
- Mannelijk geslacht was een andere belangrijke en constante onafhankelijke voorspeller van 
cardiale events bij verschillende patiënt groepen. In de algemene populatie (Hoofdstuk 2) was 
mannelijk geslacht een onafhankelijke voorspeller van harde cardiale events (cardiale sterfte 
en myocard infarct) bij patiënten met een normale test. De prognose van patiënten met een 
abnormale dobutamine stress echocardiografie was echter gerelateerd aan de Ernst van de 
linker ventrikel dysfunctie en ischemie volgens dobutamine stress echocardiografie, maar niet 
gerelateerd aan het geslacht (na correctie van andere factoren). Deze gegevens tonen aan dat 
vrouwen met een abnormale DSE net zo voortvarend behandeld moeten worden als mannen, 
omdat het risico op cardiale events niet geslacht gerelateerd was. Bij patiënten met een 
permanente pacemaker (Hoofdstuk 11) was mannelijk geslacht geen significante voorspeller 
van cardiale events, waarschijnlijk door de relatief kleine studie groep. 
- Roken was, in de meeste studies in dit proefschrift, een onafhankelijke voorspeller van 
cardiale events, samen met andere belangrijke risicofactoren zoals hypertensie, hartfalen en 
diabetes mellitus. 
 
Echocardiografische voorspellers van cardiale events: 
- Wandbewegingsstoornissen in rust waren in de meeste studies een belangrijke 
onafhankelijke variabele om de prognose te voorspellen. Echter, wandbewegingsstoornissen 
in rust waren geen voorspeller van cardiale events bij: 1) patiënten met myocard ischemie 
(waar deze laatste variabele waarschijnlijk een veel sterkere voorspeller is dan linker ventrikel 
functie in rust), 2) patiënten met een permanente pacemaker (waarschijnlijk door de relatief 
kleine studie groep), en 3) bij patiënten met (mogelijk) coronairlijden, waar de invloed van 
een linker anterior hemiblock werd onderzocht. 
- Nieuwe wandbewegingsstoornissen of myocard ischemie was de sterkste onafhankelijke 
voorspeller van cardiale events in vrijwel alle patiënt groepen (zie Tabel), ook bij patiënten 
met een rechter bundeltak block en ouderen (Hoofdstuk 4). Bij ouderen bij wie een echo niet 
goed mogelijk is kan ook een myocard perfusie scan met Tc-tetrofosmin SPECT worden 
verricht om cardiale events te voorspellen.  
Bij patiënten met een linker bundeltak block kan de diagnose van coronairlijden en het 
inschatten van de prognose een uitdaging vormen, door de aanwezigheid van preëxistente 
repolarizatie stoornissen. Om dit klinische vraagstuk te verhelderen werd een meta-analyse 
verricht (Hoofdstuk 9) van de gepubliceerde data betreffende inspanningselektrocardiografie, 
myocard perfusie scintigrafie en stress echocardiografie voor het vaststellen van coronair 
lijden en het voorspellen van cardiale events bij patiënten met een linker bundeltak block. 
Analyse van verzamelde gegevens toonde dat het risico op cardiale sterfte of een myocard 
infarct > 7 keer verhoogd was bij patiënten met een abnormale stress echo of myocard 
perfusie onderzoek, dit verschilde niet voor beide afbeeldende onderzoeken (p=0.9). 
In conclusie heeft dobutamine stress echocardiografie een toegevoegde prognostische 
waarde bij verschillende patiënt groepen, ook bij patiënten met preëxistente afwijkingen op 
het electrocardiogram in rust.  
 
In alle studies beschreven in dit proefschrift, was myocard ischemie bij stress 
echocardiografie voorspellende voor toekomstige cardiale events. Dit kan wellicht vreemd 
lijken, omdat, tegenwoordig, met een goede behandeling met medicijnen en recente 
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ontwikkelingen op het gebied van coronaire revascularizatie, men misschien verwacht dat 
patiënten die een complete behandeling krijgen dezelfde prognose hebben als patiënten met 
een normale stress echo. Verschillende factoren kunnen deze schijnbare discrepantie 
veroorzaken. Ten eerste is dobutamine stress echocardiografie een betrekkelijk nieuwe 
techniek, geïntroduceerd in het Thoraxcentrum in 1990, met een systematische en consistente 
organisatie. Substantiële klinische vooruitgang in de behandeling van coronair lijden heeft er 
plaats gevonden gedurende de lange termijn follow-up, met een mogelijke invloed op de 
interpretatie van de resultaten van de onderzoeken. Recente trials hebben het voordeel van een 
volledige behandeling met medicijnen zoals aspirine, beta-blockers, ACE-remmers, 
spironolacton en statines bij patiënten met coronair lijden. De populatie bestudeerd in dit 
proefschrift kreeg betrekkelijk weinig beta-blockers, calcium antagonisten, ace-remmers en 
statines voorgeschreven, zelfs bij patiënten met myocard ischemie. Ten tweede, ondergingen 
niet alle patiënten met myocard ischemie bij dobutamine stress echocardiografie coronaire 
revascularizatie. Er kunnen hiervoor goede klinische redenen geweest zijn; bij sommige 
patiënten kan de coronaire anatomie, hoge leeftijd en co-morbiditeit de mogelijkheden tot 
coronaire revascularizatie beperkt hebben. De beslissing om coronair angiografie te doen was 
gebaseerd op klinische gronden, door de behandelend cardioloog. In het algemeen lijkt het dat 
dobutamine stress echocardiografie niet altijd gebruikt werd om tot een klinische afweging te 
komen. Ten derde, zoals beschreven in hoofdstuk 6, lijkt het dat bij sommige patiënten 
symptomen van angina pectoris in plaats van tekenen van ischemie op dobutamine stress 
echocardiografie de reden waren om beta blockers of calcium antagonisten voor te schrijven 
en revascularizatie te verrichten. Desalniettemin, liepen de overlevingscurven van patiënten 
met een normale en abnormale dobutamine stress echo uit elkaar gedurende de gehele follow-
up, dit geeft aan dat de prognostische waarde van dobutamine stress echocardiografie 
behouden bleef gedurende de follow-up. Tenslotte kan het natuurlijk beloop van de 
onderliggende coronair4 hartziekte een reden zijn voor de slechtere prognose van patiënten 
met ischemie bij dobutamine stress echocardiografie, zelfs als deze patiënten een volledige 
behandeling met medicijnen/ coronaire revascularizatie ondergingen. 
  
Recente ontwikkelingen in technologie, zoals second harmonic imaging of het gebruik 
van contrast middelen kan geresulteerd hebben in veranderingen van sensitiviteit en 
specificiteit van dobutamine stress echocardiografie. Echocardiografie apparatuur met second 
harmonic imaging werden geïntroduceerd in 1998 in ons centrum, terwijl het gebruik van 
contrast voor het visualiseren van de linker ventrikel endocardiale grens werd geïntroduceerd 
in 1999. Deze technische ontwikkelingen kunnen hebben bijgedragen aan de verbetering van 
sensitiviteit en specificiteit van dobutamine stress echocardiografie voor het voorspellen van 
cardiale events. Bovendien kunnen andere technieken zoals automatische endocardiale grens 
detectie de precisie van stress echocardiografie verder verbeteren, omdat het bekend is dat 
deze techniek afhankelijk is van degene die de test uitvoert en dat een hoge vakbekwaamheid 
en ervaring nodig zijn. Ondanks deze beperkingen, verschaft dobutamine stress 
echocardiografie unieke informatie die belangrijk kan zijn bij het nemen van klinische 
beslissingen.  
 
 Uit de inhoud van dit proefschrift kan afgeleid worden dat het kiezen van de juiste 
behandeling bij patiënten met (mogelijk) coronair lijden gebaseerd zou moeten zijn op een 
nauwkeurige schatting van het risico op cardiale events. Het herkennen van hoogrisico 
patiënten is een essentiële stap in het nemen van beslissingen omtrent het gebruik van 
invasieve procedures en het selecteren van patiënten die naar alle waarschijnlijk baat zullen 
hebben bij deze procedures, en zo risico’s en kosten te mijden bij patiënten met een laag 
risico. Dobutamine stress echocardiografie is een effectieve test voor risico stratificatie bij 
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deze patiënten. Patiënten met een normale stress echocardiogram hadden een lage cardiale 
event rate (1-2%) en hoeven geen invasieve procedures te ondergaan. Een negatieve test heft 
een hoge negatief voorspellende waarde voor cardiale events. Patiënten met uitgebreide 
afwijkingen in het gebied van meerdere coronairen hebben een hoog risico voor sterfte en 
myocard infarct. Bij deze patiënten kan een coronair angiografie en revascularizatie 
gerechtvaardigd zijn, na evalueren van symptomen, functionele capaciteit en linker ventrikel 
functie in rust. 
 
 
Myocard vitaliteit gedetecteerd met lage dosis dobutamine infusie en tissue Doppler 
imaging. 
 
 De rol van myocardvitaliteit bij het proces van linker ventrikel remodeling na 
revascularizatie werd geëvalueerd bij een grote groep patiënten met ischemische 
cardiomyopathy in Hoofdstuk 13. Het aantal vitale segmenten was de enige voorspeller voor 
linker ventrikel remodeling. De kans op remodeling nam af als het aantal vitale segmenten 
steeg. Bij patiënten met ischemische cardiomyopathie, voorkomt de aanwezigheid van een 
substantiële hoeveelheid dysfunctioneel maar vitaal myocardweefsel het proces van linker 
ventrikel remodeling na revascularizatie en is tevens geassocieerd met een verbetering van 
hartfalen symptomen en een betere prognose. 
 In Hoofdstuk 14 wordt het korte en lange termijn effect op regionale en globale linker 
ventrikel functie van percutaan ge transplanteerde skelet myoblasten bij patiënten met 
ischemisch hartfalen geëvalueerd met 2-dimensionale echocardiografie en tissue Doppler 
imaging. Gedurende lage dosis dobutamine infusie nam de maximale systolische snelheid in 
de regio’s waar myoblasten waren geïnjecteerd significant toe gemeten met tissue Doppler 
imaging; de linker ventrikel ejectie fractie verbeterde en de eind-systolische volumes namen 
af na 1 jaar. Dus bij deze patiënten verbeterde de regionale en globale linker ventrikel 
contractiele reserve gedurende de follow-up. Het effect was ook nog na een jaar follow-up 
detecteerbaar.  
 
 
Myocardiale contrast echocardiografie. 
 
 Bij patiënten met een acuut myocard infarct is het gebruik van myocardiale contrast 
echocardiografie nuttig om een onderscheid te maken tussen reversibele myocard dysfunctie 
(myocardial stunning) en irreversibele myocardiale beschadiging (no-reflow fenomeen). In 
Hoofdstuk 15 werd de toegevoegde waarde van het meten van de eind-diastolische 
myocardiale wanddikte bepaald om herstel van regionale contractiliteit van de linker ventrikel 
te voorspellen na primaire coronaire revascularizatie. Segmenten met een eind-diastolische 
wanddikte ≥11mm met een intacte perfusie hebben de grootste kans op herstel, segmenten 
met een eind-diastolische wanddikte <11mm en intacte perfusie hebben een gemiddelde kans 
op herstel. Segmenten met een eind-diastolische wanddikte <11mm zonder perfusie hebben 
een lage kans op herstel. 
 De waarde van myocardiale contrast echocardiografie and magnetische resonantie 
onderzoek om verbetering van myocardfunctie te voorspellen na een percutane coronaire 
interventie werd geëvalueerd in Hoofdstuk 16. De sensitiviteit, specificiteit and accuratesse 
voor het voorspellen van verbetering van functie was vergelijkbaar voor myocardiale contrast 
echocardiografie, first-pass magnetische resonantie onderzoek en delayed-enhancement 
magnetische resonantie onderzoek. Dus myocardiale contrast echocardiografie en 
magnetische resonantie onderzoek kunnen nuttig zijn bij het voorspellen van verbetering van 
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myocard functie na primaire percutane interventies. Myocardiale contrast echocardiografie 
heeft een vergelijkbare accuratesse als magnetische resonantie onderzoek en kan een 
alternatief zijn voor deze techniek omdat het aan het ziekbed verricht kan worden in de acute 
fase na een myocard infarct. 
 
 
Voorspellende echocardiografie bij hypertrofische cardiomyopathie. 
 
 De incidentie, risico factoren en prognose van gedilateerde-hypokinetische evolutie 
werd onderzocht bij 222 opeenvolgende patiënten met hypertrofische cardiomyopathie 
gedurende een follow-up van 11 jaar (Hoofdstuk 17). Patiënten met gedilateerde-
hypokinetische hypertrofische cardiomyopathie waren gemiddeld jonger, hadden vaker een 
positieve familie anamnese voor hypertrofische cardiomyopathie of plotselinge sterfgevallen, 
en hadden een grotere myocardiale wanddikte dan patiënten met een “klassieke” 
hypertrofische cardiomyopathie. Cox proportional hazards regression analyse toonde dat de 
linker ventrikel wanddikte en de einddiastolische diameter (beiden gemeten met 2-D 
echocardiografie), beiden onafhankelijke voorspellers waren van cardiovasculaire sterfte.
 De rol van intracardiale echocardiografie gedurende percutane septale myocard 
ablatie bij patiënten met obstructieve hypertrofische cardiomyopathie werd geëvalueerd in 
Hoofdstuk 18. Deze onderzoekstechniek is veilig en nuttig om ethanol toediening te leiden, 
vooral om de juiste septale tak te selecteren. Het ablatie gebied (met ethanol) dat 
gevisualiseerd werd met intracardiale echocardiografie correleerde goed met metingen van het 
infarct gebied vastgesteld met delay-enhancement magnetische resonantie onderzoek, 4 dagen 
na de procedure.  
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